WO1997033174A1 - Selectively n-alkylated peptidomimetic combinatorial libraries and compounds therein - Google Patents

Selectively n-alkylated peptidomimetic combinatorial libraries and compounds therein Download PDF

Info

Publication number
WO1997033174A1
WO1997033174A1 PCT/IB1997/000349 IB9700349W WO9733174A1 WO 1997033174 A1 WO1997033174 A1 WO 1997033174A1 IB 9700349 W IB9700349 W IB 9700349W WO 9733174 A1 WO9733174 A1 WO 9733174A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
hydrogen atom
group
alkyl
propyl
Prior art date
Application number
PCT/IB1997/000349
Other languages
French (fr)
Inventor
Barbara Dorner
John M. Ostresh
Collette T. Dooley
Jutta Eichler
Richard A. Houghten
Original Assignee
Torrey Pines Institute For Molecular Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrey Pines Institute For Molecular Studies filed Critical Torrey Pines Institute For Molecular Studies
Priority to EP97908448A priority Critical patent/EP0890101A4/en
Priority to AU20405/97A priority patent/AU720632B2/en
Priority to JP09531626A priority patent/JP2001502293A/en
Publication of WO1997033174A1 publication Critical patent/WO1997033174A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates generally to novel, selectively N-alkylated compounds of Formula I below, as well as novel libraries composed of many such compounds, methods of synthesizing and screening the libraries, and methods of using the compounds.
  • the process of discovering new therapeutically active compounds for a given indication involves the screening of all compounds from available compound collections. From the compounds tested, one or more structure (s) is selected as a promising lead. A large number of related analogs are then synthesized in order to develop a structure-activity relationship and select one or more optimal compounds. With traditional one-at- a-time synthesis and biological testing of analogs, this optimization process is long and labor intensive. Adding significant numbers of new structures to the compound collections used in the initial screening step of the discovery and optimization process cannot be accomplished with traditional one-at-a-time synthesis methods, except over a time frame of months or even years. Faster methods are needed that allow for the preparation of up to thousands of related compounds in a matter of days or a few weeks. This need is particularly evident when it comes to synthesizing more complex compounds, such as the instant compounds composed of two or more monomers, each monomer possessing more than one variable substituent.
  • SCLs chemically synthesized combinatorial libraries
  • the preparation and use of synthetic peptide combinatorial libraries has been described, for example, by Dooley in U.S. Patent 5,367,053, Huebner in U.S. Patent 5,182,366, Appel et al. in WO PCT 92/09300, Geysen in published European Patent Application 0 138 855 and Pirrung in U.S. Patent 5,143,853.
  • SCLs provide the efficient synthesis of an extraordinary number of various peptides in such libraries and the rapid screening of the library which identifies lead pharmaceutical peptides.
  • the present invention combines the techniques of solid-phase synthesis of peptidomimetic compounds and the general techniques of synthesis of combinatorial libraries to prepare new selective
  • N-alkylated compounds N-alkylated compounds.
  • This invention is directed to a single selectively N-alkylated compound or a library of an approximately equimolar mixture of two more selectively N-alkylated compounds of the Formula (I):
  • R 1 and R 2 independently are a hydrogen atom, an amino protecting group, C 1 to C 12 acyl, C 3 to C 10
  • R 3 , R 5 , and R 7 are independently a hydrogen atom
  • R 4 , R 6 and R 8 are independently a C 1 to C 18 substituent group; with the proviso that all but one of R 4 , R 6 and R 8 can simultaneously be the same group;
  • R 9 is a hydrogen atom or a solid support
  • R 10 is optionally present as a C 1 to C 18 substituent group when R 1 and R 2 are other than a hydrogen atom, an amino protecting group or when both R 1 and R 2 are C 1 to C 12 acyl groups;
  • AA, BB, and CC are independently 0 to 5;
  • B is from 0 to 3 ; further wherein the stereochemistry at the carbons bonded to R 3 , R 5 , and R 7 are independently R or S or a mixture of the two; further wherein when B is 2 or 3; each R 4 and R 5 can be the same or different; with the proviso that either R 1 or R 2 can be taken with R 3 ; R 4 can be taken with R 5 ; and R 6 can be taken with R 7 ; respectively and independently, to form a subtituted or unsubstituted pyrrolidine ring;
  • X and Y are either 1) each a hydrogen atom or 2) taken together to represent a carbonyl group; and a pharmaceutically acceptable salt, solvate or hydrate thereof.
  • This invention is also directed to iterative and positional scanning methods of synthesizing the libraries of compounds described above as discussed below.
  • Another aspect of the invention is a method of selective N-alkylation as set forth below.
  • the invention comprises methods for affecting analgesia in a mammal, effecting a decrease in the postprandial rise in the blood glucose levels of a mammal after said mammal has ingested a carbohydrate load, and a method for treating microbial infections, all of which methods comprise administering a single compound of the above formula in conjunction with a pharmaceutically acceptable carrier, as set forth below.
  • the instant invention is directed to a single compound or an approximately equimolar mixture of two or more selectively N-alkylated compounds of the Formula (I) :
  • R 1 and R 2 independently are a hydrogen atom, an amino protecting group, C 1 to C 12 acyl, C 3 to C 10
  • cycloalkyl C 3 to C 6 heterocycle, C 1 to C 12 alkyl, C 1 to C 12 substituted alkyl, C 7 to C 16 alkylaryl, C 7 to C 16 substitued alkylaryl, a C 6 to C 15 alkyl heterocycle, or a substituted C 6 to C 15 alkyl heterocycle;
  • R 3, R 5, and R 7 are independently a hydrogen atom, C 1 to C 12 alkyl, C 1 to C 12 substituted alkyl, phenyl, substituted phenyl, C 7 to C 16 alkylaryl, C 7 to C 16
  • alkylaryl a C 6 to C 15 alkyl heterocycle, or a substituted C 6 to C 15 alkyl heterocycle
  • R 4 , R 6 and R B are independently a C 1 to C 18 substituent group; with the proviso that all but one of R 4 , R 6 and R ⁇ can simultaneoulsy be the same group;
  • R 9 is a hydrogen atom or a solid support
  • R 10 is optionally present as a C 1 to C 18 substituent group when R 1 and R 2 are other than a hydrogen atom or an amino protecting group;
  • AA, BB, and CC are independently 0 to 5 ;
  • B is from 0 to 3 ; further wherein the stereochemistry at the carbons bonded to R 3 , R 5 , and R 7 are independently R or S or a mixture of the two; further wherein when B is 2 or 3; each R 4 and R 5 can be the same or different; with the proviso that either R 1 or R 2 can be taken with R 3 ; R 4 can be taken with R 5 ; and R 6 can be taken with R 7 ; respectively and independently, to form a subtituted or unsubstituted pyrrolidine ring; X and Y are either 1) each a hydrogen atom or 2) taken together to represent a carbonyl group; and a pharmaceutically acceptable salt, solvate or hydrate thereof.
  • the terms used in the above Formula I having the following meanings when used in conjunction with Formula I and when used in described subsequent Formulas :
  • cycloalkyl - unsubstituted or substituted mono- or bicyclic saturated rings such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or adamantyl or rings wherein the
  • substituents are one or more hydroxy, halo, amino, protected amino, carboxy, protected carboxy, amido, nitro, trifluoromethyl, phenyl, heterocyclic rings, C 1 to C 7 acyl, C 1 to C 7 alkoxy, or C 1 to C 3 alkyl groups;
  • C 1 to C 18 Substituent Group indicates a group of the formula -CH 2 -W wherein W is chosen from the group consisting of a hydrogen atom, C 1 to C 12 alkyl, C 3 to C 10 cycloalkyl, C 1 to C 12 substituted alkyl, phenyl, substituted phenyl, C 7 to C 16 alkylaryl, C 7 to C 16 substituted alkylaryl, as those terms are defined herein;
  • C 1 to C 12 substituted alkyl denotes the above C 1 to C 12 alkyl groups that are substituted by one to three halogen, hydroxy, protected hydroxy, amino, protected amino, guanidino, C 1 to C 7 acyloxy, C 1 to C 7 acyl, nitro, carboxy, protected carboxy, carboxamide, carbonyl, carboxyl, cyano, methylsulfonylamino or C 1 to C 4 alkoxy groups.
  • the substituted alkyl groups may be substituted once or twice with the same or with different substituents; Examples of the above substituted alkyl groups include the cyanomethyl, nitromethyl, hydroxymethyl, trityloxymethyl, propionyloxymethyl, aminomethyl,
  • C 1 to C 6 substituted alkyl includes the substituted methyl group, in other words, a methyl group substituted by the same
  • substituents as the " C 1 to C 6 substituted alkyl" group include groups such as protected hydroxymethyl, (e.g.,
  • substituted phenyl specifies a phenyl group substituted with one or more, and preferably one or two, moieties chosen from the groups consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, trifluoromethyl, C 1 to C 6 alkyl, C 1 to C 7 alkoxy, C 1 to C 7 acyl, C 1 to C 7 acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino,
  • substituted phenyl includes a mono- or di (halo) phenyl group such as 2, 3 or 4-chlorophenyl, 2, 6-dichlorophenyl, 2 , 5-dichlorophenyl, 3,4-dichlorophenyl, 2, 3 or 4-bromophenyl, 3,4- dibromophenyl, 3-chloro-4-fluorophenyl, 2, 3 or 4- fluorophenyl and the like; a mono or di (hydroxy) phenyl group such as 2, 3 or 4-hydroxyphenyl, 2,4- dihydroxyphenyl, the protected-hydroxy derivatives thereof and the like; a nitrophenyl group such as 2 , 3 or 4-nitrophenyl; a cyanophenyl group, for example, 2, 3 or 4-cyanophenyl; a mono- or di (alkyl) phenyl group such as 2, 3 or 4-methylphenyl, 2,4-dimethylphenyl, 2, 3 or 4-
  • hydroxymethyl)phenyl such as 2, 3, or 4-(protected hydroxymethyl)phenyl or 3,4-di(hydroxymethyl)phenyl; a mono- or di(aminomethyl)phenyl or (protected
  • aminomethyl)phenyl such as 2, 3 or 4-(aminomethyl)phenyl or 2,4-(protected aminomethyl)phenyl; or a mono- or di (N- (methylsulfonylamino))phenyl such as 2, 3 or 4-(N- (methylsulfonylamino))phenyl.
  • a mono- or di (N- (methylsulfonylamino))phenyl such as 2, 3 or 4-(N- (methylsulfonylamino)phenyl.
  • substituted phenyl represents disubstituted phenyl groups wherein the substituents are different, for
  • halo and halogen refer to the fluoro, chloro, bromo or iodo groups. There can be one or more halogen, which are the same or different.
  • C 7 to C 16 alkylaryl denotes a C 1 to C 6 alkyl group substituted at any position by a phenyl or naphthyl ring.
  • Examples of such a group include benzyl, 2-phenylethyl, 3-phenyl(n-propyl), 4-phenylhexyl, 3- phenyl(n-amyl), 3-phenyl(sec-butyl) and the like.
  • Preferred C 7 to C 16 phenylalkyl groups are the benzyl phenylethyl napth-1-ylmethyl and napth-2-ylmethyl groups.
  • C 7 to C 16 substituted alkylaryl denotes a C 7 to C 16 alkylaryl group substituted on the C 1 to C 6 alkyl portion with one or more, and preferably one or two, groups chosen from halogen, hydroxy, protected hydroxy, oxo, protected oxo, amino, protected amino, (monosubstituted) amino, protected (monosubstituted) amino, (disubstituted) amino, guanidino, heterocyclic ring, substituted heterocyclic ring, C 1 to C 7 alkoxy, C 1 to C 7 acyl, C 1 to C 7 acyloxy, nitro, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C 1 to C 6 alkyl) carboxamide, protected N-C 1 to C 6 alkyl) carboxamide, N, N-( C i to C 6 dialkyl) carboxamide, cyano, N-((C 1 to C 1 to C
  • substituted alkyl or phenyl groups may be substituted with one or more, and preferably one or two, substituents which can be the same or different.
  • C 7 to C 16 substituted alkylaryl include groups such as 2-phenyl-1-chloroethyl, 2-(4-methoxyphenyl)ethyl, 4-(2,6-dihydroxy phenyl)n- hexyl, 2-(5-cyano-3-methoxyphenyl)n-pentyl, 3-(2,6- dimethylphenyl) n-propyl, 4-chloro-3-aminobenzyl, 6-(4- methoxyphenyl)-3-carboxy (n-hexyl), 5-(4- aminomethylphenyl)-3-(aminomethyl) n-pentyl, 5-phenyl-3- oxo-n-pent-1-yl, (4-hydroxynapth-2-yl)methyl and the like.
  • (monosubstituted) amino refers to an amino group with one substituent chosen from the group consisting of phenyl, substituted phenyl, C 1 to C 6 alkyl, C 1 to C 6 substituted alkyl, C 1 to C 7 acyl, C 2 to C 7 alkenyl, C 2 to C 7 substituted alkenyl, C 2 to C 7 alkynyl, C 7 to C 16 alkylaryl, C 7 to C 16 substituted alkylaryl and
  • the (monosubstituted) amino can additionally have an amino-protecting group as
  • (disubstituted) amino refers to amino groups with two substituents chosen from the group
  • phenyl substituted phenyl, C 1 to C 6 alkyl, C 1 to C 6 substituted alkyl, C 1 to C 7 acyl, C 2 to C 7 alkenyl, C 2 to C 7 alkynyl, C 7 to C 16 alkylaryl, C 7 to C 16 substituted alkylaryl and heterocyclic ring.
  • the two substituents can be the same or different.
  • pharmaceutically-acceptable salt encompasses those salts that form with the carboxylate anions and includes salts formed with the organic and inorganic cations such as those chosen from the alkali and alkaline earth metals, (for example, lithium, sodium, potassium, magnesium, barium and calcium); ammonium; and the organic cations (for example, dibenzylammonium, benzylammonium, 2-hydroxyethylammonium,
  • procaine protonated form of procaine, quinine and N-methylglucosamine
  • protonated forms of basic amino acids such as glycine, ornithine, histidine, phenylglycine, lysine, and arginine
  • acetic acid-like counter-ions such as acetate and trifluoroacetate .
  • carboxylate anion compounds formed by a carboxylic acid and an amino group is referred to by this term.
  • a preferred cation for the carboxylate anion is the sodium cation.
  • the term includes salts that form by standard acid-base reactions with basic groups (such as amino groups) and organic or inorganic acids. Such acids include
  • the compounds of Formula I may also exist as solvates and hydrates. Thus, these compounds may
  • carboxy-protecting group refers to one of the ester derivatives of the carboxylic acid group commonly employed to block or protect the carboxylic acid group while reactions are carried out on other functional groups on the compound.
  • carboxylic acid protecting groups include t-butyl, 4-nitrobenzyl, 4-methoxybenzyl, 3,4- dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,4,6- trimethoxybenzyl, 2,4,6-trimethylbenzyl,
  • hydroxy-protecting group refers to readily cleavable groups bonded to hydroxyl groups, such as the tetrahydropyranyl, 2-methoxyprop-2-yl,
  • a preferred hydroxy-protecting group is the tert- butyl group.
  • protected hydroxy denotes a hydroxy group bonded to one of the above hydroxy protecting groups.
  • amino-protecting group refers to substituents of the amino group commonly employed to block or protect the amino functionality while reacting other functional groups of the molecule.
  • protected (monosubstituted) amino means there is an amino-protecting group on the monosubstituted amino nitrogen atom.
  • protected amino-protecting group means there is an amino-protecting group on the monosubstituted amino nitrogen atom.
  • carboxamide means there is an amino-protecting group on the carboxamide nitrogen.
  • amino-protecting groups include the formyl ("For") group, the trityl group, the phthalimido group, the trichloroacetyl group, the trifluoro-acetyl group, the chloroacetyl, bromoacetyl, and iodoacetyl groups, urethane-type blocking groups, such as t-butoxycarbonyl ("Boc”), 2-(4-biphenylyl)propyl- 2-oxycarbonyl ("Bpoc”), 2-phenylpropyl-2-oxycarbonyl (“Poc”), 2- (4-xenyl) isopropoxycarbonyl, 1,1- diphenylethyl-1-oxycarbonyl, 1,1-diphenylpropyl-1- oxycarbonyl, 2-(3,5-dimethoxyphenyl)propyl-2-oxycarbonyl (“Ddz”), 2-(p-1oluyl)propyl-2-oxycarbonyl,
  • benzyloxycarbonyl (“Cbz”), 4-phenylbenzyloxycarbonyl, 2-methylbenzyloxy-carbonyl, ⁇ -2,4,5,- tetramethylbenzyloxycarbonyl (“Tmz”),
  • PMC 2,2,5,7,8-pentamethylchroman-6-sulfonyl group
  • Dts dithiasuccinoyl
  • Nps 2-(nitro)phenylsulfenyl group
  • diphenyl-phosphine oxide group and like amino-protecting groups.
  • the species of amino- protecting group employed is not critical so long as the derivatized amino group is stable to the conditions of the subsequent reaction (s) and can be removed at the appropriate point without disrupting the remainder of the compounds.
  • Preferred amino-protecting groups are Boc, Cbz and Fmoc.
  • Further examples of amino-protecting groups embraced by the above term are well known in organic synthesis and the peptide art and are described by, for example, T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis," 2nd ed., John Wiley and Sons, New York, NY, 1991, Chapter 7, M. Bodanzsky,
  • heterocycle denotes optionally substituted five-membered or six-membered rings that have 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms. These five-membered or six-membered rings may be saturated, fully unsaturated or partially unsaturated, with fully saturated rings being preferred.
  • An "amino-substituted heterocyclic ring” means any one of the above-described heterocyclic rings is substituted with at least one amino group.
  • Preferred heterocyclic rings include morpholino, piperidinyl, piperazinyl, tetrahydrofurano, pyrrolo, and tetrahydrothiophenyl.
  • the above optionally substituted five-membered or six-membered rings can optionally be fused to an aromatic 5-membered or 6-membered ring system, such as a pyridine or a triazole system, and preferably to a benzene ring.
  • an aromatic 5-membered or 6-membered ring system such as a pyridine or a triazole system, and preferably to a benzene ring.
  • heterocyclic ring thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl,
  • thiadiazolyl oxadiazolyl, tetrazolyl, thiatriazolyl, oxatriazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thiazinyl, oxazinyl, triazinyl, thiadiazinyl,
  • oxadiazinyl dithiazinyl, dioxazinyl, oxathiazinyl, tetrazinyl, thiatriazinyl, oxatriazinyl, dithiadiazinyl, imidazolinyl, dihydropyrimidyl, tetrahydropyrimidyl, tetrazolo[1,5-b]pyridazinyl and purinyl, as well as benzo-fused derivatives, for example benzoxazolyl, benzthiazolyl, benzimidazolyl and indolyl. Further specific examples of the above
  • heterocyclic ring systems are 6-membered ring systems containing one to three nitrogen atoms.
  • Such examples include pyridyl, such as pyrid-2-yl, pyrid-3-yl and pyrid-4-yl; pyrimidyl, preferably pyrimid-2-yl and pyrimid-4-yl; triazinyl, preferably 1,3,4-triazin-2-yl and 1,3,5-triazin-4-yl; pyridazinyl, in particular pyridazin-3-yl, and pyrazinyl.
  • pyridine N-oxides and pyridazine N-oxides are a preferred group.
  • heterocyclic ring are included in the heterocyclic thiomethyl groups listed under heading "A”.
  • C 6 to C 15 alkyl heterocycle denotes a C 1 to C 6 alkyl group substituted at any position by a heterocycle ring (heterocycle) from as described above, said heterocycle containing up to 14 carbon atoms, as long as sum of the carbon atoms of the alkyl chain (up to 6) and the carbon atoms of the heterocycle do not exceed 15.
  • substituted C 6 to C 1S alkyl heterocycle refer to a C 6 to C 15 alkyl heterocycle group substituted on the alkyl portion with the same substituents as listed for the C 7 to C 16 substituted alkylaryl groups and on the heterocycle as defined above for substituted heterocyle.
  • a preferred group of single compounds are the interior amido compounds, that is, wherein X and Y are taken together to form a carbonyl moiety.
  • interior amido single compounds are the dimers, thus, wherein B, AA, BB and CC are zero, except that AA can be zero or one when R 7 is a hydrogen atom and that CC can be zero or one when R 3 is a hydrogen atom.
  • a preferred group of interior amido dimers are those that are cleaved from the solid support and are not quaternized, thus, wherein R 9 is a hydrogen atom and R 10 is absent.
  • a preferred group of cleaved interior amido dimer single compounds are those wherein R 3 and R 7 are independently chosen from the group consiting of S- or R-methyl, S- or R-benzyl, a hydrogen atom, S- or R- (but-2-yl), S- or R-[ 4-(N-methylamino)-n-butyl], S- or R-[4-(N-ethylamino)-n-butyl], S- or R-[4-(N-allylamino)- n-butyl], S- or R-[4-(N-benzylamino)-n-butyl], S- or R- [4-(N-(napth-2-ylmethylamino)-n-butyl], S- or R- [4- (amino)-n-butyl], S- or R-[sec-butyl], S- or R- (methylsulfinyl) eth-1-yl, S- or R-
  • Type I amido dimers compounds referred to as cleaved interior amido dimers, hereafter referred to as the "Type I" amido dimers, is wherein R 6 and R 8 are independently methyl, ethyl, allyl, benzyl, or napth-2-ylmethyl.
  • a preferred group of "Type I" amido dimers are the “Type II” amido dimers, thus, wherein either R 1 or R 2 are each a hydrogen atom, or one of R 1 or R 2 is a hydrogen atom and the other is taken together with R 3 to form an S-pyrrolidine ring.
  • a preferred group of the Type II interior amido dimers is the N-terminal monomer as a proline residue, thus, wherein one of R 1 or R 2 is a hydrogen atom and the other is taken together with R 3 to form an S-pyrrolidine ring.
  • a preferred group of N-terminal proline Type II interior amido dimers occurs when R 6 is napth-2-ylmethyl and R 8 is benzyl, and more so when R 7 is S- or R-methyl, a hydrogen atom, S- or R-[3-(guanidino)-n-propyl], S- or R-[4-(N- benzylamino)-n-butyl], S-[iso-propyl], S-[2- (methylsulfinyl)ethyl], S- or R-(n-propyl), S- or R- (hydroxymethyl), S- or R-[n-butyl], R-[(napth-2- yl) methyl], or S-phenyl, and especially so when the C- terminal residue is S- or R-alanine, thus, R 7 is a S- or R-methyl.
  • Another preferred group of Type II interior amido dimers has the N-terminal residue as a
  • R 6 is ethyl and R 8 is (napth-2-yl)methyl, and especially so when R 7 is S- methyl, S-(2-(methylsulfinyl) ethyl), a hydrogen atom, S- (4-(hydroxy)benzyl) or S-[(hydroxy)methyl].
  • R 7 is S-methyl.
  • Type I interior amido dimers are wherein R 1 and R 2 are each a hydrogen atom and R 3 is R-[(N-(napth-2-ylmethyl)indol-3-yl)methyl].
  • R 6 is napth-2-ylmethyl and R 8 is benzyl, and especially so when R 7 is S- or R-[3-(guanidino)-n-propyl] or S- or R- [4-(benzylamino)-n-butyl].
  • Type I interior amido dimers occurs wherein either R 1 or R 2 is a hydrogen atom or is taken in conjunction with R 3 to form a
  • pyrrolidine ring and the other is C 1 to C 12 acyl, C 3 to C 10 cycloalkyl, C 3 to C 6 heterocycle, C 1 to C 12 alkyl, C 1 to C 12 substituted alkyl, C 7 to C 16 alkylaryl, C 7 to C 16 substitued alkylaryl, a C 6 to C 15 alkyl heterocycle, or a substituted C 6 to C 15 alkyl heterocycle.
  • Another preferred group of compounds of the above Formula I wherein a single compound is indicated is the interior amine compounds, in other words, wherein X and Y are each a hydrogen atom.
  • a preferred group of these interior amine compounds is dimers, wherein B, AA, BB and CC are zero, except that AA can be zero or one when R 7 is a hydrogen atom and that CC can be zero or one when R 3 is a hydrogen atom.
  • a preferred group of interior amine dimers is those cleaved from the solid support, thus, wherein R 9 is a hydrogen atom and R 10 is absent.
  • a preferred group of cleaved interior amine dimers is those wherein R 6 and R 8 are independently methyl, benzyl or 4-hydroxybenzyl.
  • a preferred group of these preferred cleaved interior dimers are referred to
  • Type I cleaved interior amine dimers that is, wherein R 3 and R 7 are independently benzyl or 4- hydroxybenzyl.
  • a preferred group of the Type I cleaved interior amine dimers are those wherein R 8 is benzyl, R 7 is 4-hydroxybenzyl, R 6 is methyl, and R 3 is 4-hydroxybenzyl.
  • Type I compounds are wherein a) R 1 and R 2 are the same and are methyl or a hydrogen atom; b) either Rj or R 2 is a hydrogen atom and the other is chosen from the group consisting of methyl, iso- propyl, cyclopropylmethyl, 4-hydroxymethyl, N- methylpiperidin-4-yl, and 3-(N,N-dimethylamino)-2-methyl- prop-2-en-1-yl.
  • Type I cleaved interior amine dimers are wherein R 8 is methyl, R 7 is benzyl, R 6 is 4-hydroxybenzyl, and R 3 is 4- hydroxybenzyl, and especially so wherein R 1 and R 2 are the same and are either a hydrogen atom or methyl, or one of R 1 or R 2 is a hydrogen atom and the other is methyl.
  • Type I cleaved interior amine dimers are wherein R 8 is methyl, R 7 is 4- hydroxymethyl, R 6 is benzyl, and R 3 is 4-hydroxybenzyl, and especially so wherein R 1 and R 2 are the same and are either a hydrogen atom or methyl, or one of R 1 or R 2 is a hydrogen atom and the other is methyl.
  • Another preferred class of compounds within the invention encompassed by Formula I is a library of an approximately equimolar mixture of two or more compounds.
  • a preferred group of this library of compounds are the interior amido compounds, thus, wherein X and Y are taken together to form a carbonyl group, and especially the interior amido dimers, wherein B, AA, BB and CC are zero, except that AA can be zero or one when R 7 is a hydrogen atom and that CC can be zero or one when R 3 is a hydrogen atom.
  • a preferred group of library of interior amido dimers are the resin-bound interior amido dimers, wherein R, is a solid support and R 10 is absent.
  • a preferred group of these resin bound dimers are wherein R 3 and R 7 are independently chosen from the group consisting of S- or R-methyl, S- or R-benzyl, a hydrogen atom, S- or R-(but- 2-yl), S- or R-[4-(t-butoxycarbonylamino)-n-butyl], S- or R-[sec-butyl], S- or R- (methylsulfinyl) eth-1-yl, S- or R-[ 3-(guanidino)-n-propyl], S- or R- [(N-PMO-3- (guanidino)-n-propyl], S- or R-(t-butyloxy) methyl, S- or R-[2-(t-butyloxy)ethy], S-phenyl, S- or R-[2-(
  • AA is one or zero when R 7 is a hydrogen atom
  • CC is one or zero when R 3 is a hydrogen atom
  • R 1 or R 2 are taken together with R 3 to form an S- or R- pyrrolidine or S-[4-(hydroxy)pyrrolidine].
  • a more preferred group of the library of resin- bound interior amido dimers referred to hereafter as the "Type I bound amido dimers (Library)" occurs wherein R 6 and R 8 are independently methyl, ethyl, allyl, benzyl, or napth-2-ylmethyl.
  • a preferred group of the Type I bound amido dimers is wherein either R 1 or R 2 is a hydrogen atom or is taken in conjunction with R 3 to form a pyrrolidine ring, and the other is C 1 to C 12 acyl, C 3 to C 10 cycloalkyl, C 3 to C 6 heterocycle, C 1 to C 12 alkyl, C 1 to C 12 substituted alkyl, C 7 to C 16 alkylaryl, C 7 to C 16 substitued alkylaryl, a C 6 to C 15 alkyl heterocycle, or a substituted C 6 to C 15 alkyl heterocycle.
  • Type I bound amido dimers (Library) is wherein either R 1 or R 2 are each a hydrogen atom, or one of R 1 or R 2 is a hydrogen atom and the other is taken together with R 3 to form an S- pyrrolidine ring.
  • R 9 is hydrogen and R 10 is absent.
  • a preferred group of cleaved interior amido dimers are wherein R 3 and R 7 are independently chosen from the group consisting of S- or R-methyl, S- or R- benzyl, a hydrogen atom, S- or R-(but-2-yl), S- or R-[ 4- (N-methylamino)-n-butyl], S- or R-[4-(N-ethylamino) -n- butyl], S- or R-[4-(N-allylamino)-n-butyl], S- or R-[4- (N-benzylamino)-n-butyl], S- or R-[4-(N-(napth-2- ylmethylamino)-n-butyl], S- or R-[ 4-(amino)-n-butyl], S- or R-[sec-butyl], S- or R-(methylsulfinyl)
  • a more preferred group of library of cleaved interior dimers hereinafter referred to as "Type I cleaved amido dimers", wherein R 6 and R 8 are independently methyl, ethyl, allyl, benzyl, or napth-2-ylmethyl.
  • R 1 and R 2 are the same and are each a hydrogen atom; (2) wherein R 6 is ethyl, R 3 is benzyl and R 1 and
  • R 2 are the same and are each a hydrogen atom
  • R 6 is naphth-2 -ylmethyl
  • R 3 is S- methyl
  • R 1 and R 2 are the same and are each a hydrogen atom
  • R 1 or R 2 is a hydrogen atom and the other is taken in conjunction with R 3 to form an S-pyrrolidine ring, and R 6 is napth-2-ylmethyl.
  • Another preferred group of compounds within the library of an approximately equimolar mixture of two or more compounds of Formula I are the interior amine compounds, thus, wherein in the above Formula I, X and Y are the same and are each a hydrogen atom.
  • a preferred library of interior amine compounds are those that are dimers, that is wherein B, AA, BB and CC are zero, except that AA can be zero or one when R 7 is a hydrogen atom and that CC can be zero or one when R 3 is a hydrogen atom.
  • Preferred interior amine dimers are those that have been cleaved from the solid support, wherein R 9 is a hydrogen atom and R 10 is absent.
  • a preferred group of such cleaved interior amine dimers are wherein R 3 and R 7 are independently chosen from the group consisting of S- or R-methyl, S- or R-benzyl, a hydrogen atom, S- or R- (but-2-yl), S- or R-[4-(N-methylamino)-n-butyl], S- or R- [4-(N-ethylamino)-n-butyl], S- or R-[4-(N-allylamino)-n- butyl], S- or R-[4-(N-benzylamino)-n-butyl], S- or R-[4- (N-(napth-2-ylmethylamino)-n-butyl], S- or R-[4-(amino)- n-butyl
  • AA is zero or one when R 7 is a hydrogen atom
  • CC is zero or one when R 3 is a hydrogen atom
  • S- or R-thiomethyl or when either R 1 or R 2 are taken together with R 3 to form an S- or R- pyrrolidine or S-[4-(hydroxy)pyrrolidine].
  • R fi and R 8 are independently methyl, ethyl, allyl, benzyl, or napth-2-ylmethyl.
  • Another preferred group within the library of interior amine dimers are the resin-bound compounds, thus, wherein R 9 is a solid support and R 10 is absent.
  • R 6 and R 8 are independently methyl, ethyl, allyl, benzyl, or napth-2-ylmethyl.
  • a preferred method of effecting analgesia in a mammal occurs when a single compound that is an interior amido dimer and further wherein B, AA, BB and CC are zero, R 9 is a hydrogen atom, R 8 is napth-2-ylmethyl, R 7 is S-methyl, R 6 is ethyl, R 3 is S-benzyl, and R 1 and R 2 are each a hydrogen atom is used.
  • Another preferred method of effecting analgesia in mammals utilizes a single interior amine dimer wherein further R 9 is a hydrogen atom, R 8 is benzyl, R 7 is S-methyl, R 6 is naphth-2-ylmethyl, R 3 is taken in conjunction with either R 1 or R 2 to form an S-pyrrolidine ring and the other of R 1 and R 2 a hydrogen atom.
  • a preferred method of affecting a decrease in the postprandial rise in the blood glucose of a mammal occurs wherein the single compound has X and Y taken together to form a carbonyl group, B, AA, BB and CC are zero, R 9 is a hydrogen atom, R 8 is benzyl, R 6 is naphth-2-ylmethyl, R 3 is R-(N-(naphth-2-ylmethyl)indol-3- ylmethyl), R 1 and R 2 are each hydrogen, R 10 is absent, and R 7 is chosen from the group consisting of S- (4- (N- benzylamino)-n-butyl), R-(4-(N-benzylamino)-n-butyl), S-(3-guanidino)-n-propyl), and R-(3-guanidino)-n-propyl;
  • Yet another aspect of the instant invention is a method of treating microbial infections in mammals, which comprises administering an effective amount of a single compound of Formula I in conjunction with a pharmaceutically-acceptable carrier.
  • a preferred method of treating microbial infections in mammals occurs when wherein the single compound has X and Y taken together to form a carbonyl group, B, AA, BB and CC are zero, R 9 is a hydrogen atom, R 8 is benzyl, R 6 is naphth-2-ylmethyl, R 3 is R-(N-(naphth-2-ylmethyl)indol-3-ylmethyl), R 1 and R 2 are each hydrogen, R 10 is absent, and R 7 is chosen from the group consisting of S-(4-(N-benzylamino)-n-butyl), R- (4-(N-benzylamino)-n-butyl), S-(3-guanidino)-n-propyl), and R-(3-guanidino)-n-prop
  • Another aspect of the instant invention is a method of step-wise N-alkylation of the amide bond of the N-terminal residue of a compound of the Formula (II) :
  • R 11 is independently a hydrogen atom, C 1 to C 12 alkyl, C 1 to C 12 substituted alkyl, phenyl, substituted phenyl, C 7 to C 16 alkylaryl, C 7 to C 16 substitued alkylaryl, a C 6 to C 15 alkyl heterocycleal, or a substituted C 6 to C 15 alkyl heterocycle;
  • ZZ is from zero to five
  • R 12 is a solid support or a group of the Formula (III):
  • R 14 is a C 1 to C 18 substituent group
  • W is 0 to 4.
  • R 13 is independently a hydrogen atom, C 1 to C 12 alkyl, C 1 to C 12 substituted alkyl, phenyl, substituted phenyl, C 7 to C 16 alkylaryl, C 7 to C 16 substitued alkylaryl, a C 6 to C 15 alkyl heterocycle, or a substituted C 6 to C 15 alkyl heterocycle;
  • R 15 is a solid support (when W is one) or a bond to the preceeding methylene group (when W is from two to four);
  • YY is from zero to five
  • the compound of the above formula is a) first reacted under anhydrous conditions in an inert atmosphere with an excess amount non-nucleophilic base having a pKa between about 18 to about 40; then
  • LG is leaving group
  • Q is a C 1 to C 18 substituent groups as defined above for Formula (I); and repeating steps a) and b) as necessary to drive the alkylation to completion; with the proviso that all previous internal backbone amide bonds have been previously alkylated with a C 1 to C 18 substituent group and, when W is from 2 to 4, all of the R 14 groups are not the same C 1 to C 18
  • a preferred method of step-wise N-alkylation occurs when LG is iodo or bromo and the -CH 2 -Q moiety is methyl, ethyl, allyl, benzyl or napth-2 -ylmethyl.
  • R n and R 13 are indepently chosen from the group consisting of S- or R-methyl, S- or R-benzyl, a hydrogen atom, S- or R-(but-2-yl), S- or R-[4-(t- butoxycarbonylamino)-n-butyl], S- or R-[4-(amino)-n-butyl], S- or R-[sec-butyl], S- or R-(methylsulfinyl)eth- 1-yl, S- or R-[ 3-(guanidino)-n-propyl], S- or R-[(N- PMC)-3-(guanidino)-n-propyl], S- or R-(t-butoxy)methyl, S- or R-[2-(t-butoxy)ethy], S-phenyl, S- or R-(3-(2- butoxycarbonyl)ethyl), S- or
  • R 19 , R 21 and R 23 independently are a hydrogen atom, C 1 to C 12 alkyl, C 1 to C 12 substituted alkyl, phenyl, substituted phenyl, C 7 to C 16 alkylaryl, C 7 to C 16
  • alkylaryl a C 6 to C 15 alkyl heterocycle, or a substituted C 6 to C 15 alkyl heterocycle
  • R 25 is a hydrogen atom or a solid support
  • R 20 , R 22 and R 24 are independently a C 1 to C16 substituent group
  • AA, BB and CC are independently 0 to 5;
  • B is from 0 to 3;
  • X and Y are taken together to form a carbonyl group or are separate and are each a hydrogen atom;
  • R 16 , R 17 and R 18 independently are a hydrogen atom, an amino protecting group, C 1 to C 12 acyl, C 3 to C 10 cycloalkyl, C 3 to C 6 heterocycle, C 1 to C 12 alkyl, C 1 to C 12 substituted alkyl, C 7 to C 16 alkylaryl, C 7 to C 16 substitued alkylaryl, a C 6 to C 15 alkyl heterocycle, or a substituted C 6 to C 15 alkyl heterocycle;
  • R 16 is optionally present as a C 1 to C 18 substituent group when R 1 and R 2 are other than a hydrogen atom or an amino protecting group;
  • said library of compounds is composed of SL physically separate sublibraries; wherein SL is equal to (2B + 4);
  • each sublibrary is composed of physically separate mixtures, wherein the number of said mixtures is equal to the number of different substituents incorporated at R fix , which R fix can be any one of R 19 , R 20 , R 21 , R 22 , R 23 , or R 24 in the above Formula IV;
  • step (c) Dividing the mixed solid support from step (a) into approximately equal separate portions in a number equal to the number of different substituents to be incorporated at R 24 by alkylation, alkylating each physically separate solid support mixtures with one alkyl group, then mixing said resins;
  • step (g) Dividing the mixture of solid support portions from either step (c), (e), or step (f) into approximately equal separate portions equal to the number of substituents to be placed at R 19 , coupling one such monomer containing a single R 19 to each physically
  • step (h) Dividing the mixture of portions from step (g) into a number of approximately equal separate portions, said number equal to the number of alkyl substituents at R 22 to be utilized, alkylating each said separate portion with a single alkyl group R 22 ;
  • each coupling step in the above series of steps ( (b), (d), (f) and (g) ) involves a substrate of the Formula (V) :
  • SS is a solid support
  • R 26 are two hydrogen atoms each bound to the nitrogen atom
  • R 28 is a C 1 to C 18 substituent group
  • R 27 is independently a hydrogen atom, C 1 to C 12 alkyl, C 1 to C 12 substituted alkyl, phenyl, substituted phenyl, C 7 to C 16 alkylaryl, C 7 to C 16 substitued alkylaryl, a C 6 to C 15 alkyl heterocycle, or a substituted C 6 to C 15 alkyl heterocycle;
  • R VAR can be the same or different as R 27 and is chosen from the same group of substituents as R 27 ;
  • DD and EE are independently 0 to 5 ;
  • X and Y are either taken together to form a carbonyl oxygen
  • PG is an amino protecting group other than trityl
  • A is a group, when taken with the preceeding carbonyl group; that forms an active acylating agent;
  • C is from 0 to 4.
  • LG is a leaving group under the conditions of the alkylation
  • Q is a C 1 to C 18 substituent group as defined above in Formula (I);
  • FF is 0 to 5;
  • R 31 is a hydrogen atom when R 29 is a trityl group or is a C 1 to C 18 substituent group;
  • R 30 is independently a hydrogen atom, C 1 to C 12 alkyl, C 1 to C 12 substituted alkyl, phenyl, substituted phenyl, C 7 to C 16 alkylaryl, C 7 to C 16 substitued alkylaryl, a C 6 to C 15 alkyl heterocycle, or a substituted C 6 to C 15 alkyl heterocycle; and
  • R 29 is a trityl group when R 31 is a hydrogen atom or is a group of the Formula (IX) :
  • X and Y are as X and Y above;
  • GG is 0 to 5;
  • C is from 1 to 4;
  • R 33 is independently a hydrogen atom, C 1 to C 12 alkyl, C 1 to C 12 substituted alkyl, phenyl, substituted phenyl, C 7 to C 16 alkylaryl, C 7 to C 16 substitued alkylaryl, a C 6 to C 15 alkyl heterocycle, or a substituted C 6 to C 15 alkyl heterocycle; and R 32 is a hydrogen atom if R 32 is bonded to the N- terminal amino group or otherwise it is a C 1 to C 18 substituent wherein one such C 1 to C 18 substituent differs from the other substituents; (3) Reductive alkylation of the N- terminal nitrogen group as described above in step (i) of a compound of the Formula (X) :
  • HH, II, and JJ are independently 0 to 5;
  • B is from 0 to 3;
  • R 39 , R 41 and R 37 are the same or different and are chosen from the group consisting of independently a hydrogen atom, C 1 to C 12 alkyl, C 1 to C 12 substituted alkyl, phenyl, substituted phenyl, C 7 to C 16 alkylaryl, C 7 to C 16 substitued alkylaryl, a C 6 to C 15 alkyl heterocycle, or a substituted C 6 to C 15 alkyl heterocycle;
  • R 40 and R 42 are different and are a C 1 to C 18 substituent group
  • R 34 or R 35 when B is 0, is optionally one or two hydrogen atoms attached to the nitrogen atom, or is a optionally one or more, same or different groups, chosen from the group consisting of a hydrogen atom, an amino protecting group, C 1 to C 12 acyl, C 3 to C 10 cycloalkyl, C 3 to C 6 heterocycle, C 1 to C 12 alkyl, C 1 to C 12 substituted alkyl, C 7 to C 16 alkylaryl, C 7 to C 16 substituted alkylaryl, a C 6 to C 15 alkyl heterocycle, or a substituted C 6 to C 15 alkyl heterocycle;
  • R 36 is a hydrogen or a bond to a R 34 or R 35 before the reduction occurs, and when B is from 1 to 3;
  • R 38 is a C 1 to C l ⁇ substituent group different from at least one other R 40 , R 42 or R 38 groups;
  • Yet another aspect of the invention is an iterative synthetic approach wherein the method for the iterative synthesis and screening of a library of an approximately equimolar amount of compounds of the
  • R 48 is a hydrogen atom or a solid support
  • R 45 and R 47 are different and are each a C 1 to C 18 substituent group; KK and LL are independently 0 to 5; R 44 and R 46 are independently chosen from the group consisting of independently a hydrogen atom, C 1 to C 12 alkyl, C 1 to C 12 substituted alkyl, phenyl, substituted phenyl, C 7 to C 16 alkylaryl, C 7 to C 16 substitued alkylaryl, a C 6 to C 15 alkyl heterocycle, or a substituted C 6 to C 15 alkyl heterocycle;
  • R 43 is one or two hydrogen atoms, or groups of the formula R a, R b and R c , wherein R a and R b independently are a hydrogen atom, an amino protecting group, C 1 to C 12 acyl, C 3 to C 10 cycloalkyl, C 3 to C 6 heterocycle, C 1 to C 12 alkyl, C 1 to C 12 substituted alkyl, C 7 to C 16 alkylaryl, C 7 to C 16 substitued alkylaryl, a C 6 to C 15 alkyl heterocycle, or a substituted C 6 to C 15 alkyl heterocycle; R c is
  • R a and R b are other than a hydrogen atom or an amino
  • step (m) Coupling the monomer containing the most active R 44 substituent to each of the separate portions of resin from step (1); (n) Alkylating each of the portions from step (m) with the best alkyl group at R 45 determined in step (k);
  • step (q) Alkylating each separate resin portion from step (p) with an alkylating agent placing the best alkyl group at R 47 as such alkyl group was determined in step (o);
  • step (r) Coupling to each separate portion of resin the monomer containing the best R 44 substituent as such substituent was determined in step (k); (s) Alkylating each separate portion of resin with a group that was the best alkyl group R 45 as such group determined in step (k);
  • each of the above coupling steps (b), (h), (1), (m), (p) or (r), involves a substrate of the Formula (XII) :
  • SS is a solid support
  • R 49 is two hydrogen atoms
  • R 51 is a C 1 to C 18 substituent group
  • R 50 is independently a hydrogen atom, C 1 to C 12 alkyl, C 1 to C 12 substituted alkyl, phenyl, substituted phenyl, C 7 to C 16 alkylaryl, C 7 to C 16 substitued alkylaryl, a C 6 to C 15 alkyl heterocycle, or a substituted C 6 to C 15 alkyl heterocycle;
  • R VAR2 can be the same or different as R 50 and is chosen from the same group of substituents as R 50 ;
  • MM and NN are independently 0 to 5;
  • X and Y are either taken together to form a carbonyl group or are separate and are each a hydrogen atom;
  • PG is an amino protecting group other than trityl
  • A is a group, when taken with the preceeding carbonyl group; that forms an active acylating agent; and C is 0 or 1;
  • LG is a leaving group under the conditions of the alkylation;
  • Q is a C 1 to C 18 substituent group;
  • 00 is 0 to 5;
  • X and Y are taken together to form a carbonyl group; or are separate and are each a hydrogen atom;
  • R 54 is a hydrogen atom if R 52 is a trityl group or is a C 1 to C 18 substituent group;
  • R 53 is independently a hydrogen atom, C 1 to C 12 alkyl, C 1 to C 12 substituted alkyl, phenyl, substituted phenyl, C 7 to C 16 alkylaryl, C 7 to C 16 substitued alkylaryl, a C 6 to C 15 alkyl heterocycle, or a substituted C 6 to C 15 alkyl heterocycle;
  • R 52 is a trityl group if R 54 is a hydrogen atom or is a group of the Formula (XVI) :
  • X and Y are as X and Y above;
  • PP is 0 to 5;
  • R 55 is a trityl group
  • R 56 is independently a hydrogen atom, C 1 to C 12 alkyl, C 1 to C 12 substituted alkyl, phenyl, substituted phenyl, C 7 to C 16 alkylaryl, C 7 to C 16 substitued alkylaryl, a C 6 to C 15 alkyl heterocycle, or a substituted C 6 to C 15 alkyl heterocycle; and
  • QQ and RR are independently 0 to 5;
  • R 58 and R 60 are the same or different and are chosen from the group consisting of independently of a hydrogen atom, C 1 to C 12 alkyl, C 1 to C 12 substituted alkyl, phenyl, substituted phenyl, C 7 to C 16 alkylaryl, C 7 to C 16 substitued alkylaryl, a C 6 to C 15 alkyl heterocycle, or a substituted C 6 to C 15 alkyl heterocycle;
  • R 59 and R 61 are the same or different and are a C 1 to C 18 substituent group;
  • R 57 is either two hydrogen atoms attached to the nitrogen atom, or is a single hydrogen atom and another group bonded to the nitrogen atom which groups is selected from the group consisting of a hydrogen atom, an amino protecting group, C 1 to C 12 acyl, C 3 to C 10
  • cycloalkyl C 3 to C 6 heterocycle, C 1 to C 12 alkyl, C 1 to C 12 substituted alkyl, C 7 to C 16 alkylaryl, C 7 to C 16 substitued alkylaryl, a C 6 to C 15 alkyl heterocycle, or a substituted C 6 to C 15 alkyl heterocycle;
  • substitutent at R 1 , R 2 and R 10 would be separate variables that could be synthesized and screened by the above iterative method. Due to their location in the molecule, these substituents, if present, would be screened to find the best substituent before the N-terminal monomer and the attendant N-alkyl group could be determined.
  • variable substituents and the optimum substituents at the remaining positions could be determined by the positional scanning approach.
  • the N-terminal nitrogen can be reductively alkylated and quarternized and the
  • R 4 and R 5 do not have to be the same as the other R 4 and R 5 groups present in the molecule. Cleavage from the solid support led to peptidomimetics of the Formula I (wherein R 9 is hydrogen, each having diversity positions at the amino acid side chain positions (R 3 , R 5 and R 7 ), at the amide alkyl groups (R 4 , R 6 , R 8 ), and at the N-terminal groups (R 1 , R 2 and R 10 ).
  • lithium t-butoxide was found to be more effective for the successive formation of the amide anions.
  • Reaction "i” represents the coupling of the C-terminus of peptide-like residue to an amino-derivatized solid support.
  • an peptide-like residue with amino terminus protected by a base or weak-acid labile protecting group, such as Fmoc is converted to a good acylating agent in situ using known reagents and conditions.
  • reagents include carbodiimide reagents (eg. N,N'-dicyclohexylcarbodiimide (DCC) and N,N'-diiso-propylcarbodiimide in conjunction with 1-hydroxybenzotriazole) in an aprotic, polar solvent such as DMF.
  • LG is a good leaving group under the S n 2
  • reaction labelled “iv” in Scheme 1 is a repeat of the selective N- alkylation procedure, including the preliminary N- protection steps, of reaction "ii”.
  • Reaction "v” shows the removal of the trityl group from the amino-terminus of the bound residue as before followed by the removal of the selectively-N-alkylated molecule from the amino- derivatized residue with hydrogen fluoride.
  • the free amino terminus can be acylated with a C 1 to C 12 acyl group, using well-known conditions as described in Staftková, M., et al., Drug Development Research, 33:146 (1994) (herein incorporated by reference). It is preferable, however, to add the R 10 (alkyl) substituent before reductive alkylation. Such an alkylation proceeds under the same alkylation conditions used for the R 4 , R 6 , and R 8 groups. Finally, while still resin-bound, or after cleavage from the resin, the interior amide groups can be reduced (i.e.
  • X and Y taken together form a carbonyl group to X and Y are each a hydrogen atom.
  • Such a reduction is known in the art (see, for instance, Dooley, C.T., et al., Analgesia, INRC Proceedings, 1:400 (1995)).
  • R 9 is a hydrogen atom or a solid (resin)
  • mild, soluble hydrogenation catalysts such as a boric acid/trimethylborate/borane-tetrahydrofuran combination can be used.
  • Trt-O-Leu-MBHA resin p-methylbenzhydrylamine
  • Methyl iodide, allyl bromide and benzyl bromide were used initially as alkylating agents.
  • the individual crude alkylated products were analyzed by RP-HPLC and matrix assisted laser desorption ionization-mass spectroscopy (MALDI-MS) to determine their purity and identity.
  • MALDI-MS matrix assisted laser desorption ionization-mass spectroscopy
  • the amide alkyl groups in the second X (R 8 ) and second 0 positions (R 6 ) were: methyl, ethyl, allyl, benzyl or naphthylmethyl.
  • combinatorial library consists of 250 mixtures (50 amino acids x 5 alkyl groups), each of which is composed of 230 compounds (46 amino acids x 5 alkyl groups), and was prepared applying the divide, couple and recombine process, also independently reported as the "mixing and portioning” and "split synthesis” approaches (Lam, K.S., et al., Nature, 354:82 (1991); Furka, A., et al., Int. J.
  • control resins were prepared having the formula Trt-Phe-Leu-NHMe-MBHA and Trt-Ala-Trp-NHMe-MBHA. These control resins were permethylated at the first amide position to determine the completeness of the second alkylation. Following trityl removal, starting material was not detected by RP-HPLC or MALDI-MS for any of the five crude alkylation control products.
  • the highly acid labile amide linkage between the peptidomimetic and the MBHA resin linker does not permit the acid labile side chain protecting groups to be removed prior to final cleavage from the resin.
  • the mixtures were cleaved from the resin under standard high hydrogen fluoride cleavage conditions (Houghten, R.A., et al., Int. J. Pept. Protein Res., 27:673 (1986)) and obtained as lyophilized powders following extraction with 50% aqueous
  • the nonsupport-bound library mixtures were screened in solution in radio-receptor, antimicrobial and enzyme inhibition assays. Deconvolution of the highly active mixtures was carried out by both iterative and positional scanning methods. The iterative method is set forth in Dooley, et al., Science, 266:2019-2022 (1994) and the positional scanning method is set forth in U.S. Patent Application Serial No. 07/943,709, herein
  • the instant invention is directed to screening sublibraries of the selectively N-alkylated componds of Formula I wherein each sublibrary has an R group defined, and all other R groups are synthesized with the desired subtstituents, and defining each single variable in a similar grouping of sublibrairies and screening for biological activity, until all such
  • variable positions have been defined and screened for the desired activity.
  • One skilled in the art would realize that this approach could also be applied in the situation wherein each sublibrary has to R groups defined, using a modification of the above techniques.
  • the reduction of the interior amide of the compounds of Formula I is another means for the chemical transformation of such compounds which adds stability and can enhance activity.
  • a number of reagents are
  • Diborane has the advantage that
  • a newly synthesized compound can be purified using a method such as reverse phase high performance liquid chromatography (RP-HPLC) or other methods of separation based on the size or charge of the compound. Furthermore, the purified compound can be characterized using these and other well known methods such as amino acid analysis and mass spectrometry.
  • RP-HPLC reverse phase high performance liquid chromatography
  • the compounds can be assayed for receptor binding activity using the radioreceptor assay (Examples III and IV) or other assays outlined below, including the glycosidase assay (Example V).
  • the compounds of the present invention can be used in in vitro assays to study the opiate receptor subtypes.
  • a detectable marker such as a radioisotope
  • the compounds after being labeled with a detectable marker such as a radioisotope, can be contacted with the receptor sample under conditions which specifically favor binding to a particular receptor subtype. Unbound receptor and compound can be removed, for example, by washing with a saline solution, and bound receptor can then be detected using methods well known to those skilled in the art. Therefore, the compounds of the present invention are useful in vitro for the diagnosis of relevant opioid receptor subtypes, and in particular the ⁇ type, in brain and other tissue samples.
  • the compounds are also useful in vivo.
  • certain of the instant compounds can be used in vivo diagnostically to localize opioid receptor subtypes.
  • the compounds are also useful as drugs to treat pathologies associated with other compounds which interact with the opioid receptor system. It can be envisioned that these compounds can be used for
  • morphine is a centrally acting pain killer.
  • Morphine has a number of deleterious effects in the periphery which are not required for the desired analgesic effects, such as constipation and pruritus (itching). While it is known that the many peptides do not readily cross the blood- brain barrier and, therefore, elicit no central effect, the subject peptides can have value in blocking the periphery effects of morphine, such as constipation and pruritus.
  • compositions comprising the compounds of Formula I in a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents.
  • compositions will, in general, contain an effective amount of the active reagent
  • compositions can take the form of tablets, pills, capsules, powders, enterically coated or other protected formulations (such as by binding on ion exchange resins or other carriers, or packaging in lipid protein vesicles or adding
  • sustained release formulations e.g. ophthalmic drops
  • solutions e.g. ophthalmic drops
  • suspensions elixirs, aerosols, and the like.
  • Water, saline, aqueous dextrose, and glycols are preferred liquid carriers, particularly (when isotonic) for
  • the carrier can be selected from various oils including those of petroleum, animal, vegetable or synthetic origin, for example, peanut oil, soybean oil, mineral oil, sesame oil, and the like.
  • Suitable pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like.
  • compositions may be subjected to conventional pharmaceutical procedures such as
  • sterilization and may contain conventional pharmaceutical additives such as preservatives, stabilizing agents, wetting or emulsifying agents, salts for adjusting osmotic pressure, buffers, and the like.
  • This invention provides methods of effecting treating a mammal comprising the step of administering a therapeutically effective amount of a pharmaceutical composition of this invention to a subject.
  • a therapeutically effective amount is that amount necessary to alleviate the condition from which the mammal suffers.
  • composition of a compound of Formula I is administered via any of the usual and acceptable methods known in the art, either singly or in combination with another compound of the present invention.
  • compounds or compositions can thus be administered orally, sublingually, topically (e.g., on the skin or in the eyes), parenterally (e.g., intramuscularly,
  • the administration can be conducted in single unit dosage form with continuous therapy or in single dose therapy ad libitum.
  • the therapeutic methods of the present invention are practiced when the relief of symptoms is specifically required or perhaps imminently so. In another embodiment, the method is effectively practiced as continuous or prophylactic treatment.
  • the particular dosage of pharmaceutical composition to be administered to the subject will depend on a variety of considerations including the nature of the disease, the severity thereof, the schedule of administration, the age and physical characteristics of the subject, and so forth. Proper dosages may be
  • Topical dosages may utilize formulations containing active peptides and a liquid carrier or excipient, with multiple daily applications being appropriate.
  • Fluorenylmethoxycarbonyl (Fmoc) amino acid derivatives were purchased from Calbiochem-Novabiochem Corp. (San Diego, CA, USA), Bachem Bioscience Inc.
  • MBHA resin (1% divinylbenzene, 100 - 200 mesh, 0.9 mmol/g substitution), was received from
  • Fmoc-His(Trt)- OH and Fmoc-D-His(Trt)-OH were also used in the N- terminal position of the library.
  • the library described below was synthesized using simultaneous multiple peptide synthesis (Houghten, R.A., Proc. Natl. Acad. Sci. USA, 82:5131 (1985).
  • the solid support (MBHA resin) was contained in 230
  • polypropylene mesh packets 250 mg resin per packet
  • the only amino acids which required repetitive couplings were Fmoc-L-Gln-OH, Fmoc-D-Gln-OH, Fmoc-L-Arg(Pmc)-OH and Fmoc-D-Lys(Boc)-OH. Removal of the Fmoc protecting group was accomplished by shaking the resin packets in 20% piperidine/DMF (1 x 3 min, 1 x 10 min; 2 L) followed by a wash cycle (5 x DMF, 2 x IPA, 3 x DCM; approximately 8 mL per packet).
  • the resin of the 230 library packets was combined, mixed in DCM (2 L; 15 h shaking), and dried.
  • the resin was divided into 250 polypropylene mesh packets (packet size 3 cm x 3cm; each containing 310 mg resin).
  • the resin packets prepared as described above, were washed (1 x DCM; approximately 8 mL per packet), treated twice with 2% TFA in DCM (1 x 2 min, 1 x 30 min; 2 L), and washed (1 x DCM, 2 x IPA, 2 x DCM, 1 x MeOH; approximately 8 mL per packet).
  • the 250 mixture resin packets were cleaved 24 at a time with hydrogen fluoride (5 mL per resin packet with 0.35 mL anisole added as scavenger) using a multiple vessel cleavage apparatus (Kornheim, W., et al., Int. J. Pept. Protein Res., 25:414 (1985)).
  • the resulting mixtures were extracted by sonicating with 50% aqueous acetonitrile (3 x 5 ml).
  • the resulting solutions were lyophilized and relyophilized twice more from 50% aqueous acetonitrile.
  • the peptidomimetic compound was synthesized using simultaneous multiple peptide synthesis (Merrifield, R. B. J. Am. Chem. Soc. 1963, 85, 2149; Houghten, R. A. Proc. Natl. Acad. Sci. USA 1985, 82, 5131) and Fmoc strategy.
  • the solid support (MBHA resin) was contained in a polypropylene mesh packet (100 mg resin per packet; packet size 3 cm x 3 cm).
  • Removal of the Fmoc protecting group was accomplished by shaking the resin packet in 20% piperidine/DMF (1 x 3 min, 1 x 10 min; 2 L) followed by a wash cycle (5 x DMF, 2 x IPA, 3 x DCM).
  • the resin packet (0.09 mmol of free N- ⁇ -amino groups) was shaken for 2 h in a 0.077 M solution of trityl chloride (0.45 mmol) in DCM/DMF (9:1, 5.84 mL) containing DIEA (2.61 mmol, 0.45 mL). After a short wash procedure (1 x DMF, 1 x 5% DIEA, 1 x DCM), the
  • the resin packet was washed (1 x DCM; approximately 5 mL), treated twice with 2% TFA in DCM (1 x 3 min, 1 x 30 min), and washed (1 x DCM, 2 x IPA, 2 x DCM, 1 x MeOH; approximately 5 mL). 5. Coupling of the second amino acid deriva tive and second alkylation
  • Resin packets containing resin bound compounds with free N-terminal amino groups were shaken in a solution of methanol (MeOH) 20%/dichloromethane (DCM) 79%/acetic acid 1% (for one resin packet containing 0.05 mmol amine 4 ml of solvent were used - enugh to cover the resin packet) and 2 - 10 equivalents of the aldehyde or ketone (depending on their reactivity). After 20 minutes, 2-10 equivalents of a 1 M solution of sodium cyanoborohydride in N,N-dimethylformamide (DMF) were added and the reaction mixture shaken for 60 min. The resin packets were washed using the following washing sequence: 5 x DMF, 1 x DCM, 1 x MeOH (for one resin packet of the size mentioned above approximately 5 ml of solvent for each step). The completeness of the
  • reaction mixture was shaken for 60 min.
  • the resin packet was washed using the following washing sequence: 5 x DMF, 1 x DCM, 1 x MeOH, approximately 5 ml of solvent for each step.
  • the completeness of the formation of the secondary amines was tested using the Kaiser test [if necessary the reaction can be repeated, also by using a different solvent system like DMF containing 1% acetic acid].
  • Reduction can either be performed on solid support [procedure A] or in solution [procedure B].
  • the resin packet was washed with DMF (2 x 1 min x 5ml), DCM (2 x 1 min x 5 ml), MeOH (1 x 1 min x 5 ml), DMF (2 x 1 min x 5ml), DCM (2 x 1 min x 5 ml) and MeOH (1 x 1 min x 5 ml).
  • the tubes were cooled to room temperature and 5ml methanol were added dropwise to remove excess reducing agent. Excess solvent was removed by immersion of the tube in a 55°C water bath under a constant nitrogen flow (10-15 psi). The compound subsequently underwent
  • the compound was cleaved from the resin with hydrogen fluoride (5 mL per resin packet with 0.35 mL anisole added as scavenger) using a multiple vessel cleavage apparatus (Houghten, R. A., et al., Int. J.
  • This example describes the identification of individual compounds, either contained within a synthetic combinatorial library mixture or prepared separately, as inhibitors of the ⁇ -selective opioid peptide [ 3 H]-[D-Ala 2 , MePhe 4 , Gly-Ol 5 enkephalin ([ 3 H]-DAMGO). Individual peptides were identified as capable of inhibiting [ 3 H] - DAMGO by a radioreceptor assay. As detailed below, the compound libraries of the instant invention were screened at a single
  • Protein content of the crude homogenates ranged from
  • polypropylene tubes Each tube contained 0.5 ml of membrane suspension, 3 nM of the ⁇ -selective opioid peptide [ 3 H]-DAMGO (specific activity 36 Ci/mmol), 0.08 mg/ml compound mixture and Tris-HCl buffer in a total volume of 0.65 ml. Assay tubes were incubated for 60 min at 25°C. The reaction was terminated by filtration through GF-B filters (Wallac, Inc., Gaithersburg, MD). The filters were subsequently washed with 6 ml Tris-HCl buffer at 4°C. Bound radioactivity was counted on a Beta-plate Liquid Scintillation Counter (Life Technologies, Gaithersburg, MD) and expressed in counts per minute (cpm).
  • Inter- and intra-assay variation standard curves were determined by incubation of [ 3 H] - DAMGO in the presence of 0.13-3900 nM of unlabeled DAMGO.
  • Competitive inhibition assays were performed as above using serial dilutions of the peptide mixtures. IC 50 values were then calculated using the software GRAPHPAD (ISI, San Diego, CA). IC 50 values of less than 1000 nM are indicative of highly active opioid compounds which bind to the ⁇ receptor, with particularly active
  • Assays demonstrating selective inhibition of binding to kappa oppiate receptors for K receptors were carried out using [ 3 H]-U69,593 (3 nM, specific activity 62 Ci/mmol) as the radioligand and tissue homogenates prepared from guinea pig brains (cortex and cerebellum) using Tris buffer containing 100 ⁇ M PMSF, 5 mM MgCl 2 and 1 mg/ml BSA, pH 7.4. Sample tubes were incubated for 2.5 hr. Standard curves were prepared using 0.05-6300 nM naloxone.
  • ⁇ -Glucosidase Inhibitor ⁇ -Glucosidases are not only essential to carbohydrate metabolism, but also vital for the
  • Inhibitors of these enzymes are therefore of high therapeutic potential.
  • ⁇ -glucosidase inhibitors are potent oral anti-diabetics
  • the most active inhibitors are compounds of Formula I wherein X and Y are taken together to form a carbonyl group, B is zero, AA, BB, and CC are zero except were noted, R 9 is a hydrogen atom, R 8 is benzyl, R 6 is naphth-2-ylmethyl, R 3 is S- (N- (naphth-2-ylmethyl)indol-3-ylmethyl), R 1 and R 2 are each hydrogen, R 10 is absent, and R 7 is as set forth in the following Table 3 :

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The instant invention is directed to a single, selectively N-alkylated compound and libraries of such compounds as set forth in Formula (I). Furthermore, the instant invention is directed to methods of effecting analgesia, a decrease in the postprandial rise in the blood glucose levels of a mammal after ingestion of a carbohydrate load by said mammal, and treating microbial infections, utilizing such a single compound of Formula (I) in conjunction with a pharmaceutically-acceptable carrier. Also, the instant invention is directed to methods for selective alkylation, positional scanning and iteraitve synthetic and screening technologies.

Description

SELECTIVELY N-ALKYLATED PEPTIDOMIMETIC
COMBINATORIAL LIBRARIES AND COMPOUNDS THEREIN
This application claims the benefit of U.S.
Provisional Application No. 60/ , filed March 5, 1996, which was converted from U.S. Serial No.
08/611,390, and is incorporated herein by reference.
FIELD OF THE INVENTION
The present invention relates generally to novel, selectively N-alkylated compounds of Formula I below, as well as novel libraries composed of many such compounds, methods of synthesizing and screening the libraries, and methods of using the compounds.
BACKGROUND INFORMATION
The process of discovering new therapeutically active compounds for a given indication involves the screening of all compounds from available compound collections. From the compounds tested, one or more structure (s) is selected as a promising lead. A large number of related analogs are then synthesized in order to develop a structure-activity relationship and select one or more optimal compounds. With traditional one-at- a-time synthesis and biological testing of analogs, this optimization process is long and labor intensive. Adding significant numbers of new structures to the compound collections used in the initial screening step of the discovery and optimization process cannot be accomplished with traditional one-at-a-time synthesis methods, except over a time frame of months or even years. Faster methods are needed that allow for the preparation of up to thousands of related compounds in a matter of days or a few weeks. This need is particularly evident when it comes to synthesizing more complex compounds, such as the instant compounds composed of two or more monomers, each monomer possessing more than one variable substituent.
Solid-phase techniques for the synthesis of peptides have been extensively developed and
combinatorial libraries of peptides have been generated with great success. During the past four years there has been substantial development of chemically synthesized combinatorial libraries (SCLs) made up of peptides. The preparation and use of synthetic peptide combinatorial libraries has been described, for example, by Dooley in U.S. Patent 5,367,053, Huebner in U.S. Patent 5,182,366, Appel et al. in WO PCT 92/09300, Geysen in published European Patent Application 0 138 855 and Pirrung in U.S. Patent 5,143,853. Such SCLs provide the efficient synthesis of an extraordinary number of various peptides in such libraries and the rapid screening of the library which identifies lead pharmaceutical peptides.
Substituent limitations have been overcome for mixtures of peptides and peptidomimetics through the use of solid phase techniques instead of the more traditional solution-phase ones. An important step in the
development of solid-phase techniques was the discovery of methods to identify active individual compounds from soluble mixtures of large numbers of compounds, as described, for example by Rutter in U.S. Patent 5,010,175 and Simon in WO PCT 91/19735. These soluble mixtures, however, have never before been applied to compounds with amide backbones that have different substituent on each amide nitrogen. Until now, it was possible by previously known methods to add only the same specific substituent to each and every nitrogen atom of the amide backbone. Thus, improved methods were needed to synthesize such selectively N-alkylated amide compounds. This invention satisfies these needs and provides related advantages as well. The present
invention overcomes the known limitations to the
shortcomings of combinatorial chemistry with respect to selective N-alkylation. The present invention combines the techniques of solid-phase synthesis of peptidomimetic compounds and the general techniques of synthesis of combinatorial libraries to prepare new selective
N-alkylated compounds.
SUMMARY OF THE INVENTION This invention is directed to a single selectively N-alkylated compound or a library of an approximately equimolar mixture of two more selectively N-alkylated compounds of the Formula (I):
Figure imgf000006_0001
Wherein :
R1 and R2 independently are a hydrogen atom, an amino protecting group, C1 to C12 acyl, C3 to C10
cycloalkyl, C3 to C6 heterocycle, C1 to C12 alkyl, C1 to C12 substituted alkyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle; R3, R5, and R7 are independently a hydrogen atom,
C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl,
substituted phenyl, C7 to C16 alkylaryl, C7 to C16
substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle; R4 , R6 and R8 are independently a C1 to C18 substituent group; with the proviso that all but one of R4, R6 and R8 can simultaneously be the same group;
R9 is a hydrogen atom or a solid support;
R10 is optionally present as a C1 to C18 substituent group when R1 and R2 are other than a hydrogen atom, an amino protecting group or when both R1 and R2 are C1 to C12 acyl groups;
AA, BB, and CC are independently 0 to 5;
B is from 0 to 3 ; further wherein the stereochemistry at the carbons bonded to R3, R5, and R7 are independently R or S or a mixture of the two; further wherein when B is 2 or 3; each R4 and R5 can be the same or different; with the proviso that either R1 or R2 can be taken with R3; R4 can be taken with R5 ; and R6 can be taken with R7; respectively and independently, to form a subtituted or unsubstituted pyrrolidine ring;
X and Y are either 1) each a hydrogen atom or 2) taken together to represent a carbonyl group; and a pharmaceutically acceptable salt, solvate or hydrate thereof.
This invention is also directed to iterative and positional scanning methods of synthesizing the libraries of compounds described above as discussed below. Another aspect of the invention is a method of selective N-alkylation as set forth below. Furthermore, the invention comprises methods for affecting analgesia in a mammal, effecting a decrease in the postprandial rise in the blood glucose levels of a mammal after said mammal has ingested a carbohydrate load, and a method for treating microbial infections, all of which methods comprise administering a single compound of the above formula in conjunction with a pharmaceutically acceptable carrier, as set forth below.
DETAILED DESCRIPTION OF INVENTION
The instant invention is directed to a single compound or an approximately equimolar mixture of two or more selectively N-alkylated compounds of the Formula (I) :
Figure imgf000008_0001
Wherein : R1 and R2 independently are a hydrogen atom, an amino protecting group, C1 to C12 acyl, C3 to C10
cycloalkyl, C3 to C6 heterocycle, C1 to C12 alkyl, C1 to C12 substituted alkyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
R3, R5, and R7 are independently a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16
substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
R4 , R6 and RB are independently a C1 to C18 substituent group; with the proviso that all but one of R4, R6 and Rβ can simultaneoulsy be the same group;
R9 is a hydrogen atom or a solid support;
R10 is optionally present as a C1 to C18 substituent group when R1 and R2 are other than a hydrogen atom or an amino protecting group;
AA, BB, and CC are independently 0 to 5 ;
B is from 0 to 3 ; further wherein the stereochemistry at the carbons bonded to R3, R5, and R7 are independently R or S or a mixture of the two; further wherein when B is 2 or 3; each R4 and R5 can be the same or different; with the proviso that either R1 or R2 can be taken with R3; R4 can be taken with R5 ; and R6 can be taken with R7; respectively and independently, to form a subtituted or unsubstituted pyrrolidine ring; X and Y are either 1) each a hydrogen atom or 2) taken together to represent a carbonyl group; and a pharmaceutically acceptable salt, solvate or hydrate thereof. The terms used in the above Formula I having the following meanings when used in conjunction with Formula I and when used in described subsequent Formulas :
C3 to C10 cycloalkyl - unsubstituted or substituted mono- or bicyclic saturated rings such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or adamantyl or rings wherein the
substituents are one or more hydroxy, halo, amino, protected amino, carboxy, protected carboxy, amido, nitro, trifluoromethyl, phenyl, heterocyclic rings, C1 to C7 acyl, C1 to C7 alkoxy, or C1 to C3 alkyl groups;
C3 to C6 heterocycle - unsubstituted or substituted mono- or bicyclic rings containing 3 to 6 carbons and from one to three nitrogen, oxygen, sulfur atoms such as azetidine, pyrrolidine, pyrazolidine, piperidine, piperazine, perhydroazepine or tropane, oxazole, thiazole, pyrazole, thiophenyl and pyranyl rings wherein the substituents are one or more hydroxy, protected hydroxy, halo, amino, protected amino,
monosubstituted amino, disubstituted amino, carboxy, protected carboxy, amido, nitro, trifluoromethyl, phenyl, or C1 to C3 alkyl groups; C1 to C12 Alkyl - straight-chain or branched carbon chain optionally containing a C3 to C7 saturated or partially saturated ring, wherein the carbon chain may also optionally be partially unsaturated, such as methyl, ethyl, tert-butyl, iso-propyl, 6-(cyclohexyl)-n-hexyl, allyl, n-octyl, 3-(cyclopentyl)-n-pentyl,
methylcyclopropyl, and the like;
The term C1 to C18 Substituent Group indicates a group of the formula -CH2-W wherein W is chosen from the group consisting of a hydrogen atom, C1 to C12 alkyl, C3 to C10 cycloalkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substituted alkylaryl, as those terms are defined herein;
The term "C1 to C12 substituted alkyl," denotes the above C1 to C12 alkyl groups that are substituted by one to three halogen, hydroxy, protected hydroxy, amino, protected amino, guanidino, C1 to C7 acyloxy, C1 to C7 acyl, nitro, carboxy, protected carboxy, carboxamide, carbonyl, carboxyl, cyano, methylsulfonylamino or C1 to C4 alkoxy groups. The substituted alkyl groups may be substituted once or twice with the same or with different substituents; Examples of the above substituted alkyl groups include the cyanomethyl, nitromethyl, hydroxymethyl, trityloxymethyl, propionyloxymethyl, aminomethyl,
carboxymethyl, allyloxycarbonylmethyl,
allyloxycarbonylaminomethyl, carbamoylmethyl,
methoxymethyl, ethoxymethyl, t-butoxymethyl,
acetoxymethyl, chloromethyl, bromomethyl, iodomethyl, 6- hydroxyhexyl, 2,4-dichloro (n-butyl), 2-amino (iso-pro- pyl), 2-carbamoylethyl and the like. A preferred group of examples within the above "C1 to C6 substituted alkyl" group includes the substituted methyl group, in other words, a methyl group substituted by the same
substituents as the " C1 to C6 substituted alkyl" group. Examples of the substituted methyl group include groups such as protected hydroxymethyl, (e.g.,
tetrahydropyranyloxymethyl), acetoxymethyl,
carbamoylmethyl, chloromethyl, bromomethyl and
iodomethyl.
The term "substituted phenyl" specifies a phenyl group substituted with one or more, and preferably one or two, moieties chosen from the groups consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, trifluoromethyl, C1 to C6 alkyl, C1 to C7 alkoxy, C1 to C7 acyl, C1 to C7 acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino,
(monosubstituted) amino, protected (monosubstituted) amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C1 to C6 alkyl) carboxamide, protected N-(C1 to C6 alkyl) carboxamide, N,N-di(C1 to C6 alkyl) carboxamide, trifluoromethyl, N-((C1 to C6 alkyl) sulfonyl) amino, N- (phenylsulfonyl) amino or phenyl, substituted or unsubstituted, such that, for example, a biphenyl or naphthyl group results.
Examples of the term "substituted phenyl" includes a mono- or di (halo) phenyl group such as 2, 3 or 4-chlorophenyl, 2, 6-dichlorophenyl, 2 , 5-dichlorophenyl, 3,4-dichlorophenyl, 2, 3 or 4-bromophenyl, 3,4- dibromophenyl, 3-chloro-4-fluorophenyl, 2, 3 or 4- fluorophenyl and the like; a mono or di (hydroxy) phenyl group such as 2, 3 or 4-hydroxyphenyl, 2,4- dihydroxyphenyl, the protected-hydroxy derivatives thereof and the like; a nitrophenyl group such as 2 , 3 or 4-nitrophenyl; a cyanophenyl group, for example, 2, 3 or 4-cyanophenyl; a mono- or di (alkyl) phenyl group such as 2, 3 or 4-methylphenyl, 2,4-dimethylphenyl, 2, 3 or 4- (iso-propyl)phenyl, 2, 3 or 4-ethylphenyl, 2, 3 or 4-(n- propyl)phenyl and the like; a mono or di (alkoxy) phenyl group, for example, 2,6-dimethoxyphenyl, 2, 3 or 4- methoxyphenyl, 2, 3 or 4-ethoxyphenyl, 2, 3 or 4- (isopropoxy) phenyl, 2, 3 or 4- (t-butoxy) phenyl, 3-ethoxy- 4-methoxyphenyl and the like; 2, 3 or 4- trifluoromethylphenyl; a mono- or dicarboxyphenyl or (protected carboxy)phenyl group such as 2, 3 or 4- carboxyphenyl or 2,4-di(protected carboxy)phenyl; a mono- or di(hydroxymethyl)phenyl or (protected
hydroxymethyl)phenyl such as 2, 3, or 4-(protected hydroxymethyl)phenyl or 3,4-di(hydroxymethyl)phenyl; a mono- or di(aminomethyl)phenyl or (protected
aminomethyl)phenyl such as 2, 3 or 4-(aminomethyl)phenyl or 2,4-(protected aminomethyl)phenyl; or a mono- or di (N- (methylsulfonylamino))phenyl such as 2, 3 or 4-(N- (methylsulfonylamino))phenyl. Also, the term
"substituted phenyl" represents disubstituted phenyl groups wherein the substituents are different, for
example, 3-methyl-4-hydroxyphenyl, 3-chloro-4- hydroxyphenyl, 2-methoxy-4-bromophenyl, 4-ethyl-2- hydroxyphenyl, 3-hydroxy-4-nitrophenyl, 2-hydroxy 4- chlorophenyl and the like.
The terms "halo" and "halogen" refer to the fluoro, chloro, bromo or iodo groups. There can be one or more halogen, which are the same or different.
Preferred halogens are chloro and fluoro.
The term "C7 to C16 alkylaryl" denotes a C1 to C6 alkyl group substituted at any position by a phenyl or naphthyl ring. Examples of such a group include benzyl, 2-phenylethyl, 3-phenyl(n-propyl), 4-phenylhexyl, 3- phenyl(n-amyl), 3-phenyl(sec-butyl) and the like.
Preferred C7 to C16 phenylalkyl groups are the benzyl phenylethyl napth-1-ylmethyl and napth-2-ylmethyl groups.
The term "C7 to C16 substituted alkylaryl" denotes a C7 to C16 alkylaryl group substituted on the C1 to C6 alkyl portion with one or more, and preferably one or two, groups chosen from halogen, hydroxy, protected hydroxy, oxo, protected oxo, amino, protected amino, (monosubstituted) amino, protected (monosubstituted) amino, (disubstituted) amino, guanidino, heterocyclic ring, substituted heterocyclic ring, C1 to C7 alkoxy, C1 to C7 acyl, C1 to C7 acyloxy, nitro, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C1 to C6 alkyl) carboxamide, protected N-C1 to C6 alkyl) carboxamide, N, N-(Ci to C6 dialkyl) carboxamide, cyano, N-((C1 to C6 alkylsulfonyl) amino, thiol, C1 to C4 alkylthio, C1 to C4 alkylsulfonyl groups; and/or the phenyl group may be substituted with one or more, and preferably one or two, substituents chosen from halogen, hydroxy, protected hydroxy, cyano, nitro, C1 to C6 alkyl, C1 to C7 alkoxy, C1 to C7 acyl, C1 to C7 acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino,
(monosubstituted) amino, protected (monosubstituted) amino, (disubstituted) amino, carboxamide, protected carboxamide, N-(C1 to C6 alkyl) carboxamide, protected N-(C1 to C6 alkyl) carboxamide, N, N-di(C1 to C6 alkyl) carboxamide, trifluoromethyl, N-((C1 to C6 alkyl) sulfonyl) amino, N-
(phenylsulfonyl) amino or a phenyl group, substituted or unsubstituted, for a resulting biphenyl or naphthyl group. The substituted alkyl or phenyl groups may be substituted with one or more, and preferably one or two, substituents which can be the same or different.
Examples of the term "C7 to C16 substituted alkylaryl" include groups such as 2-phenyl-1-chloroethyl, 2-(4-methoxyphenyl)ethyl, 4-(2,6-dihydroxy phenyl)n- hexyl, 2-(5-cyano-3-methoxyphenyl)n-pentyl, 3-(2,6- dimethylphenyl) n-propyl, 4-chloro-3-aminobenzyl, 6-(4- methoxyphenyl)-3-carboxy (n-hexyl), 5-(4- aminomethylphenyl)-3-(aminomethyl) n-pentyl, 5-phenyl-3- oxo-n-pent-1-yl, (4-hydroxynapth-2-yl)methyl and the like. The term "(monosubstituted) amino" refers to an amino group with one substituent chosen from the group consisting of phenyl, substituted phenyl, C1 to C6 alkyl, C1 to C6 substituted alkyl, C1 to C7 acyl, C2 to C7 alkenyl, C2 to C7 substituted alkenyl, C2 to C7 alkynyl, C7 to C16 alkylaryl, C7 to C16 substituted alkylaryl and
heterocyclic ring. The (monosubstituted) amino can additionally have an amino-protecting group as
encompassed by the term "protected
(monosubstituted) amino."
The term "(disubstituted) amino" refers to amino groups with two substituents chosen from the group
consisting of phenyl, substituted phenyl, C1 to C6 alkyl, C1 to C6 substituted alkyl, C1 to C7 acyl, C2 to C7 alkenyl, C2 to C7 alkynyl, C7 to C16 alkylaryl, C7 to C16 substituted alkylaryl and heterocyclic ring. The two substituents can be the same or different.
The term "pharmaceutically-acceptable salt" encompasses those salts that form with the carboxylate anions and includes salts formed with the organic and inorganic cations such as those chosen from the alkali and alkaline earth metals, (for example, lithium, sodium, potassium, magnesium, barium and calcium); ammonium; and the organic cations (for example, dibenzylammonium, benzylammonium, 2-hydroxyethylammonium,
bis(2-hydroxyethyl)ammonium, phenylethylbenzylammonium, dibenzylethylenediammonium, and like cations). Other cations encompassed by the above term include the
protonated form of procaine, quinine and N-methylglucosamine, and the protonated forms of basic amino acids such as glycine, ornithine, histidine, phenylglycine, lysine, and arginine, and acetic acid-like counter-ions such as acetate and trifluoroacetate .
Furthermore, any zwitterionic form of the instant
compounds formed by a carboxylic acid and an amino group is referred to by this term. A preferred cation for the carboxylate anion is the sodium cation. Furthermore, the term includes salts that form by standard acid-base reactions with basic groups (such as amino groups) and organic or inorganic acids. Such acids include
hydrochloric, sulfuric, phosphoric, acetic, succinic, citric, lactic, maleic, fumaric, palmitic, cholic, pamoic, mucic, D-glutamic, D-camphoric, glutaric, phthalic, tartaric, lauric, stearic, salicyclic,
methanesulfonic, benzenesulfonic, sorbic, picric, benzoic, cinnamic, and the like acids.
The compounds of Formula I may also exist as solvates and hydrates. Thus, these compounds may
crystallize with, for example, waters of hydration, or one, a number of, or any fraction thereof of molecules of the mother liquor solvent. The solvates and hydrates of such compounds are included within the scope of this invention. The term "carboxy-protecting group" as used herein refers to one of the ester derivatives of the carboxylic acid group commonly employed to block or protect the carboxylic acid group while reactions are carried out on other functional groups on the compound. Examples of such carboxylic acid protecting groups include t-butyl, 4-nitrobenzyl, 4-methoxybenzyl, 3,4- dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,4,6- trimethoxybenzyl, 2,4,6-trimethylbenzyl,
pentamethylbenzyl, 3,4-methylenedioxybenzyl, benzhydryl, 4,4'-dimethoxytrityl, 4,4',4"-trimethoxytrityl, 2- phenylpropyl, trimethylsilyl, t-butyldimethylsilyl, phenacyl, 2,2,2-trichloroethyl, β-(trimethylsilyl)ethyl, β-(di(n-butyl)methylsilyl) ethyl, p-toluenesulfonylethyl, 4-nitrobenzylsulfonylethyl, allyl, cinnamyl, 1-
(trimethylsilylmethyl)-propenyl and like moieties. The species of carboxy-protecting group employed is not critical so long as the derivatized carboxylic acid is stable to the conditions of subsequent reaction (s) and can be removed at the appropriate point without
disrupting the remainder of the molecule. Further examples of these groups are found in C.B. Reese and E. Haslam, "Protective Groups in Organic Chemistry," J.G.W. McOmie, Ed., Plenum Press, New York, NY, 1973, Chapter 5, respectively, and T.W. Greene and P.G.M. Wuts,
"Protective Groups in Organic Synthesis," 2nd ed., John Wiley and Sons, New York, NY, 1991, Chapter 5, each of which is incorporated herein by reference. A related term is "protected carboxy," which refers to a carboxy group substituted with one of the above carboxy- protecting groups.
The term "hydroxy-protecting group" refers to readily cleavable groups bonded to hydroxyl groups, such as the tetrahydropyranyl, 2-methoxyprop-2-yl,
1-ethoxyeth-1-yl, methoxymethyl, β-methoxyethoxymethyl, methylthiomethyl, t-butyl, t-amyl, trityl,
4-methoxytrityl, 4,4'-dimethoxytrityl,
4,4',4"-trimethoxytrityl, benzyl, allyl, trimethylsilyl, (t-butyl)dimethylsilyl, 2,2,2-trichloroethoxycarbonyl groups and the like.
Further examples of hydroxy-protecting groups are described by C.B. Reese and E. Haslam, "Protective Groups in Organic Chemistry," J.G.W. McOmie, Ed., Plenum Press, New York, NY, 1973, Chapters 3 and 4,
respectively, and T.W. Greene and P.G.M. Wuts,
"Protective Groups in Organic Synthesis," Second Edition, John Wiley and Sons, New York, NY, 1991, Chapters 2 and 3. A preferred hydroxy-protecting group is the tert- butyl group. The related term "protected hydroxy" denotes a hydroxy group bonded to one of the above hydroxy protecting groups.
The term "amino-protecting group" as used herein refers to substituents of the amino group commonly employed to block or protect the amino functionality while reacting other functional groups of the molecule. The term "protected (monosubstituted) amino" means there is an amino-protecting group on the monosubstituted amino nitrogen atom. In addition, the term "protected
carboxamide" means there is an amino-protecting group on the carboxamide nitrogen.
Examples of such amino-protecting groups include the formyl ("For") group, the trityl group, the phthalimido group, the trichloroacetyl group, the trifluoro-acetyl group, the chloroacetyl, bromoacetyl, and iodoacetyl groups, urethane-type blocking groups, such as t-butoxycarbonyl ("Boc"), 2-(4-biphenylyl)propyl- 2-oxycarbonyl ("Bpoc"), 2-phenylpropyl-2-oxycarbonyl ("Poc"), 2- (4-xenyl) isopropoxycarbonyl, 1,1- diphenylethyl-1-oxycarbonyl, 1,1-diphenylpropyl-1- oxycarbonyl, 2-(3,5-dimethoxyphenyl)propyl-2-oxycarbonyl ("Ddz"), 2-(p-1oluyl)propyl-2-oxycarbonyl,
cyclopentanyloxycarbonyl,
1-methylcyclopentanyloxycarbonyl, cyclohexanyloxy- carbonyl, 1-methylcyclohexanyloxycarbonyl,
2-methylcyclohexanyloxycarbonyl,
2-(4-toluylsulfonyl)ethoxycarbonyl,
2-(methylsulfonyl)ethoxycarbonyl, 2-(triphenylphosphino)- ethoxycarbonyl, 9-fluorenylmethoxycarbonyl ("Fmoc"), 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl,
1-(trimethylsilylmethyl)prop-1-enyloxycarbonyl,
5-benzisoxalylmethoxycarbonyl,
4-acetoxybenzyloxycarbonyl,
2,2,2-trichloroethoxycarbonyl, 2-ethynyl-2- propoxycarbonyl, cyclopropylmethoxycarbonyl,
isobornyloxycarbonyl, 1-piperidyloxycarbonyl,
benzyloxycarbonyl ("Cbz"), 4-phenylbenzyloxycarbonyl, 2-methylbenzyloxy-carbonyl, α-2,4,5,- tetramethylbenzyloxycarbonyl ("Tmz"),
4-methoxybenzyloxycarbonyl, 4-fluorobenzyloxycarbonyl, 4-chlorobenzyloxycarbonyl, 3-chlorobenzyloxycarbonyl, 2-chlorobenzyloxycarbonyl, 2,4-dichlorobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 3-bromobenzyloxycarbonyl,
4-nitrobenzyloxycarbonyl, 4-cyanobenzyloxycarbonyl, 4-(decyloxy)benzyloxycarbonyl and the like; the
benzoylmethylsulfonyl group,
2,2,5,7,8-pentamethylchroman-6-sulfonyl group ("PMC") dithiasuccinoyl ("Dts"), the 2-(nitro)phenylsulfenyl group ("Nps"), the diphenyl-phosphine oxide group and like amino-protecting groups. The species of amino- protecting group employed is not critical so long as the derivatized amino group is stable to the conditions of the subsequent reaction (s) and can be removed at the appropriate point without disrupting the remainder of the compounds. Preferred amino-protecting groups are Boc, Cbz and Fmoc. Further examples of amino-protecting groups embraced by the above term are well known in organic synthesis and the peptide art and are described by, for example, T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis," 2nd ed., John Wiley and Sons, New York, NY, 1991, Chapter 7, M. Bodanzsky,
"Principles of Peptide Synthesis," 1st and 2nd revised ed., Springer-Verlag, New York, NY, 1984 and 1993, and J.M. Stewart and J.D. Young, "Solid Phase Peptide
Synthesis," 2nd ed., Pierce Chemical Co., Rockford, IL, 1984, E. Atherton and R.C. Shephard, "Solid Phase Peptide Synthesis - A Practical Approach" IRL Press, Oxford, England (1989), each of which is incorporated herein by reference. The related term "protected amino" defines an amino group substituted with an amino-protecting group discussed above.
The term "heterocycle" denotes optionally substituted five-membered or six-membered rings that have 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms. These five-membered or six-membered rings may be saturated, fully unsaturated or partially unsaturated, with fully saturated rings being preferred. An "amino-substituted heterocyclic ring" means any one of the above-described heterocyclic rings is substituted with at least one amino group. Preferred heterocyclic rings include morpholino, piperidinyl, piperazinyl, tetrahydrofurano, pyrrolo, and tetrahydrothiophenyl.
Furthermore, the above optionally substituted five-membered or six-membered rings can optionally be fused to an aromatic 5-membered or 6-membered ring system, such as a pyridine or a triazole system, and preferably to a benzene ring.
The following ring systems are examples of the heterocyclic (whether substituted or unsubstituted) radicals denoted by the term "heterocyclic ring" : thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl,
thiadiazolyl, oxadiazolyl, tetrazolyl, thiatriazolyl, oxatriazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thiazinyl, oxazinyl, triazinyl, thiadiazinyl,
oxadiazinyl, dithiazinyl, dioxazinyl, oxathiazinyl, tetrazinyl, thiatriazinyl, oxatriazinyl, dithiadiazinyl, imidazolinyl, dihydropyrimidyl, tetrahydropyrimidyl, tetrazolo[1,5-b]pyridazinyl and purinyl, as well as benzo-fused derivatives, for example benzoxazolyl, benzthiazolyl, benzimidazolyl and indolyl. Further specific examples of the above
heterocyclic ring systems are 6-membered ring systems containing one to three nitrogen atoms. Such examples include pyridyl, such as pyrid-2-yl, pyrid-3-yl and pyrid-4-yl; pyrimidyl, preferably pyrimid-2-yl and pyrimid-4-yl; triazinyl, preferably 1,3,4-triazin-2-yl and 1,3,5-triazin-4-yl; pyridazinyl, in particular pyridazin-3-yl, and pyrazinyl. The pyridine N-oxides and pyridazine N-oxides, and the pyridyl, pyrimid-2-yl, pyrimid-4-yl, pyridazinyl and the 1,3,4-triazin-2-yl radicals, are a preferred group.
The substituents for the optionally substituted heterocyclic ring systems, and further examples of the 5- and 6- membered ring systems discussed above, are found in W. Durckheimer et al., U.S. Pat. No. 4,278,793, issued July 14, 1981, columns 9 through 21 and columns 188 through 233, herein incorporated by reference. (In columns 33 through 188, examples of the term
"heterocyclic ring" are included in the heterocyclic thiomethyl groups listed under heading "A".)
The term "C6 to C15 alkyl heterocycle" denotes a C1 to C6 alkyl group substituted at any position by a heterocycle ring (heterocycle) from as described above, said heterocycle containing up to 14 carbon atoms, as long as sum of the carbon atoms of the alkyl chain (up to 6) and the carbon atoms of the heterocycle do not exceed 15. Similarly, the term "substituted C6 to C1S alkyl heterocycle" refer to a C6 to C15 alkyl heterocycle group substituted on the alkyl portion with the same substituents as listed for the C7 to C16 substituted alkylaryl groups and on the heterocycle as defined above for substituted heterocyle.
The above single compound or library of an approximately equal molar mixture of two or more
compounds has several preferred embodiments.
Specifically, in the embodiment where a single compound is indicated, a preferred group of single compounds are the interior amido compounds, that is, wherein X and Y are taken together to form a carbonyl moiety. A
preferred group of interior amido single compounds are the dimers, thus, wherein B, AA, BB and CC are zero, except that AA can be zero or one when R7 is a hydrogen atom and that CC can be zero or one when R3 is a hydrogen atom. In turn, a preferred group of interior amido dimers are those that are cleaved from the solid support and are not quaternized, thus, wherein R9 is a hydrogen atom and R10 is absent. A preferred group of cleaved interior amido dimer single compounds are those wherein R3 and R7 are independently chosen from the group consiting of S- or R-methyl, S- or R-benzyl, a hydrogen atom, S- or R- (but-2-yl), S- or R-[ 4-(N-methylamino)-n-butyl], S- or R-[4-(N-ethylamino)-n-butyl], S- or R-[4-(N-allylamino)- n-butyl], S- or R-[4-(N-benzylamino)-n-butyl], S- or R- [4-(N-(napth-2-ylmethylamino)-n-butyl], S- or R- [4- (amino)-n-butyl], S- or R-[sec-butyl], S- or R- (methylsulfinyl) eth-1-yl, S- or R-acetamido, S- or R - (N,N-dimethyl) acetamido, S- or R- (N,N-diethyl) acetamido, S- or R-(N,N-diallyl) acetamido, S- or R- (N- allyl) acetamido, S- or R- (N,N-dibenzyl)acetamido, S- or R- (N-benzyl) acetamido, S- or R-(N,N-di(napth-2- ylmethyl))acetamido, S- or R-(N-(napth-2- ylmethyl))acetamido, S- or R-propionamido, S-or R- (N,N- dimethyl) propionamido, S- or R-(N,N-diethyl)propionamido, S- or R-(N,N-diallyl) propionamido, S- or R-(N,N- dibenzyl)propionamido, S- or R-(N,N-di(napth-2- ylmethyl)propionamido, S- or R-[3-(guanidino)-n-propyl], S- or R- [(N,N-diallyl)-3-guanidino-n-propyl], S- or R- [(N,N,N'-triallyl)-3-guanidino-n-propyl], S- or R- [(N,N,N'-trimethyl)-3-(guanidino)-n-propyl], S- or R- [(N,N,N'-triethyl)-3-(guanidino)-n-propyl], S- or R- hydroxymethyl, S- or R-[1 -(hydroxy)ethyl], S-phenyl, S- or R-[3-(carboxy)-n-propyl], S- or R-[ iso-propyl], S- or R-[(indol-3-yl)methyl], S- or R-[(N-(methyl)indol -3- yl)methyl], S- or R-[(N-(ethyl) indol-3-yl)methyl], S- or R-[(N-(allyl)indol-3-yl)methyl], S- or R-[(N- (benzyl)indol-3-yl)methyl], S- or R-[(N-(naphth-2- ylmethyl)indol-3-yl)methyl], S- or R-(4-(methoxy))benzyl, S- or R-(4-(ethoxy))benzyl, S- or R-(4-(allyloxy))benzyl, S- or R-[4-hydroxybenzyl], S- or R-(n-butyl), S- or R- (n- propyl), S- or R-[(napth-2-yl) methyl], AA is zero or one when R7 is a hydrogen atom, CC is zero or one when R3 is hydrogen atom, S- or R-[cyclohexylmethyl], S- or R- thiomethyl, or when either R1 or R2 are taken together with R3 to form an S- or R- pyrrolidine or S-[4- (hydroxy)pyrrolidine].
An especially preferred group of single
compounds referred to as cleaved interior amido dimers, hereafter referred to as the "Type I" amido dimers, is wherein R6 and R8 are independently methyl, ethyl, allyl, benzyl, or napth-2-ylmethyl. A preferred group of "Type I" amido dimers are the "Type II" amido dimers, thus, wherein either R1 or R2 are each a hydrogen atom, or one of R1 or R2 is a hydrogen atom and the other is taken together with R3 to form an S-pyrrolidine ring. A preferred group of the Type II interior amido dimers is the N-terminal monomer as a proline residue, thus, wherein one of R1 or R2 is a hydrogen atom and the other is taken together with R3 to form an S-pyrrolidine ring. A preferred group of N-terminal proline Type II interior amido dimers occurs when R6 is napth-2-ylmethyl and R8 is benzyl, and more so when R7 is S- or R-methyl, a hydrogen atom, S- or R-[3-(guanidino)-n-propyl], S- or R-[4-(N- benzylamino)-n-butyl], S-[iso-propyl], S-[2- (methylsulfinyl)ethyl], S- or R-(n-propyl), S- or R- (hydroxymethyl), S- or R-[n-butyl], R-[(napth-2- yl) methyl], or S-phenyl, and especially so when the C- terminal residue is S- or R-alanine, thus, R7 is a S- or R-methyl. Another preferred group of Type II interior amido dimers has the N-terminal residue as a
S-phenylalanine, and more so wherein R6 is ethyl and R8 is (napth-2-yl)methyl, and especially so when R7 is S- methyl, S-(2-(methylsulfinyl) ethyl), a hydrogen atom, S- (4-(hydroxy)benzyl) or S-[(hydroxy)methyl]. Of a special note within this preferred group of compounds is the compound wherein R7 is S-methyl.
Another preferred group of Type I interior amido dimers are wherein R1 and R2 are each a hydrogen atom and R3 is R-[(N-(napth-2-ylmethyl)indol-3-yl)methyl]. Of note within this preferred group of Type I compounds are wherein R6 is napth-2-ylmethyl and R8 is benzyl, and especially so when R7 is S- or R-[3-(guanidino)-n-propyl] or S- or R- [4-(benzylamino)-n-butyl].
Yet another preferred group of Type I interior amido dimers occurs wherein either R1 or R2 is a hydrogen atom or is taken in conjunction with R3 to form a
pyrrolidine ring, and the other is C1 to C12 acyl, C3 to C10 cycloalkyl, C3 to C6 heterocycle, C1 to C12 alkyl, C1 to C12 substituted alkyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle.
Another preferred group of compounds of the above Formula I wherein a single compound is indicated is the interior amine compounds, in other words, wherein X and Y are each a hydrogen atom. A preferred group of these interior amine compounds is dimers, wherein B, AA, BB and CC are zero, except that AA can be zero or one when R7 is a hydrogen atom and that CC can be zero or one when R3 is a hydrogen atom. In turn, a preferred group of interior amine dimers is those cleaved from the solid support, thus, wherein R9 is a hydrogen atom and R10 is absent. A preferred group of cleaved interior amine dimers is those wherein R6 and R8 are independently methyl, benzyl or 4-hydroxybenzyl. A preferred group of these preferred cleaved interior dimers are referred to
hereafter as "Type I cleaved interior amine dimers", that is, wherein R3 and R7 are independently benzyl or 4- hydroxybenzyl. A preferred group of the Type I cleaved interior amine dimers are those wherein R8 is benzyl, R7 is 4-hydroxybenzyl, R6 is methyl, and R3 is 4-hydroxybenzyl. A more preferred group of these Type I compounds are wherein a) R1 and R2 are the same and are methyl or a hydrogen atom; b) either Rj or R2 is a hydrogen atom and the other is chosen from the group consisting of methyl, iso- propyl, cyclopropylmethyl, 4-hydroxymethyl, N- methylpiperidin-4-yl, and 3-(N,N-dimethylamino)-2-methyl- prop-2-en-1-yl. Another preferred group of Type I cleaved interior amine dimers are wherein R8 is methyl, R7 is benzyl, R6 is 4-hydroxybenzyl, and R3 is 4- hydroxybenzyl, and especially so wherein R1 and R2 are the same and are either a hydrogen atom or methyl, or one of R1 or R2 is a hydrogen atom and the other is methyl.
Yet another preferred group of Type I cleaved interior amine dimers are wherein R8 is methyl, R7 is 4- hydroxymethyl, R6 is benzyl, and R3 is 4-hydroxybenzyl, and especially so wherein R1 and R2 are the same and are either a hydrogen atom or methyl, or one of R1 or R2 is a hydrogen atom and the other is methyl.
Another preferred class of compounds within the invention encompassed by Formula I is a library of an approximately equimolar mixture of two or more compounds. A preferred group of this library of compounds are the interior amido compounds, thus, wherein X and Y are taken together to form a carbonyl group, and especially the interior amido dimers, wherein B, AA, BB and CC are zero, except that AA can be zero or one when R7 is a hydrogen atom and that CC can be zero or one when R3 is a hydrogen atom.
A preferred group of library of interior amido dimers are the resin-bound interior amido dimers, wherein R, is a solid support and R10 is absent. A preferred group of these resin bound dimers are wherein R3 and R7 are independently chosen from the group consisting of S- or R-methyl, S- or R-benzyl, a hydrogen atom, S- or R-(but- 2-yl), S- or R-[4-(t-butoxycarbonylamino)-n-butyl], S- or R-[sec-butyl], S- or R- (methylsulfinyl) eth-1-yl, S- or R-[ 3-(guanidino)-n-propyl], S- or R- [(N-PMO-3- (guanidino)-n-propyl], S- or R-(t-butyloxy) methyl, S- or R-[2-(t-butyloxy)ethy], S-phenyl, S- or R-[2-(t- butoxycarbonyl)ethyl], S- or R-[iso-propyl], S- or R-[(N- (t-butoxycarbonyl) indol-3-yl)methyl], S- or R- [4- hydroxybenzyl], S- or R-[ (4-(t-butyloxy))benzyl], S- or R-(n-propyl), S- or R-(n-butyl), S- or R-[(napth-2- yl)methyl], S- or R-(2-carboxyethyl), S- or R- (cyclohexylmethyl), S-[(4-methoxybenzylthio)methyl], S-or R-[(4- methylbenzylthio)methyl], S- or R-thiomethyl, S- or R-[ 4-(N-methyl-N-(t-butoxycarbonyl) amino)-n-butyl], S- or R-[ 4-(N-ethyl(N-(t-butoxycarbonyl) amino)-n-butyl], S- or R-[4-(N-allyl(N-(t-butoxycarbonyl) amino)-n-butyl], S- or R-[4-(N-benzyl(N-(t-butoxycarbonyl) amino)-n-butyl], S- or R-[4-(N-(naphth-2-yl)(N-(t-butoxycarbonyl) amino) -n- butyl], S- or R-acetamido, S- or R-[2-(N,N- dimethylamino)ethyl], S- or R- (N, N-diethyl)acetamido, S- or R-(N,N-diallyl)acetamido, S- or R-(N-allyl)acetamido, S- or R-(N,N-dibenzyl)acetamido, S- or R- (N- benzyl) acetamido, S- or R- (N, N-di(napth-2- ylmethyl))acetamido, S- or R-(N-(napth-2- ylmethyl))acetamido, S- or R- propionamido, S- or R-(N,N- dimethyl)propionamido, S- or R- (N,N-diethyl)propionamido, S- or R-(N,N-diallyl)propionamido, S- or R-(N,N- dibenzyl)propionamido, S- or R-(N,N-di(napth-2- ylmethyl)propionamido, S- or R-[(N,N'-diallyl-N-PMC)-3- guanidino-n-propyl], S- or R-[(N,N',N''-trimethyl-N-PMC)- 3-(guanidino)-n-propyl], S- or R-[(N,N',N''-triethyl-N- PMC)-3-(guanidino)-n-propyl], S- or R-[N,N'' triallyl- N-PMC-3-(guanidino)-n-propyl], S- or R-[(indol-3- yl)methyl], S- or R-[(N-(methyl)indol-3-yl)methyl], S- or R-[(N-(ethyl)indol-3-yl)methyl], S- or R-[(N- (allyl)indol-3-yl)methyl], S- or R-[(N-(benzyl)indol-3- yl)methyl], S- or R-[(N-(naphth-2-ylmethyl) indol -3- yl)methyl], S- or R-(4-(methoxy))benzyl, S- or R-(4-
(allyloxy))benzyl, S- or R-(4-(ethoxy))benzyl, S- or R- (4-(benzoxy))benzyl, S- or R-(4-(naphth-2- ylmethoxy))benzyl, AA is one or zero when R7 is a hydrogen atom, CC is one or zero when R3 is a hydrogen atom, or when either R1 or R2 are taken together with R3 to form an S- or R- pyrrolidine or S-[4-(hydroxy)pyrrolidine].
A more preferred group of the library of resin- bound interior amido dimers, referred to hereafter as the "Type I bound amido dimers (Library)", occurs wherein R6 and R8 are independently methyl, ethyl, allyl, benzyl, or napth-2-ylmethyl. A preferred group of the Type I bound amido dimers (Library) is wherein either R1 or R2 is a hydrogen atom or is taken in conjunction with R3 to form a pyrrolidine ring, and the other is C1 to C12acyl, C3 to C10 cycloalkyl, C3 to C6 heterocycle, C1 to C12 alkyl, C1 to C12 substituted alkyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle.
Another preferred group of the Type I bound amido dimers (Library) is wherein either R1 or R2 are each a hydrogen atom, or one of R1 or R2 is a hydrogen atom and the other is taken together with R3 to form an S- pyrrolidine ring.
Another preferred group of interior amido dimers (Library) are those that have been cleaved from the solid support, hereinafter referred to as "cleaved interior amido dimers (Library)", and in the above
Formula I corresponds to wherein R9 is hydrogen and R10 is absent. A preferred group of cleaved interior amido dimers are wherein R3 and R7 are independently chosen from the group consisting of S- or R-methyl, S- or R- benzyl, a hydrogen atom, S- or R-(but-2-yl), S- or R-[ 4- (N-methylamino)-n-butyl], S- or R-[4-(N-ethylamino) -n- butyl], S- or R-[4-(N-allylamino)-n-butyl], S- or R-[4- (N-benzylamino)-n-butyl], S- or R-[4-(N-(napth-2- ylmethylamino)-n-butyl], S- or R-[ 4-(amino)-n-butyl], S- or R-[sec-butyl], S- or R-(methylsulfinyl)eth-1-yl, S- or R- acetamido, S- or R-[2-(N,N-dimethyl)acetamido], S- or R-(N, N-diethyl)acetamido, S- or R-(N,N- diallyl) acetamido, S- or R-(N-allyl)acetamido, S- or R- (N,N-dibenzyl) acetamido, S- or R-(N-benzylacetamido, S- and R-(N,N-di(napth-2-ylmethyl)acetamido, S- and R- (N- (napth-2-ylmethyl)acetamido, S- or R-(N,N- dimethyl) propionamido, S- or R-(N,N-diethyl)propionamido, S- or R-(N,N-dially)propionamido, S- or R-(N,N- dibenzyl)propionamido, S- or R- (N,N-di(napth-2- ylmethyl)propionamido, S- or R-
[3-(guanidino)-n-propyl], S- or R-[(N,N-diallyl)-3- guanidino-n-propyl], S- or R-[(N,N,N'-triallyl)-3- guanidino-n-propyl], S- or R-[(N,N,N'-trimethyl)-3-
(guanidino)-n-propyl], S- or R-[(N,N,N'-triethyl)-3-
(guanidino)-n-propyl], S- or R-hydroxymethyl, S- or R- [1
-(hydroxy)ethyl], S-phenyl, S- or R-[2-(carboxy)ethyl], S- or R-[ iso-propyl], S- or R-[(indol-3-yl)methyl], S- or R-[(N-(methyl)indol-3-yl)methyl], S- or R-[(N-
(ethyl)indol-3-yl) methyl], S- or R-[(N-(allyl)indol-3- yl)methyl], S- or R-[(N-(benzyl)indol-3-yl) methyl], S- or R-[(N-(naphth-2-ylmethyl)indol-3-yl)methyl], S- or R-(4- (methoxy))benzyl, S- or R-(4-(ethoxy))benzyl, S- or R-(4-
(allyloxy))benzyl, S- or R-[4-hydroxybenzyl], S- or R-(n- butyl), S- or R-(n-propyl), S- or R-[(napth-2-yl) methyl], AA is zero when R7 is hydrogen, CC is zero or one when R3 is a hydrogen atom, S- or R- (cyclohexylmethyl), S- or R- thiomethyl, or when either R1 or R2 are taken together with R3 to form an S- or R- pyrrolidine or S-[4-
(hydroxy)pyrrolidine].
A more preferred group of library of cleaved interior dimers, hereinafter referred to as "Type I cleaved amido dimers", wherein R6 and R8 are independently methyl, ethyl, allyl, benzyl, or napth-2-ylmethyl.
Spetific examples of the Type I cleaved amido dimers occur when : (1) wherein R6 is napth-2-ylmethyl, R3 is R-
[(N-(naphth-2-ylmethyl)indol-3-yl) methyl], and R1 and R2 are the same and are each a hydrogen atom; (2) wherein R6 is ethyl, R3 is benzyl and R1 and
R2 are the same and are each a hydrogen atom;
(3) wherein R6 is naphth-2 -ylmethyl, R3 is S- methyl, R1 and R2 are the same and are each a hydrogen atom; and
(4) wherein either R1 or R2 is a hydrogen atom and the other is taken in conjunction with R3 to form an S-pyrrolidine ring, and R6 is napth-2-ylmethyl. Another preferred group of compounds within the library of an approximately equimolar mixture of two or more compounds of Formula I are the interior amine compounds, thus, wherein in the above Formula I, X and Y are the same and are each a hydrogen atom. A preferred library of interior amine compounds are those that are dimers, that is wherein B, AA, BB and CC are zero, except that AA can be zero or one when R7 is a hydrogen atom and that CC can be zero or one when R3 is a hydrogen atom. Preferred interior amine dimers (Library) are those that have been cleaved from the solid support, wherein R9 is a hydrogen atom and R10 is absent. A preferred group of such cleaved interior amine dimers are wherein R3 and R7 are independently chosen from the group consisting of S- or R-methyl, S- or R-benzyl, a hydrogen atom, S- or R- (but-2-yl), S- or R-[4-(N-methylamino)-n-butyl], S- or R- [4-(N-ethylamino)-n-butyl], S- or R-[4-(N-allylamino)-n- butyl], S- or R-[4-(N-benzylamino)-n-butyl], S- or R-[4- (N-(napth-2-ylmethylamino)-n-butyl], S- or R-[4-(amino)- n-butyl], S- or R-[sec-butyl], S- or R-(2-aminoethyl), S- or R-(methylsulfinyl) eth-1-yl, S- or R-[2-(N,N- dimethylamino) ethyl], S- or R-(N, N-diethylamino) ethyl, S- or R-(N,N-diallylamino) ethyl, S- or R- (N- allylamino) ethyl, S- or R-(N,N-dibenzylamino) ethyl, S- or R-(N-benzylamino)ethyl, S- and R-(N,N-di(napth-2- ylmethylamino))ethyl, S- and R-(N-(napth-2- ylmethylamino))ethyl, S- or R-(N-propyl)amine, S- or R- (N,N-dimethylamino) propyl, S- or R-(N,N- diethylamino) propyl, S- or R-(N,N-diallylamino)propyl, S- or R-(N,N-dibenzylamino) propyl, S- or R-(N,N-di(napth-2- ylmethylamino) propyl, S- or R-[3-(guanidino)-n-propyl], S- or R- [(N,N-diallyl)-3-guanidino-n-propyl], S- or R- [(N,N,N'-triallyl)-3-guanidino-n-propyl], S- or R-
[(N,N,N'-trimethyl)-3-(guanidino)-n-propyl], S- or R- [(N,N,N'-triethyl)-3-(guanidino)-n-propyl], S- or R- hydroxymethyl, S- or R-[1 -(hydroxy)ethyl], S-phenyl, S- or R-[3-(hydroxy)-n-propyl], S- or R-[ iso-propyl], S- or R-[(indol-3-yl) methyl], S- or R-[(N-(methyl)indol -3- yl) methyl], S- or R-[(N-(ethyl)indol-3-yl)methyl], S- or R-[(N-(allyl)indol-3-yl)methyl], S- or R-[(N- (benzyl)indol-3-yl)methyl], S- or R-[(N-(naphth-2- ylmethyl)indol-3-yl) methyl], S- or R-(4-(methoxy))benzyl, S- or R-(4-(ethoxy))benzyl, S- or R-(4-
(allyloxy))benzyl, S- or R-(4-hydroxybenzyl), S- or R- (n- butyl), S- or R-(n-propyl), S- or R-[(napth-2-yl)methyl], AA is zero or one when R7 is a hydrogen atom, CC is zero or one when R3 is a hydrogen atom, S- or R- (cyclohexylmethyl), S- or R-thiomethyl, or when either R1 or R2 are taken together with R3 to form an S- or R- pyrrolidine or S-[4-(hydroxy)pyrrolidine]. A preferred group of dimers within the immediately preceeding
preferred group occurs when Rfi and R8 are independently methyl, ethyl, allyl, benzyl, or napth-2-ylmethyl. Another preferred group within the library of interior amine dimers are the resin-bound compounds, thus, wherein R9 is a solid support and R10 is absent.
A preferred group of the resin-bound interior amine dimers (Library) occurs wherein R3 and R7 are
independently chosen from the group consisting of S- or R-methyl, S- or R-benzyl, a hydrogen atom, S- or R-(but- 2-yl), S- or R-[4-(N-methylamino)-n-butyl], S- or R-[4- (N,N-dimethylamino)-n-butyl], S- or R-[4-(N-ethylamino)- n-butyl], S- or R-[4-(N-methyl-N-ethylamino)-n-butyl], S- or R-[4-(N-allylamino)-n-butyl], S- or R-[4-(N-methyl-N- alkylamino)-n-butyl), S- or R-[4-(N-benzylamino)-n- butyl], S- or R-[4-(N-methyl-N-benzylamino)-n-butyl], S- or R-[4-(N-(napth-2-ylmethylamino)-n-butyl], S- or R-[4- (N-methyl-N-naphth-2-ylmethylamino)-n-butyl], S- or R- [4-(amino)-n-butyl], S- or R-[sec-butyl], S- or R-(2- aminoethyl), S- or R-(methylsulfinyl)eth-1-yl, S- or R- acetamido, S- or R-[2-(N,N-dimethylamino)ethyl], S- or R- (N, N-diethylamino)ethyl, S- or R-(N,N- diallylamino)ethyl, S- or R-(n-allylamino)ethyl, S- or R- (N,N-dibenzylamino)ethyl, S- or R-(N-benzylamino)ethyl, S- or R-(N,N-di(napth-2-ylmethylamino))ethyl, S- or R-(N- (napth-2-ylmethylamino))ethyl, S- or R-(N-propylamine), S- or R-propionamido, S- or R-(N,N-dimethylamino)propyl, S- or R-(N,N-diethylamino) propyl, S- or R-(N,N- diallylamino) propyl, S- or R-(N,N-dibenzylamino)propyl, S- or R-(N,N-di(napth-2-ylmethylamino)propyl, S- or R-[3- (N-PMC-guanidino)-n-propyl], S- or R-[(N,N'-diallyl-N- PMC)-3-guanidino-n-propyl], S- or R-[(N,N',N'*-triallyl- N-PMC)-3-guanidino-n-propyl], S- or R-[(N,N',N''- trimethyl-N-PMC)-3-(guanidino)-n-propyl], S- or R-
[(N,N',N''-triethyl-N-PMC)-3-(guanidino)-n-propyl], S- or R-hydroxymethyl, S- or R-[1 -(hydroxy)ethyl], S-phenyl, S- or R-[3-(hydroxy)-n-propyl], S- or R-[ iso-propyl], S- or R-[(indol-3-yl) methyl], S- or R-[(N-(methyl)indol- 3-yl)methyl], S- or R-[(N-(ethyl)indol-3-yl)methyl], S- or R-[(N-(allyl)indol-3-yl) methyl], S- or R-[(N- (benzyl)indol-3-yl) methyl], S- or R-[(N-(naphth-2- ylmethyl)indol-3-yl) methyl], S- or R-(4-(methoxy))benzyl, S- or R-(4-(ethoxy))benzyl, S- or R-(4-(allyloxy))benzyl, S- or R-[4-hydroxybenzyl], S- or R-[n-butyl], S- or R-(n- propyl), S- or R-[(napth-2-yl)methyl], AA is zero or one when R7 is a hydrogen atom, CC is zero or one when R3 is a hydrogen atom, S- or R-[cyclohexylmethyl], S- or R- [thiomethyl], or when either R1 or R2 are taken together with R3 to form an S- or R- pyrrolidine or S-[4-
(hydroxy)pyrrolidine]. A still more preferred group within the library of resin bound interior amine dimers occurs when R6 and R8 are independently methyl, ethyl, allyl, benzyl, or napth-2-ylmethyl. Another aspect of the instant invention is a method for effecting analgesia in a mammal, which
comprises administering an effective amount of a single compound of Formula I in conjunction with a
pharmaceutically-acceptable carrier. A preferred method of effecting analgesia in a mammal occurs when a single compound that is an interior amido dimer and further wherein B, AA, BB and CC are zero, R9 is a hydrogen atom, R8 is napth-2-ylmethyl, R7 is S-methyl, R6 is ethyl, R3 is S-benzyl, and R1 and R2 are each a hydrogen atom is used. Another preferred method of effecting analgesia in mammals utilizes a single interior amine dimer wherein further R9 is a hydrogen atom, R8 is benzyl, R7 is S-methyl, R6 is naphth-2-ylmethyl, R3 is taken in conjunction with either R1 or R2 to form an S-pyrrolidine ring and the other of R1 and R2 a hydrogen atom.
Another aspect of the instant invention is a method of effecting a decrease in the postprandial rise in blood glucose of a mammal after ingestion of a
carbohydrate load by said mammal, which comprises
administering an effective amount of a single compound of Formula I in conjunction with a pharmaceutically- acceptable carrier. A preferred method of affecting a decrease in the postprandial rise in the blood glucose of a mammal occurs wherein the single compound has X and Y taken together to form a carbonyl group, B, AA, BB and CC are zero, R9 is a hydrogen atom, R8 is benzyl, R6 is naphth-2-ylmethyl, R3 is R-(N-(naphth-2-ylmethyl)indol-3- ylmethyl), R1 and R2 are each hydrogen, R10 is absent, and R7 is chosen from the group consisting of S- (4- (N- benzylamino)-n-butyl), R-(4-(N-benzylamino)-n-butyl), S-(3-guanidino)-n-propyl), and R-(3-guanidino)-n-propyl;
Yet another aspect of the instant invention is a method of treating microbial infections in mammals, which comprises administering an effective amount of a single compound of Formula I in conjunction with a pharmaceutically-acceptable carrier. A preferred method of treating microbial infections in mammals occurs when wherein the single compound has X and Y taken together to form a carbonyl group, B, AA, BB and CC are zero, R9 is a hydrogen atom, R8 is benzyl, R6 is naphth-2-ylmethyl, R3 is R-(N-(naphth-2-ylmethyl)indol-3-ylmethyl), R1 and R2 are each hydrogen, R10 is absent, and R7 is chosen from the group consisting of S-(4-(N-benzylamino)-n-butyl), R- (4-(N-benzylamino)-n-butyl), S-(3-guanidino)-n-propyl), and R-(3-guanidino)-n-propyl).
Another aspect of the instant invention is a method of step-wise N-alkylation of the amide bond of the N-terminal residue of a compound of the Formula (II) :
Figure imgf000038_0001
Wherein : R11 is independently a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycleal, or a substituted C6 to C15 alkyl heterocycle;
ZZ is from zero to five;
And R12 is a solid support or a group of the Formula (III):
(III)
Figure imgf000039_0001
Wherein R14 is a C1 to C18 substituent group;
Wherein W is 0 to 4;
R13 is independently a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
R15 is a solid support (when W is one) or a bond to the preceeding methylene group (when W is from two to four);
YY is from zero to five;
Wherein the compound of the above formula is a) first reacted under anhydrous conditions in an inert atmosphere with an excess amount non-nucleophilic base having a pKa between about 18 to about 40; then
b) reacting the resulting anion under anhydrous conditions in an inert atmosphere in a polar aprotic solvent with an excess amount of an alkylting agent of the formula
(LG) -Q Wherein LG is leaving group;
Q is a C1 to C18 substituent groups as defined above for Formula (I); and repeating steps a) and b) as necessary to drive the alkylation to completion; with the proviso that all previous internal backbone amide bonds have been previously alkylated with a C1 to C18 substituent group and, when W is from 2 to 4, all of the R14 groups are not the same C1 to C18
substituent group.
A preferred method of step-wise N-alkylation occurs when LG is iodo or bromo and the -CH2-Q moiety is methyl, ethyl, allyl, benzyl or napth-2 -ylmethyl. A further preferred method of step-wise N-alkylation occurs wherein Rn and R13 are indepently chosen from the group consisting of S- or R-methyl, S- or R-benzyl, a hydrogen atom, S- or R-(but-2-yl), S- or R-[4-(t- butoxycarbonylamino)-n-butyl], S- or R-[4-(amino)-n-butyl], S- or R-[sec-butyl], S- or R-(methylsulfinyl)eth- 1-yl, S- or R-[ 3-(guanidino)-n-propyl], S- or R-[(N- PMC)-3-(guanidino)-n-propyl], S- or R-(t-butoxy)methyl, S- or R-[2-(t-butoxy)ethy], S-phenyl, S- or R-(3-(2- butoxycarbonyl)ethyl), S- or R-[iso-propyl], S- or R-[(N- (t-butoxycarbonyl) indol-3-yl)methyl], S- or R-[4- hydroxybenzyl], S- or R-[(4-(t-butoxy))benzyl], S- or R- [n-propyl], S- or R-(n-butyl), S- or R-[(napth-2- yl)methyl], S- or R-(cyclohexylmethyl), S-[(4- methoxybenzylthio)methyl], S-[(4- methylbenzylthio)methyl], S- or R-thiomethyl, S- or R-[4- (N-methyl-(N-(t-butoxycarbonyl))amino)-n-butyl], S- or R- [ 4-(N-ethyl-(N-(t-butoxycarbonyl))amino)-n-butyl], S- or R-[4-(N-allyl-(N-(t-butoxycarbonyl))amino)-n-butyl], S- or R-[4-(N-benzyl-(N-(t-butoxycarbonyl))amino)-n-butyl], S- or R-[4-(N-(naphth-2-yl)-(N-(t-butoxycarbonyl))amino)- n-butyl], S- or R-[2-(N,N-dimethyl)acetamido], S- or R- acetamido, S- or R-(N, N-diethyl)acetamido, S- or R- (N,N-diallyl)acetamido, S- or R-(n-allyl)acetamido, S- or R-(N,N-dibenzyl)acetamido, S- or R-(N-benzyl)acetamido, S- or R-(N,N-di(napth-2-ylmethyl))acetamido, S- or R- (N- (napth-2-ylmethyl))acetamido, S- or R-n-propylamine, S- or R-propionamido, S- or R-(N,N-dimethyl)propionamido, S- or R-(N,N-diethyl)propionamido, S- or R-(N,N- diallyl) propionamido, S- or R-(N,N-dibenzyl)propionamido, S- or R-(N,N-di(napth-2-ylmethyl)propionamido, S- or R- [(N,N'-diallyl-N-PMC)-3-guanidino-n-propyl], S- or R- [(N,N',N''-trimethyl-N-PMC)-3-(guanidino)-n-propyl], S- or R-[(N,N',N''-triethyl-N-PMC)-3-(guanidino)-n-propyl], S- or R-[N,N',N''-triallyl-N-PMC)-3-guanidino-n-propyl], S- or R-[(indol-3-yl) methyl], S- or R-[(N-(methyl)indol- 3-yl)methyl], S- or R-[(N-(ethyl)indol-3-yl) methyl], S- or R-[(N-(allyl)indol-3-yl)methyl], S- or R-[(N- (benzyl)indol-3-yl) methyl], S- or R-[(N-(naphth-2- ylmethyl)indol-3-yl) methyl], S- or R-(4-(methoxy))benzyl, S- or R-(4-(ethoxy))benzyl, S- or R-(4-(allyloxy))benzyl, S- or R-(4-(benzoxy)benzyl, S- or R-(4-(naphth-2- ylnethoxy) benzyl, ZZ is one or zero when R11 is a hydrogen atom, YY is one or zero when R13 is a hydrogen atom, or when either R13 is taken together with R14 to form an S- or R- pyrrolidine or S-[4-(hydroxy)pyrrolidine].
Another aspect of the instant invention
utilizes the positional scanning method and is a method of synthesizing and testing for biological activity a library of an approximately equimolar amount of compounds of the following Formula (IV):
Figure imgf000043_0001
Wherein in the above Formula (IV) :
R19, R21 and R23 independently are a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16
substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
R25 is a hydrogen atom or a solid support; R20, R22 and R24 are independently a C1 to C16 substituent group;
AA, BB and CC are independently 0 to 5;
B is from 0 to 3;
X and Y are taken together to form a carbonyl group or are separate and are each a hydrogen atom;
R16, R17 and R18 independently are a hydrogen atom, an amino protecting group, C1 to C12 acyl, C3 to C10 cycloalkyl, C3 to C6 heterocycle, C1 to C12 alkyl, C1 to C12 substituted alkyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle; R16 is optionally present as a C1 to C18 substituent group when R1 and R2 are other than a hydrogen atom or an amino protecting group;
Wherein said library of compounds is composed of SL physically separate sublibraries; wherein SL is equal to (2B + 4);
Further wherein each sublibrary is composed of physically separate mixtures, wherein the number of said mixtures is equal to the number of different substituents incorporated at Rfix, which Rfix can be any one of R19, R20, R21, R22, R23, or R24 in the above Formula IV;
Wherein the compounds of the above Formula IV are synthesized and tested as follows:
(a) For each sublibrary SL, choosing Rfix from R19, R20, R21, R22, R23, or R24 ;
(b) Dividing a solid support into
approximately equal separate portions with the number of portions equal to the number of substituents to be incorporated at R23, and couple each physically separate portions of solid support to one of the monomers
containing a single substituent at R23, then mixing all of said physically separate portions;
(c) Dividing the mixed solid support from step (a) into approximately equal separate portions in a number equal to the number of different substituents to be incorporated at R24 by alkylation, alkylating each physically separate solid support mixtures with one alkyl group, then mixing said resins;
(d) When B is 1 through 3, dividing each of said solid support portions into a number of
approximately equal separate portions, said number equal to the number of substituents at R21, coupling one of the monomers containing a single substituent R23 to each separate solid support portion then mixing said portions; (e) When B is 1 to 3, separating said mixture of solid support portions into a number of approximately equal separate portions, said number equal to the number of alkyl substituents at R20, alkylating each physically separate portion with one such alkylating agent, and mixing all the resultant solid support
portions;
(f) Optionally repeating steps (d) and (e) one or two times when B is two or three,
respectively; (g) Dividing the mixture of solid support portions from either step (c), (e), or step (f) into approximately equal separate portions equal to the number of substituents to be placed at R19, coupling one such monomer containing a single R19 to each physically
separate solid support portion, and mixing said portions; (h) Dividing the mixture of portions from step (g) into a number of approximately equal separate portions, said number equal to the number of alkyl substituents at R22 to be utilized, alkylating each said separate portion with a single alkyl group R22;
(i) Optionally adding R17 and/or R18 by reductive alkylation;
(j) Optionally adding the quaternary substituent R16; (k) Optionally reducing the interior amides, thus converting X and Y taken together are a carbonyl oxygen to wherein each X and Y is a hydrogen atom; and
(1) Cleaving said molecules from the solid support;
(m) Testing each portion of each SL sublibraries in the appropriate biological screen or screens; and determining from the results of said screens which substitutent at Rfix is the best. (n) Optionally synthesizing the molecule of Formula (I) containing the best (Rfix) substitutent at
R19 , R20 , R21 , R22 , R23 , or R24 ; With the proviso that for each sublibrary SL the first solid support mixing step immediately following the introduction of Rfix is omitted;
Further wherein: (1) each coupling step in the above series of steps ( (b), (d), (f) and (g) ) involves a substrate of the Formula (V) :
Figure imgf000047_0001
With an excess of an active acylating form of the monomer of the Formula (VI) :
Figure imgf000047_0002
Wherein in the above Formulas (V) and (VI) :
SS is a solid support;
R26 are two hydrogen atoms each bound to the nitrogen atom;
R28 is a C1 to C18 substituent group;
R27 is independently a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
RVAR can be the same or different as R27 and is chosen from the same group of substituents as R27;
DD and EE are independently 0 to 5 ;
X and Y are either taken together to form a carbonyl oxygen;
PG is an amino protecting group other than trityl;
A is a group, when taken with the preceeding carbonyl group; that forms an active acylating agent; and
C is from 0 to 4;
(2) Each alkylating step in the above steps (c), (e), (f) and (h) requires reacting a substrate of the Formula (VII):
Figure imgf000049_0001
With an excess of an alkylating agent of the Formula (VIII): (VIII) (LG)-Q
Under anhydrous conditions, and an inert atmosphere in a polar, aprotic solvent;
Wherein in the above Formulas (VII) and (VIII) :
LG is a leaving group under the conditions of the alkylation;
Q is a C1 to C18 substituent group as defined above in Formula (I);
FF is 0 to 5;
X and Y are taken together to form a carbonyl oxygen; R31 is a hydrogen atom when R29 is a trityl group or is a C1 to C18 substituent group;
R30 is independently a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle; and
R29 is a trityl group when R31 is a hydrogen atom or is a group of the Formula (IX) :
Figure imgf000050_0001
Wherein in the above Formula (IX) :
X and Y are as X and Y above;
GG is 0 to 5;
C is from 1 to 4;
R33 is independently a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle; and R32 is a hydrogen atom if R32 is bonded to the N- terminal amino group or otherwise it is a C1 to C18 substituent wherein one such C1 to C18 substituent differs from the other substituents; (3) Reductive alkylation of the N- terminal nitrogen group as described above in step (i) of a compound of the Formula (X) :
( )
Figure imgf000051_0001
Under mildly acidic conditions with a ketone or aldehyde containing the R34 and/or R35 groups followed by the treatment of a reducing agent;
Wherein in the above Formula (X) :
X and Y are taken together to form a carbonyl oxygen;
HH, II, and JJ are independently 0 to 5;
B is from 0 to 3;
R39 , R41 and R37 are the same or different and are chosen from the group consisting of independently a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
R40 and R42 are different and are a C1 to C18 substituent group;
R34 or R35 when B is 0, is optionally one or two hydrogen atoms attached to the nitrogen atom, or is a optionally one or more, same or different groups, chosen from the group consisting of a hydrogen atom, an amino protecting group, C1 to C12 acyl, C3 to C10 cycloalkyl, C3 to C6 heterocycle, C1 to C12 alkyl, C1 to C12 substituted alkyl, C7 to C16 alkylaryl, C7 to C16 substituted alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
R36 is a hydrogen or a bond to a R34 or R35 before the reduction occurs, and when B is from 1 to 3; R38 is a C1 to Clβ substituent group different from at least one other R40, R42 or R38 groups;
(4) Optional reduction of the amide bonds as described above in step (j) of a compound of Formula (X) wherein X and Y are taken together to form a carbonyl groups, before or after it is cleaved from the solid support, using a boron reducing agent.
(5) Optionally quaternization of the terminal amino groups with an excess amount of alkylating agent of above of the formula:
(LG)-Q Where (LG) and Q have the same meanings as above in a polar, aprotic solvent.
It will be obvious to one skilled in the art that, in the above positional scanning method, the substituents at R34, R35 and R36 can be designated as "Rfix", such that the number of sublibraries SL would be
increased by one, two or three, respectively, depending on how many of these three "R" groups are varied.
Yet another aspect of the invention is an iterative synthetic approach wherein the method for the iterative synthesis and screening of a library of an approximately equimolar amount of compounds of the
Formula (XI):
Figure imgf000053_0001
Wherein in the above Formula (XI) :
R48 is a hydrogen atom or a solid support;
R45 and R47 are different and are each a C1 to C18 substituent group; KK and LL are independently 0 to 5; R44 and R46 are independently chosen from the group consisting of independently a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
X and Y are either taken together to form a carbonyl group or are separate and are each a hydrogen atom; R43 is one or two hydrogen atoms, or groups of the formula Ra, Rb and Rc , wherein Ra and Rb independently are a hydrogen atom, an amino protecting group, C1 to C12 acyl, C3 to C10 cycloalkyl, C3 to C6 heterocycle, C1 to C12 alkyl, C1 to C12 substituted alkyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle; Rc is
optionally present as a C1 to C18 substituent group when Ra and Rb are other than a hydrogen atom or an amino
protecting group; and Wherein the method comprises:
(a) Splitting a solid support into a number of approximately equal, separate portions, the number of said portions being equal to the number of monomers containing different substituent groups at R46; (b) Coupling a monomer containing one of the number of substituent groups at R46 to a separate portion of the solid support;
(c) Mixing all of the separate portions of solid support;
(d) Splitting the solid support mixture into approximately equal, separate portions, the number of portions equal to the number of different substituents to be added at R47; (e) Alkylating each separate portion of solid support with a single alkylating agent, each agent containing a unique alkyl group at R47, thus adding a single alkyl group at R47 to the plurality of the
compounds bonded to each separate portion of solid support;
(f) Mixing all of the separate portions of solid support ;
(g) Splitting the solid support mixture into a number of approximately equal separate portions, the number of said portions equal to the number of different substituents to be added at R44 ;
(h) Coupling each monomer containing a single substituent group at R44 to a separate portion of the solid support, thus coupling a single different monomer to the plurality of the compounds bonded to each separate portion of the resin;
(i) Splitting each of the separate portions of solid support into a number of approximately equal physically-separate portions, wherein the number of portions is equal to the number of different substituents to be added by alkylation at R45;
(j) Alkylating each separate portion of solid support with a separate alkylating agent containing a single different R45 group, thus adding a single different alkyl group at R45 to the plurality of the compound bonded to each separate portion of the resin;
(k) Cleaving the generated compound mixtures of Formula (XI) from each separate portion of solid support and testing each separate mixture from each separate portion of solid support in the appropriate biological screen or screens, and determining from the results of said screens which mixture contains the best combination of substituents at R44 and R45; (1) Repeating steps (a) through (e), wherein the substituents at R46 and R47 are the same used in said original steps (a) through (e);
(m) Coupling the monomer containing the most active R44 substituent to each of the separate portions of resin from step (1); (n) Alkylating each of the portions from step (m) with the best alkyl group at R45 determined in step (k);
(o) Cleaving each separate mixture of compounds of the above Formula (XI) from the solid support, testing each separate mixture of compounds in the same biological screens as in step (k), and
determining the most active substituent at R47 in those screens; (p) Repeating steps (a) and (b), wherein the same group of monomers containing the various substituent R46 are used as in the original step (a);
(q) Alkylating each separate resin portion from step (p) with an alkylating agent placing the best alkyl group at R47 as such alkyl group was determined in step (o);
(r) Coupling to each separate portion of resin the monomer containing the best R44 substituent as such substituent was determined in step (k); (s) Alkylating each separate portion of resin with a group that was the best alkyl group R45 as such group determined in step (k);
(t) Cleaving each separate compound from the solid support, and testing each separate mixture of compound separately in the same screens as in steps (o) and (k) in order to determine the best substituents at R46 ;
(aa) Optionally reductively alkylating and quaternizing the N-terminal amino group (R43) , either before or after cleavage of the compound from the solid support; and
(bb) Optionally reducing the interior amide groups before or after cleavage of the compound from the solid support such that X and Y in Formula (XI) are each a hydrogen atom;
Further wherein:
(1) each of the above coupling steps (b), (h), (1), (m), (p) or (r), involves a substrate of the Formula (XII) :
Figure imgf000058_0001
With an excess of an active acylating form of the monomer of the Formula (XIII) :
Figure imgf000059_0001
Wherein in the above Formulas (XII) and (XIII) :
SS is a solid support;
R49 is two hydrogen atoms;
R51 is a C1 to C18 substituent group
R50 is independently a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
RVAR2 can be the same or different as R50 and is chosen from the same group of substituents as R50;
MM and NN are independently 0 to 5;
X and Y are either taken together to form a carbonyl group or are separate and are each a hydrogen atom;
PG is an amino protecting group other than trityl;
A is a group, when taken with the preceeding carbonyl group; that forms an active acylating agent; and C is 0 or 1;
(2) Each of the above alkylating steps (e), (j), (1), (m), (q) and (s), requires reacting a substrate of the Formula (XIV) :
Figure imgf000060_0001
With an excess of an alkylating agent of the Formula (XV) :
(xv) (LG)-Q Under anhydrous conditions, and an inert atmosphere in a polar, aprotic solvent;
Wherein in the above Formulas (XIV) and (XV):
LG is a leaving group under the conditions of the alkylation; Q is a C1 to C18 substituent group;
00 is 0 to 5;
X and Y are taken together to form a carbonyl group; or are separate and are each a hydrogen atom;
R54 is a hydrogen atom if R52 is a trityl group or is a C1 to C18 substituent group;
R53 is independently a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
R52 is a trityl group if R54 is a hydrogen atom or is a group of the Formula (XVI) :
Figure imgf000061_0001
Wherein in the above Formula (XVI) :
X and Y are as X and Y above;
PP is 0 to 5;
R55 is a trityl group;
R56 is independently a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle; and
(3) Optional reductive alkylation of the N-terminal nitrogen group of a compound of the
Formula (XVII):
Figure imgf000062_0001
Under mildly acidic conditions with a ketone or aldehyde containing the R1 and/or R2 groups followed by treatment with a reducing agent;
Wherein in the above Formula (XVII) :
X and Y are taken together to form a carbonyl group;
QQ and RR are independently 0 to 5;
R58 and R60 are the same or different and are chosen from the group consisting of independently of a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle; R59 and R61 are the same or different and are a C1 to C18 substituent group;
R57 is either two hydrogen atoms attached to the nitrogen atom, or is a single hydrogen atom and another group bonded to the nitrogen atom which groups is selected from the group consisting of a hydrogen atom, an amino protecting group, C1 to C12 acyl, C3 to C10
cycloalkyl, C3 to C6 heterocycle, C1 to C12 alkyl, C1 to C12 substituted alkyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
(4) Optional reduction of the amide bonds of a compound of Formula (XI), before or after it is cleaved from the solid support, using a boron-based reducing agent, such as borane or sodium borohydride, and the like.
In the above iterative synthetic approach, it would be obvious to one skilled in the art the method could easily be extended to encompass a library of all of the compounds of Formula I, in other words, such that repeating the coupling; alkylation and testing steps described above be applied to compounds within the scope of Formula I, wherein B is 1, 2, or 3. Furthermore, it would be obvious to one skilled in the art that
substitutent at R1, R2 and R10 would be separate variables that could be synthesized and screened by the above iterative method. Due to their location in the molecule, these substituents, if present, would be screened to find the best substituent before the N-terminal monomer and the attendant N-alkyl group could be determined.
Finally, one skilled in the art would be able to combine the above iterative and positional scanning approaches in order to conserve resources and time. For example, in libraries where B in the above Formula I is 1, 2, or 3, the iterative approach could be used to determine the optimum substituents on the last two
variable substituents and the optimum substituents at the remaining positions could be determined by the positional scanning approach.
Simultaneous multiple solid phase methodology (Merrifield, R.B., J. Am. Chem. Soc., 85:2149 (1963)) was the basic technology used to synthesize and design the peptidomimetic library set forth in Formula I. A solid phase-based synthetic method was developed to
successively alkylate each amide bond following its formation. In this library, different alkylating agents were used to create increased molecular diversity and to eliminate the hydrogen bonding potential of the amide functionality. Optionally, the N-terminal nitrogen can be reductively alkylated and quarternized and the
interior amide bonds can be reduced (i.e., X and Y are each a hydrogen atom). In Formula I, when B is 2 or 3, R4 and R5 do not have to be the same as the other R4 and R5 groups present in the molecule. Cleavage from the solid support led to peptidomimetics of the Formula I (wherein R9 is hydrogen, each having diversity positions at the amino acid side chain positions (R3, R5 and R7), at the amide alkyl groups (R4, R6, R8), and at the N-terminal groups (R1 , R2 and R10).
Although a number of methods for the permethylation of peptides in solution (Hakomori, S.-I., J. Biochem 55:205 (1964); Vilkas, E., et al., Tetrahedron Letters, 26:3089 (1968); Challis, B.C., et al., The
Chemistry of Amides, Zabicky, J. Ed.; Interscience: New York, 1970, pp. 731-857; are known, the permethylation of resin-bound peptides, using sodium hydride for the formation of amide anions, was reported only recently (Ostresh et al., Proc. Natl. Acad. Sci, USA
91:11138-11142 (1994)). For the purpose of a stepwise alkylation following each amino acid coupling on the solid support, lithium t-butoxide was found to be more effective for the successive formation of the amide anions.
As an important prerequisite for the synthesis of this library, reproducible conditions for the N-amide alkylations had to be established for the base treatment of solid phase-bound amino acids or peptides. The reactions were carried out under an anhydrous nitrogen atmosphere, and the amino acid or peptide resin of interest was treated with excess lithium t-butoxide in tetrahydrofuran. Following removal of excess base, the alkylating agent in an aprotic, polar solvent such as dimethyl sulfoxide was reacted with the resin-bound compound. The alkylation reaction mixture was then removed and the base and alkylation treatments were repeated to drive the alkylation reaction to completion. Potential racemization during alkylation was studied using analytical reversed-phase high performance liquid chromatography (RP-HPLC); the four possible permethylated stereoisomers of Phe-Leu-NH2 were used as reference standards. (Ostresh, J.M., et al., Peptides 94:
Proceedings of the 23rd European Peptide Symposium, Maia, H.L.S. Ed.; Escom: Leiden, 1995, pp. 416-417). The maximum percentage of racemization found following repeated base and methylation treatments was < 1%.
The techniques for the synthesis of the
selectively N-alkylated compounds of Formula I are well known in the art, with the exception of the selective N- alkylation procedures discussed above. These techniques can be conveniently discussed in conjunction with Scheme 1:
Figure imgf000067_0001
In the above Scheme 1, Reaction "i" represents the coupling of the C-terminus of peptide-like residue to an amino-derivatized solid support. For instance, an peptide-like residue with amino terminus protected by a base or weak-acid labile protecting group, such as Fmoc, is converted to a good acylating agent in situ using known reagents and conditions. Such reagents include carbodiimide reagents (eg. N,N'-dicyclohexylcarbodiimide (DCC) and N,N'-diiso-propylcarbodiimide in conjunction with 1-hydroxybenzotriazole) in an aprotic, polar solvent such as DMF. (Such couplings were repeated if necessary.) In the reaction labelled as "ii" in Scheme 1, the N- terminal protecting group was removed and replaced with a trityl group, which was found to protect such group during the next interior, selective N-alkylation step. Under anhydrous conditions and an inert atmosphere, the tritylated residue was treated with an excess amount of lithium t-butoxide in a polar, aprotic solvent (such as tetrahydrofuran), followed by the addition of an excess of an alkylating agent of the formula
(LG)-Q wherein LG is a good leaving group under the Sn2
conditions of the reaction (such as bromo, iodo, tosyl, triflate and the like), and Q forms a C1 to C18 linear, branched, cyclic, saturated, partially or fully
unsaturated alkyl group, as described above in conjuction with the "C1 to C18 substituent group" of R4, R6, and R8 of Formula I. Multiple repetitions of such alkylating conditions are often necessary. The reaction denoted as "iii" in the above Scheme 1 denotes the steps necessary to couple a second (and any additional) monomer (as defined in Formula II) the recently N-alkylated resin- bound residue. Thus, the trityl protecting group is removed under weakly acidic conditions (2%
trifluoroacetic acid), the deprotected molecule
neutralized then coupled with and FMOC-protected amino acid (or one bearing an equivalent protecting group) using the same conditions for coupling the first residue to the amino-deriviatized resin. The reaction labelled "iv" in Scheme 1 is a repeat of the selective N- alkylation procedure, including the preliminary N- protection steps, of reaction "ii". Reaction "v" shows the removal of the trityl group from the amino-terminus of the bound residue as before followed by the removal of the selectively-N-alkylated molecule from the amino- derivatized residue with hydrogen fluoride. One skilled in the art would recognize that subsequent residues could be added then selectively alkylated before removal of the amino-derivatized according to the steps set forth in Scheme 1, thus yielding compounds of Formula I wherein B is 1, 2 or 3. Furthermore, while still attached to the resin, it is advantages to derivatize the N-terminal amino group to form compounds wherein at least one of R1 and R2 is other than hydrogen, and where possibly R10 is present. R1 and R2 groups are most frequently added by the process of reductive alkylation, as set forth (Borch, R.F., et al., J, Am, Chem. Soc., 93:2897 (1971); Coy, D.H., et al., Tetrahedron, 44:835 (1988); Staftkova, M., et al., Drug Development Research, 33:146 (1994) (herein incorporated by reference) . Thus, appropriate aldehyde or ketone is added to the resin-bound compounds under mildly acidic conditions to effect Schiff-base (imine)
formation, which imine is reduced to the substituted amine by sodium cyanoborohydride, or other mild reducing agent. Additionally, the free amino terminus can be acylated with a C1 to C12 acyl group, using well-known conditions as described in Staftková, M., et al., Drug Development Research, 33:146 (1994) (herein incorporated by reference). It is preferable, however, to add the R10 (alkyl) substituent before reductive alkylation. Such an alkylation proceeds under the same alkylation conditions used for the R4, R6, and R8 groups. Finally, while still resin-bound, or after cleavage from the resin, the interior amide groups can be reduced (i.e. X and Y taken together form a carbonyl group to X and Y are each a hydrogen atom.) Such a reduction is known in the art (see, for instance, Dooley, C.T., et al., Analgesia, INRC Proceedings, 1:400 (1995)). Thus, for both situations (i.e., when R9 is a hydrogen atom or a solid (resin)) mild, soluble hydrogenation catalysts such as a boric acid/trimethylborate/borane-tetrahydrofuran combination can be used.
Individual model compounds were used to study the modification of amino acid side chains during the alkylation conditions. Fifty N-trityl (triphenylmethyl; Trt) dipeptide resins, designated Trt-O-Leu-MBHA resin (MBHA = p-methylbenzhydrylamine) were alkylated where O represents a single proteinogenic L-amino acid, their D- counterparts, or 11 other individual "unnatural" amino acids. Aspartic acid was excluded from the 20
proteinogenic amino acids, since multiple products were formed following base treatment and alkylation. Methyl iodide, allyl bromide and benzyl bromide were used initially as alkylating agents. The individual crude alkylated products were analyzed by RP-HPLC and matrix assisted laser desorption ionization-mass spectroscopy (MALDI-MS) to determine their purity and identity.
(Ostresh, J.M., et al., Peptides 94: Proceedings of the 23rd European Peptide Symposium, Maia, H.L.S. Ed.; Escom: Leiden, 1995, pp. 463-464). During the alkylation procedure, the functional groups of the amino acid side chains were reproducibly modified. Based on preliminary evidence the following modifications were observed: 1) the ε-monoalkyl amine was formed during alkylation when the e-amino group of lysine was protected with Boc; 2) the unprotected amide functionality of the side chains of L-asparagine and L-glutamine, when alkylated with any of the three alkylating agents, yielded dialkyl amides, whereas allylation and benzylation of the D-isomers led to mono and dialkyl amides, indicating stereochemical hindrance of the diastereomers; 3) the 2,2,5,7,8- pentamethylchroman-6 -sulfonyl (Pmc) protected arginine side chain yielded the trimethyl derivative following permethylation and di- and triallyl derivatives following perallylation, but was negligibly alkylated following perbenzylation; 4) when unprotected, the reactive indole nitrogen of tryptophan was alkylated; 5) the use of 2- bromo-Cbz protection for tyrosine resulted in formation of the methyl and allyl ether analogs and any O-benzyl products formed using benzyl bromide in the alkylation were cleaved during the hydrogen fluoride treatment; and 6) when tyrosine hydroxyl was t-Bu protected, the side chain was unmodified. Although not studied in detail, glutamic acid t-Bu ester led to multiple products
following repeated alkylations. Other amino acid
derivatives having side chains with potentially reactive functionalities, including serine, threonine,
hydroxyproline (all protected as their t-Bu ether), methionine (sulfoxide), and tryptophan (Boc), did not undergo any modification during the alkylation step.
Repetitive alkylations of trityl-protected N-terminal glycine and β-alanine led to side products containing additional alkyl groups as detected by MALDI-MS.
The combinatorial library of compounds of
Formula I (wherein B=0) has an OOXX format, where O represents a defined position and X represents a mixture position. Forty-six different amino acids (cysteine and histidine were excluded since analogs containing these amino acids were found to have significant side reactions and/or incomplete reaction during the alkylation
procedure) were incorporated into the first X position (R3), and 50 different amino acids were incorporated into the first O position (R7). The amide alkyl groups in the second X (R8) and second 0 positions (R6) were: methyl, ethyl, allyl, benzyl or naphthylmethyl. This
combinatorial library consists of 250 mixtures (50 amino acids x 5 alkyl groups), each of which is composed of 230 compounds (46 amino acids x 5 alkyl groups), and was prepared applying the divide, couple and recombine process, also independently reported as the "mixing and portioning" and "split synthesis" approaches (Lam, K.S., et al., Nature, 354:82 (1991); Furka, A., et al., Int. J.
Pept . Protein Res . , 37 : 487 ( 1991 ) ) . The stepwise
synthesis was carried out on the solid phase by
alternating amino acid attachment and alkylation of the previously formed amide bond as outlined in Figure 1.
Standard Fmoc chemistry for the incorporation of amino acids was used with MBHA resin as the solid support.
Alkylation of the amide bond between the C-terminal amino acid and the MBHA linker was found to significantly decrease the stability of the amide-resin linkage to acidolytic conditions. (Kornreich, W., et al., Int. J. Pept. Protein Res., 25:414 (1985)). The amino groups were protected with the bulky trityl group to avoid modification of the N-terminal amine during the
manipulation of the amide groups of the resin-bound compounds. The five alkyl halides [methyl iodide, ethyl iodide, allyl bromide, benzyl bromide, and 2- (bromomethyl)naphthalene] were reacted with the
previously formed amide anions using repeated treatments of the alkylation method described above. Replicates of control resins Trt-Leu-MBHA and Trt-Trp-MBHA were added during each of the five separate alkylation treatments on the solid phase resins. The R8 residues were introduced at the same time, enabling the completeness of each of these reactions to be determined. A second amino acid derivative was then coupled to these control resins following removal of the trityl group with 2%
trifluoroacetic acid in dichloromethane. This resulted in the generation of individual compounds having the formulas H2N-Phe-Leu-NHR and H2N-Ala-Trp (R)-NHR (R = methyl, ethyl, allyl, benzyl, or naphthylmethyl). No starting material was detected by RP-HPLC for the crude compounds following three treatments with methyl iodide and ethyl iodide. Allylation, benzylation and
naphthylmethylation required six repetitions of the alkylation procedure, with generally less than 10% starting material remaining (as determined by RP-HPLC). In case of the Ala-Trp controls up to 40% of
monoalkylated material was seen (using RP-HPLC). The 230 resins containing the first two library positions were then combined, thoroughly mixed and divided into 250 equal portions (50 x 5 library resin packets). Following trityl removal, the second group of protected amino acids was added (cysteine and histidine included), the Fmoc group was removed, and the free amino groups were again reacted with trityl chloride. The newly formed amide bond was then alkylated as described above, with the exception that five repetitions of the alkylation
procedure were carried out. For this second alkylation step, control resins were prepared having the formula Trt-Phe-Leu-NHMe-MBHA and Trt-Ala-Trp-NHMe-MBHA. These control resins were permethylated at the first amide position to determine the completeness of the second alkylation. Following trityl removal, starting material was not detected by RP-HPLC or MALDI-MS for any of the five crude alkylation control products. The highly acid labile amide linkage between the peptidomimetic and the MBHA resin linker does not permit the acid labile side chain protecting groups to be removed prior to final cleavage from the resin. Thus, the mixtures were cleaved from the resin under standard high hydrogen fluoride cleavage conditions (Houghten, R.A., et al., Int. J. Pept. Protein Res., 27:673 (1986)) and obtained as lyophilized powders following extraction with 50% aqueous
acetonitrile. The yields of some of the crude control compounds were found to be sequence-dependent. During the final acidic Trt removal, compounds having bulky alkyl residues in position R2 were partially cleaved from the resin. (Gisin, B.F., et al., J. Am. Chem. Soc.,
94:3102 (1972)). Compounds of the formula H2N-Phe-N (R)-Leu-NHMe
(R = methyl, ethyl, allyl, benzyl or naphthylmethyl) were individually synthesized using the described method to provide material as analytical controls. Following purification by preparative RP-HPLC, the identity of each compound was confirmed by RP-HPLC, MALDI-MS, HR-MS, microanalysis, and NMR.
The nonsupport-bound library mixtures were screened in solution in radio-receptor, antimicrobial and enzyme inhibition assays. Deconvolution of the highly active mixtures was carried out by both iterative and positional scanning methods. The iterative method is set forth in Dooley, et al., Science, 266:2019-2022 (1994) and the positional scanning method is set forth in U.S. Patent Application Serial No. 07/943,709, herein
incorporated by reference.
The immediately preceeding description sets forth in general the reaction techniques utilized in synthesizing the selectively N-alkylated compounds of Formula I. These techniques can be utilize in one of two strategic approaches for finding the most active
compound; the iterative approach or the positional scanning approach. The iterative approach is well-known and is set forth in general in Houghten et al . , Nature, 354, 84-86 (1991); and Dooley et al . , Science, 266, 2019- 2022 (1994); herein incorporated by reference. In the iterative approach, for example, sublibraries of a molecule having six variable groups are made wherein the first two variables are defined. (With reference to
Figure, an example for this discussion would have B is 1, R10 is absent, R1 and R2 are each a hydrogen atom, with R8 through R3 as the six variable groups.) Each of the compounds with the two defined variable groups is reacted with all of the other possibilites at the other four variable groups. These sub-libraries are each tested to define the identity of the third varible in the sub-library having the highest activity in the screen of choice is determined. A new sub-library with the first three variable poisitions defined is reacted again with all the other possibilities at the remaining three undefined variable positions. As before, the identity of the fourth variable position in the sub-library having the highest activity is determined, and a new set of sub- libraries, with four defined variable regions, is
synthesized. This process is repeated for all six
variables, yielding the compound with each variable contributing to the highest desired activity in the screening pocess. Promising compounds from this process can then be synthesized on larger scale in traditional single-compound synthetic methods for further biological investigation.
The positional-scanning approach has been described for various organic libraries and for various peptide libraries (see, for example, R. Houghten et al . PCT/US91/08694, S.P.A. Fodor and L. Stryer and U.S.
Patent Application No. 07/876,792, herein incorporated by reference). However, the positional-scanning approach has never been applied to the selectively N-alkylated compounds of the instant Formula I. In the positional scanning approach sublibraries are made defining only one variable with each set of sublibraries- and all possible sublibraires with each single variable defined (and all other possibilities at all of the other variable
positions) is made and tested. From the instant
description one skilled in the art could synthesize libraries wherein 2 fixed positions are defined at a time. From the testing of each single-variable defined library, the optimum substituent at that position is determined, pointing to the optimum or at least a series of compounds having a maximum of the desired biological activity. As this approach is applied to the selectively N-alkylated compounds of Formula I, sublibraries where each possibility of any one R group (e.g. R8) is defined and all other possibilities of the remaining R groups are synthesized and screened for the desired activity. Thus, the number of sublibraries for compounds with a single position defined will be the number of different
substituents desired at that position, and the number of all the compounds in each sublibrary will be the product of the number of substituents at each of the other varibles. Thus, the instant invention is directed to screening sublibraries of the selectively N-alkylated componds of Formula I wherein each sublibrary has an R group defined, and all other R groups are synthesized with the desired subtstituents, and defining each single variable in a similar grouping of sublibrairies and screening for biological activity, until all such
variable positions have been defined and screened for the desired activity. One skilled in the art would realize that this approach could also be applied in the situation wherein each sublibrary has to R groups defined, using a modification of the above techniques. The reduction of the interior amide of the compounds of Formula I is another means for the chemical transformation of such compounds which adds stability and can enhance activity. A number of reagents are
available and well known for the reduction of amides to amines such as those disclosed in Wann et al., JOC,
46:257 (1981) and Raucher et al., Tett.Le.., 21:14061 (1980), both of which are incorporated herein by
reference. Diborane has the advantage that
trimethylborate, the only by-product in the reaction workup, is volatile and is therefore readily removed by evaporation in solution phase reduction. The use of excess diborane in refluxing tetrahydrofuran permits simple aliphatic and aromatic amides to be rapidly, and often quantitative be reduced into their corresponding amines. A newly synthesized compound can be purified using a method such as reverse phase high performance liquid chromatography (RP-HPLC) or other methods of separation based on the size or charge of the compound. Furthermore, the purified compound can be characterized using these and other well known methods such as amino acid analysis and mass spectrometry.
After manufacture, the compounds can be assayed for receptor binding activity using the radioreceptor assay (Examples III and IV) or other assays outlined below, including the glycosidase assay (Example V).
Because some of the compounds of the present invention bind to the μ receptor, they can be used in in vitro assays to study the opiate receptor subtypes. For example, in a sample receptor of unknown type or origin, the compounds, after being labeled with a detectable marker such as a radioisotope, can be contacted with the receptor sample under conditions which specifically favor binding to a particular receptor subtype. Unbound receptor and compound can be removed, for example, by washing with a saline solution, and bound receptor can then be detected using methods well known to those skilled in the art. Therefore, the compounds of the present invention are useful in vitro for the diagnosis of relevant opioid receptor subtypes, and in particular the μ type, in brain and other tissue samples.
In addition to their utility in in vitro
screening methods, the compounds are also useful in vivo. For example, certain of the instant compounds can be used in vivo diagnostically to localize opioid receptor subtypes. The compounds are also useful as drugs to treat pathologies associated with other compounds which interact with the opioid receptor system. It can be envisioned that these compounds can be used for
therapeutic purposes to block the peripheral effects of a centrally acting pain killer. For instance, morphine is a centrally acting pain killer. Morphine, however, has a number of deleterious effects in the periphery which are not required for the desired analgesic effects, such as constipation and pruritus (itching). While it is known that the many peptides do not readily cross the blood- brain barrier and, therefore, elicit no central effect, the subject peptides can have value in blocking the periphery effects of morphine, such as constipation and pruritus.
This invention provides pharmaceutical compositions comprising the compounds of Formula I in a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically acceptable carrier" encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents.
Suitable pharmaceutical carriers and their formulations are described in Martin, REMINGTON'S
PHARMACEUTICAL SCIENCES, 15th Ed. (Mack Publishing Co., Easton 1975). Such compositions will, in general, contain an effective amount of the active reagent
together with a suitable amount of carrier so as to prepare the proper dosage form for proper administration to the subject. Useful pharmaceutical carriers for the preparation of the pharmaceutical compositions can be solids, liquids or gases. Thus, the compositions can take the form of tablets, pills, capsules, powders, enterically coated or other protected formulations (such as by binding on ion exchange resins or other carriers, or packaging in lipid protein vesicles or adding
additional terminal amino acids), sustained release formulations, solutions (e.g. ophthalmic drops),
suspensions, elixirs, aerosols, and the like. Water, saline, aqueous dextrose, and glycols are preferred liquid carriers, particularly (when isotonic) for
injectable solutions. The carrier can be selected from various oils including those of petroleum, animal, vegetable or synthetic origin, for example, peanut oil, soybean oil, mineral oil, sesame oil, and the like.
Suitable pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like.
The compositions may be subjected to conventional pharmaceutical procedures such as
sterilization and may contain conventional pharmaceutical additives such as preservatives, stabilizing agents, wetting or emulsifying agents, salts for adjusting osmotic pressure, buffers, and the like.
This invention provides methods of effecting treating a mammal comprising the step of administering a therapeutically effective amount of a pharmaceutical composition of this invention to a subject. As used herein, the term "therapeutically effective amount" is that amount necessary to alleviate the condition from which the mammal suffers.
In the practice of the therapeutic methods of the present invention, an effective amount of a
pharmaceutical composition of a compound of Formula I is administered via any of the usual and acceptable methods known in the art, either singly or in combination with another compound of the present invention. These
compounds or compositions can thus be administered orally, sublingually, topically (e.g., on the skin or in the eyes), parenterally (e.g., intramuscularly,
intravenously, subcutaneously or intradermally), or by inhalation, and in the form of either solid, liquid or gaseous dosage including tablets, suspensions, and aerosols, as is discussed in more detail above. The administration can be conducted in single unit dosage form with continuous therapy or in single dose therapy ad libitum.
In one embodiment, the therapeutic methods of the present invention are practiced when the relief of symptoms is specifically required or perhaps imminently so. In another embodiment, the method is effectively practiced as continuous or prophylactic treatment.
In the practice of the therapeutic methods of the invention, the particular dosage of pharmaceutical composition to be administered to the subject will depend on a variety of considerations including the nature of the disease, the severity thereof, the schedule of administration, the age and physical characteristics of the subject, and so forth. Proper dosages may be
established using clinical approaches familiar to the medicinal arts. It is presently believed that dosages in the range 0.1 of 100 mg of a compound of this invention per kilogram of subject body weight will be useful, and a range of 1 to 100 mg per kg generally preferred where the administration is by injection or ingestion. Topical dosages may utilize formulations containing active peptides and a liquid carrier or excipient, with multiple daily applications being appropriate. Fluorenylmethoxycarbonyl (Fmoc) amino acid derivatives were purchased from Calbiochem-Novabiochem Corp. (San Diego, CA, USA), Bachem Bioscience Inc.
(Philadelphia, PA, USA) and Bachem California (Torrance, CA, USA). MBHA resin, (1% divinylbenzene, 100 - 200 mesh, 0.9 mmol/g substitution), was received from
Peninsula Laboratories, Inc (Belmont, CA, USA). N,N'- Diisopropylcarbodiimide (DIC) and 1-hydroxybenzotriazole (HOBT) were purchased from Chem Impex International (Wood Dale, IL, USA), trifluoroacetic acid from Halocarbon (River Edge, NJ, USA) and hydrogen fluoride from Air Products (San Marcos, CA, USA). All other reagents and anhydrous solvents (DMSO, THF) were purchased from
Aldrich Chemical Company (Milwaukee, WI, USA). The solvents dichloromethane (DCM), dimethylformamide (DMF) , isopropanol (IPA), and methanol were obtained from Fisher Scientific (Fair Lawn, NJ, USA). All reagents and solvents were used without further purification. MALDI- MS analyses were carried out on a Kratos Analytical
Compact MALDI II (Ramsey, NJ, USA). HR-FAB-MS were recorded at the University of California Riverside Mass Spectrometry Facility, Department of Chemistry
(Riverside, CA, USA) on a ZAB mass spectrometer.
Analytical RP-HPLC was performed on a Beckman System Gold instrument (Beckman Instruments, Fullerton, CA, USA).
Samples were analyzed using Vydac 218TP54 C18 columns (0.46 x 25 cm). Preparative RP-HPLC purification was performed on a Waters Delta Prep 3000 instrument
(Millipore, Waters Division, San Francisco, CA, USA).
Samples were purified using Waters Delta-Pak C18 columns (2.5 x 10 cm). All gradients reported were linear in eluent A (0.05% TFA aqueous) and eluent B (0.05% TFA in acetonitrile); flow rates were 1 mL/min (analytical) and 20 mL/ min (preparative); the eluent was monitored at 214 nm. Routine 1H NMR and 13C NMR spectra were recorded on a Varian Gemini 200 (200 MHz). Microanalyses were performed at Galbraith Laboratories, Inc. (Knoxville, TN, USA). Library synthesis
Amino acid derivatives
The following amino acid derivatives were used in synthesizing a combinatorial library according to Formula I above: Fmoc-Ala-OH, Fmoc-Phe-OH, Fmoc-Gly-OH, Fmoc-Ile-OH, Fmoc-Lys (Boc) -OH, Fmoc-Leu-OH, Fmoc- Met(O)-OH, Fmoc-Asn-OH, Fmoc-Pro-OH, Fmoc-Gln-OH, Fmoc- Arg(Pmc)-OH, Fmoc-Ser ( t-Bu) -OH, Fmoc-Thr ( t-Bu) -OH, Fmoc- Val-OH, Fmoc-Trp(Boc) -OH, Fmoc-Trp-OH, Fmoc-Tyr (2BrCbz)- OH, Fmoc-Tyr (t-Bu) -OH, Fmoc-D-Ala-OH, Fmoc-D-Phe-OH,
Fmoc-D-Ile-OH, Fmoc-D-Lys (Boc) -OH, Fmoc-D-Leu-OH, Fmoc-D- Asn-OH, Fmoc-D-Pro-OH, Fmoc-D-Gln-OH, Fmoc-D-Ser ( t-Bu)- OH, Fmoc-D-Thr ( t-Bu) -OH, Fmoc-D-Val-OH, Fmoc-D-Trp (Boc)- OH, Fmoc-D-Trp-OH, Fmoc-D-Tyr ( t-Bu)-OH, Fmoc-D-Arg (Pmc)- OH, Fmoc-L-Nle-OH, Fmoc-D-Nle-OH, Fmoc-L-Nve-OH, Fmoc-D- Nve-OH, Fmoc-L-Nal-OH, Fmoc-D-Nal-OH, Fmoc-L-Phg-OH, Fmoc-L-Glu(t-Bu) -OH, Fmoc-D-Glu ( t-Bu)-OH, Fmoc-β-Ala-OH, Fmoc-L-Cha-OH, Fmoc-D-Cha-OH, and Fmoc-Hyp ( t-Bu)-OH.
Fmoc-Cys(MeOBn)-OH (MeOBn = 4-methoxybenzyl), Fmoc-Cys(MeBn)-OH (MeBn = 4-methylbenzyl), Fmoc-His(Trt)- OH and Fmoc-D-His(Trt)-OH were also used in the N- terminal position of the library.
EXAMPLE I A. Synthesis of the combinatorial library
1. Coupling of the first amino acid derivative
The library described below was synthesized using simultaneous multiple peptide synthesis (Houghten, R.A., Proc. Natl. Acad. Sci. USA, 82:5131 (1985). The solid support (MBHA resin) was contained in 230
polypropylene mesh packets (250 mg resin per packet;
packet size 3 cm x 3 cm). For use in the synthesis of control compounds, 40 additional polypropylene mesh packets were prepared containing MBHA resin (100 mg).
After the common wash and neutralization steps were carried out (1 x DCM, 2 x 5% DIEA, 2 x DCM, 2 x DMF; approximately 8 mL per packet; all resin packets were completely covered with solvent) on all of the resin packets, the individual resin packets were separated into 46 groups, each containing five packets for the addition of the 46 amino acid derivatives used in the first coupling step. Fmoc-Leu-OH and Fmoc-Trp-OH were added to two groups of 20 control resin packets. Amino acid couplings were carried out on each of the 46 groups of five library resin packets by vigorously shaking 44 groups in a solution (67.5 mL) of 0.1 M Fmoc amino acid derivative (6.75 mmol)/DIC/HOBt in DMF overnight (Fmoc- Gly coupling required only 75 min); for the other two groups, library resin packets and control packets were vigorously shaken in a solution (175.5 mL) of 0.1 M Fmoc- L-Leu (17.55 mmol) /DIC/HOBt and 0.1 M of Fmoc-L-Trp
(17.55 mmol) /DIC/HOBT in DMF overnight. The resin packets were washed (2 x DMF, 1 x DCM, 1 x MeOH;
approximately 8 mL per packet) and the completeness of amino acid coupling was verified using the ninhydrin test (Kaiser, E.T., et al., Anal, Biochem, 34:595 (1970)).
The only amino acids which required repetitive couplings were Fmoc-L-Gln-OH, Fmoc-D-Gln-OH, Fmoc-L-Arg(Pmc)-OH and Fmoc-D-Lys(Boc)-OH. Removal of the Fmoc protecting group was accomplished by shaking the resin packets in 20% piperidine/DMF (1 x 3 min, 1 x 10 min; 2 L) followed by a wash cycle (5 x DMF, 2 x IPA, 3 x DCM; approximately 8 mL per packet).
2. Tri tylation of the N- terminal amino group Following removal of the Fmoc group, the 270 resin packets (a total of 55 mmol of free N-α-amino groups) were shaken for 3 h in a 0.077 M solution of trityl chloride (276.75 mmol) in DCM/DMF (9:1, 3.6 L) containing diisopropylethylamine (DIEA, 1.6 mol, 280 mL). After a short wash procedure (1 x DMF, 1 x 5% DIEA, 1 x DCM; approximately 8 mL per packet), the tritylation procedure was repeated twice more by shaking overnight in a 0.05 M solution of trityl chloride in DCM (5.5 L) containing the same amount of base and washed (2 x DMF, 1 x 5% DIEA, 3 x DCM, 1 x MeOH; approximately 8 mL per packet). The completeness of the trityl coupling was verified for each of the 46 different amino acid resins using the bromophenol blue color test (Krchnak, V., et al., Coll. Czech. Chem. Comm., 53:2542 (1988)). 3. Alkylation of the first amide posi tion
All manipulations were performed under a nitrogen atmosphere and strictly anhydrous conditions. The 270 resin packets were dried overnight at 50 mTorr. Each of five groups, containing 46 amino acid resin packets plus control resin packets (including four Trt- Leu-MBHA packets and four Trt-Trp-MBHA packets), were placed in one of five separate round-bottom flasks - one for each of the five alkylation reactions. Each flask contained the same amount of available amide groups
(11.07 mmol each). 1 M lithium t-butoxide in THF (220 mmol, 220 mL) and THF (220 mL) were added to each of the five reaction vessels and shaken at room temperature for 15 min. Excess base solution was removed by cannulation. Following addition of DMSO (440 mL), the individual alkylating agent was added (665 mmol i.e., 41.4 mL methyl iodide; 53.1 mL ethyl iodide; 57.5 mL allyl bromide; 79.0 mL benzyl bromide). 2-(Bromomethyl)naphthalene (665 mmol, 147 g) was dissolved in DMSO (440 mL) and
transferred as a solution to the reaction vessel. The reaction mixture was vigorously shaken for 2 h at room temperature. The alkylation solution was removed by cannulation and the entire procedure repeated twice more. The resulting resin packets were washed (3 x DMF, 2 x IPA, 3 x DCM, 1 x MeOH; approximately 8 mL per packet) and dried. Following complete drying of the resin packets overnight at 50 mTorr, the process described above was repeated three times for allylation,
benzylation and naphthylmethylation (each alkylation, 2 x 2 h and 1 x 5 h). 4 . Recombine, mix and divide the resin
The resin of the 230 library packets was combined, mixed in DCM (2 L; 15 h shaking), and dried. The resin was divided into 250 polypropylene mesh packets (packet size 3 cm x 3cm; each containing 310 mg resin).
5. Removal of the tri tyl protecting group
The resin packets, prepared as described above, were washed (1 x DCM; approximately 8 mL per packet), treated twice with 2% TFA in DCM (1 x 2 min, 1 x 30 min; 2 L), and washed (1 x DCM, 2 x IPA, 2 x DCM, 1 x MeOH; approximately 8 mL per packet).
6. Coupling of the second amino acid deriva tive and second alkyla tion
The amino acid coupling (using the 50 different amino acid derivatives), Fmoc removal, tritylation of the free amino groups, alkylation of the previously formed amide bond and trityl removal were performed as described above. Trt-Phe-Leu-NMe-MBHA resin packets and Trt-Ala- Trp(Me(-NMe-MBHA resin packets were added as control resins during alkylation. The second amide position was treated five times for alkylation (methylation and ethylation, each 5 x 2 h; allylation, benzylation and naphthylmethylation, each 3 x 2 h and 2 x 3 h). 7. HF cleavage
The 250 mixture resin packets were cleaved 24 at a time with hydrogen fluoride (5 mL per resin packet with 0.35 mL anisole added as scavenger) using a multiple vessel cleavage apparatus (Kornreich, W., et al., Int. J. Pept. Protein Res., 25:414 (1985)). The resulting mixtures were extracted by sonicating with 50% aqueous acetonitrile (3 x 5 ml). The resulting solutions were lyophilized and relyophilized twice more from 50% aqueous acetonitrile.
8 . Individual compounds
Individual compounds were prepared in the same manner as described for the library synthesis. The alkylations were generally performed with repetitions. Following HF cleavage, the crude individual compounds were purified by preparative RP-HPLC. Condition for preparative HPLC:vydac C18; linear gradient 25-55%B, in 30 min; eluent A: 0.05% TFA aqueous; eluent B:0.05% TFA in acetonitrile; flow rate: 20 mL/min; the eluent was
monitored at 214 nm.
Phenylalanyl-N-methyl-leucinemethylamide. Yield after preparative HPLC (TFA salt): 59.8%. 1H NMR (200 MHz, CDCl3; mixture of conformers; selected data for the major conformer; ratio 78 : 22) : δ = 0.85 (m; 6H), 1.23 - 1.57 (m; 2H), 1.71 - 1.85 (m; 1H), 2.65 (s; 3H), 2.7 (d; 3H), 3.01 - 3.28 (m; 2H), 4.51 - 4.58 (m; 2H), 6.85 (m; 1H), 7.15 - 7.28 (m; 5H), 8.5 (br; 2H). 13C NMR (200 MHz, CDCl3; selected data for major
conformer): δ = 22.0, 22.7, 24.7, 26.1, 32.6, 36.8, 37.4, 51.7, 57.8, 128.1, 129.1, 129.4, 133.4, 168.9, 170.1. MALDI-MS: 307 (M+2), 329 (M+Na). Anal, calcd. for C19H28F3N3O4 (TFA salt): C, 54.39; H, 6.73; N, 10.02. Found: C, 54.19; H, 7.03; N, 9.99. HR-FAB-MS calcd. for C17H28N3O2 (MH+) 306.2175, found 306.2165.
Phenylalanyl-N-ethyl-leucinemethylamide. Yield after preparative HPLC (TFA salt): 18.8%. 1H NMR (200 MHz, CDCl3; selected data for major conformer; ratio 72 : 28) : δ= 0.75 - 1.15 (m; 9H), 1.35 - 1.60 (ra; 2H), 1.95 - 2.20 (m; 1H), 2.66 (d; 3H), 2.85 - 3.45 (m; 4H), 3.97 (m; 1H), 4.41 (m; 1H), 6.99 (m; 1H), 7.18 - 7.40 (m; 5H), 8.2 - 9.2 (br; 2H). 13C NMR (200 MHz, CDCl3; selected data for major conformer): δ = 14.3, 22.9, 23.1, 25.7, .26.6, 38.3, 43.5, 52.2, 58.3, 128.6, 129.6, 130.1, 134.1,
169.3, 171.2. MALDI-MS: 321 (M+1), 343 (M+Na). Anal, calcd. for C20H30F3N3O4 (TFA salt): C, 55.399; H, 6.9789; N, 9.697. Found: C, 54.39; H, 6.97; N, 9.47. HR-FAB-MS calcd. for C1BH30N3O2 (MH+) m/z = 320.2331, found m/z = 320.2335.
Phenylalanyl-N-allyl-leucinemethylamide. Yield after preparative HPLC (TFA salt): 20.05%. 1H NMR (200 MHz, CDCl3; selected data for major conformer; ratio 71 : 29) : δ = 0.76 - 0.90 (m; 6H), 1.27 - 1.50 (m; 2H), 1.98 - 2.08 (m; 1H), 2.68 (d; 3H), 3.02 - 3.60 (m; 4H), 4.18 (m; 1H), 4.41 - 4.49 (m; 1H), 5.12 - 5.24 (m; 2H), 5.56 - 5.78 (m; 1H), 6.99 (m; 1H), 7.21 - 7.36 (m; aromatic protons), 8.35 - 9.35 (br; 2H). 13C NMR (200 MHz, CDCl3; selected data for major conformer): δ = 22.3, 25.0, 26.0, 37.8, 49.9, 51.8, 58.0, 119.9, 128.1, 129.1, 129.5, 132.1, 133.5, 169.1, 170.4. MALDI-MS: 333 (M+1), 355 (M+Na). Anal, calcd. for C21H30F3N3O4 (TFA salt): C, 56.60; H, 6.79; N, 9.44. Found: C, 56.00; H, 6.83; N, 9.23. HR-FAB-MS calcd. for C19H30N3O2 (MH+)m/z = 332.2331, found m/z = 332.2335.
Phenylalanyl-N-benzyl-leucinemethylamide. Yield after preparative HPLC (TFA salt): 20.34%. 1H NMR (200 MHz, CDCl3; selected data for major conformer; ratio 65 : 35) : δ=0.72 - 0.89 (m; 6H), 1.02 - 1.53 (m; 2H), 1.87 - 2.11 (m; 1H), 2.52 (d; 3H), 2.98 - 3.45 (m; 2H), 4.05 - 4.79 (m; 4H), 6.92 (m; 1H), 7.08 - 7.38 (m; 10H), 8.20 - 9.20 (br; 2H) . 13C NMR (200 MHz, CDCl3; selected data for major conformer): δ = 22.0, 22.9, 25.5, 26.0, 37.7, 38.1, 47.3, 52.5, 57.9, 127.2, 127.7, 128.2, 129.3,
129.8, 133.5, 134.9, 169.7, 170.6. MALDI-MS: 383 (M+l), 405 (M+Na). Anal, calcd. for C25H32F3N3O4 (TFA salt) : C, 60.58; H, 6.512; N, 8.48. Found: C, 60.33; H, 6.41; N, 8.43. HR-FAB-MS calcd. for C23H32N302 (MH+) m/z = 382.2487, found m/z = 382.2511.
Phenylalanyl-N-naphthylmethyl-leucinemethylamide. Yield after preparative HPLC (TFA salt): 18.54%. 1H NMR (200 MHz, CDCl3 selected data for major conformer; ratio 67 : 33): δ = 0.70 - 0.90 (m; 6H), 1.15 - 1.58 (m; 2H), 1.94 - 2.13 (m; 1H), 2.44 (d; 3H), 3.04 - 3.49 (m; 2H), 4.20 - 4.90 (m; 4H), 6.90 - 6.99 (m; 1H), 7.08 - 7.89 (m; 12H), 8.1 - 9.5 (br; 2H). 13C NMR (200 MHz, CDCl3; selected data for major conformer) : δ = 22.0, 23.0, 25.5, 25.7, 37.7, 38.1, 52.6, 57.7, 124.6 - 134.2 (aromatic carbons) , 169.8, 170.5. MALDI-MS: 433 (M+l) , 455 (M+Na) . Anal, calcd. for C29H34F3N304 (TFA salt) : C, 63.82; H, 6.28; N, 7.70. Found: C, 63.96; H, 6.27; N, 7.76. HR-FAB-MS calcd. for C27H34N302 (MH+) m/z = 432.2643, found m/z = 432.2663.
EXAMPLE II
A. Synthesis of the resin bound peptidomimetic compound H2N-Tyr(tBu)-N(Me)-Tyr(tBu)-N(Bzl)-resin
1. Coupling of the first amino acid derivative
The peptidomimetic compound was synthesized using simultaneous multiple peptide synthesis (Merrifield, R. B. J. Am. Chem. Soc. 1963, 85, 2149; Houghten, R. A. Proc. Natl. Acad. Sci. USA 1985, 82, 5131) and Fmoc strategy. The solid support (MBHA resin) was contained in a polypropylene mesh packet (100 mg resin per packet; packet size 3 cm x 3 cm).
After the neutralization and wash steps were carried out [1 x DCM, 2 x 5% N,N-diisopropylethylamine (DIEA), 2 x DCM, 2 x DMF; approximately 5mL for each washing step] the resin packet was vigorously shaken in a solution (5.4 mL) of 0.1 M Fmoc-L-Tyr(tBu)-OH (0.54 mmol) /DIC/HOBt in DMF overnight. The resin packet was washed (2 x DMF, 1 x DCM, 1 x MeOH) and the completeness of amino acid coupling was verified using the ninhydrin test (Kaiser, E. T.; Colescott, R. L.; Blossinger, C. D.; Cook, P. I. Anal. Biochem. 1970, 34 , 595). One
repetitive coupling was required. Removal of the Fmoc protecting group was accomplished by shaking the resin packet in 20% piperidine/DMF (1 x 3 min, 1 x 10 min; 2 L) followed by a wash cycle (5 x DMF, 2 x IPA, 3 x DCM).
2. Tri tyla tion of the N- terminal amino group
The resin packet (0.09 mmol of free N-α-amino groups) was shaken for 2 h in a 0.077 M solution of trityl chloride (0.45 mmol) in DCM/DMF (9:1, 5.84 mL) containing DIEA (2.61 mmol, 0.45 mL). After a short wash procedure (1 x DMF, 1 x 5% DIEA, 1 x DCM), the
tritylation procedure was repeated three more times by shaking overnight in a 0.077 M solution of trityl
chloride in DCM (5.84 mL), for 3 h in a 0.077 M solution of trityl chloride in DCM/DMF (9:1, 5.84 mL) and again overnight in a 0.05 M solution of trityl chloride in DCM (9 mL), containing the same amount of base. The resin packet was washed (2 x DMF, 1 x 5% DIEA, 3 x DCM, 1 x MeOH) and a small resin sample was tested for the completeness of the trityl coupling using the bromophenol blue color test (Krchftak, V.; Vagner, J.; Safaϊ, P.;
Lebl, M. Coll . Czech . Chem . Comm. 1988, 53 , 2542). 3. Alkylation of the firs t amide posi tion
All manipulations were performed under a nitrogen atmosphere and strictly anhydrous conditions. The resin packet was dried overnight at 50 mTorr. 1 M lithium t-butoxide in THF (1.8 mmol, 1.8 mL) and THF (1.8 mL) were added to the reaction vessel containing the resin packet (0.09 mmol amide groups) and it was shaken at room temperature for 15 min. Excess base solution was removed by cannulation. Following addition of DMSO (3.6 mL), benzyl bromide (5.4 mmol, 0.64 mL) was added. The reaction mixture was vigorously shaken for 2 h at room temperature. The alkylation solution was removed by cannulation and the entire procedure repeated twice more. The resulting resin packet was washed (3 x DMF, 2 x IPA, 3 x DCM, 1 x MeOH; approximately 5 mL) and dried.
Following complete drying of the resin packet overnight at 50 mTorr, the process described above was repeated again two times. 4. Removal of the tri tyl protecting group
The resin packet was washed (1 x DCM; approximately 5 mL), treated twice with 2% TFA in DCM (1 x 3 min, 1 x 30 min), and washed (1 x DCM, 2 x IPA, 2 x DCM, 1 x MeOH; approximately 5 mL). 5. Coupling of the second amino acid deriva tive and second alkylation
The coupling of Fmoc-L-Tyr(tBu)-OH to the resin bound compound, the Fmoc removal, and the tritylation (only three treatments were required) of the free amino groups were performed as described above. 6. Alkylation of the second amide posi tion
All manipulations and the base treatment were performed as described above. For the alkylation DMSO (3.6 mL) and methyl iodide (5.4 mmol, 0.34 mL) were added. The reaction mixture was vigorously shaken for 2 h at room temperature. The alkylation solution was removed by cannulation and the entire procedure repeated twice more. The resulting resin packet was washed (3 x DMF, 2 x IPA, 3 x DCM, 1 x MeOH; approximately 5 mL) and the trityl protecting group removed as described above.
B. Synthesis of (CH3)2CH-NH-Tyr(tBu)-N(Me)-Tyr(tBu)- N(Bzl)-resin
1. Reductive alkylation
This procedure was adapted from those known in the art: Borch, R.F., et al., J. Am. Chem. Soc., 93:2897 (1971); Coy, D.H., et al., Tetrahedron, 44:835 (1988); Staftkova, M., et al., Drug Development Research, 33:146 (1994) (herein incorporated by reference).
Resin packets containing resin bound compounds with free N-terminal amino groups were shaken in a solution of methanol (MeOH) 20%/dichloromethane (DCM) 79%/acetic acid 1% (for one resin packet containing 0.05 mmol amine 4 ml of solvent were used - enugh to cover the resin packet) and 2 - 10 equivalents of the aldehyde or ketone (depending on their reactivity). After 20 minutes, 2-10 equivalents of a 1 M solution of sodium cyanoborohydride in N,N-dimethylformamide (DMF) were added and the reaction mixture shaken for 60 min. The resin packets were washed using the following washing sequence: 5 x DMF, 1 x DCM, 1 x MeOH (for one resin packet of the size mentioned above approximately 5 ml of solvent for each step). The completeness of the
formation of secondary amines can be tested using hte Kaiser test. If necessary the reaction can be repeated, also by using a different solvent system like DMF
containing 1% acetic acid.
The applicability of this reaction to all amino acid derivatives used in the peptidomimetic library was applied to sets of 50 model dipeptide resins (OL-resins). Following HF cleavage, the model compounds were analyzed by HPLC and MALDI-MS. This procedure was carried out as described in R.F. Borch, et al., J. Am. Chem. Soc.,
93:2897-2904 (1971); D.H. Coy, et al., Tetrahedron,
44:835-841(1988); and M. Stankova, et al., Drug
Development Research, 33:146-156 (1994) (all of which are herein incorporated by reference).
Following neutralization (3 x 5% DIEA, 2 x DCM) and a washing step (1 x DMF/ 2 % acetic acid), the resin packet was shaken in a solution of MeOH 20%/DCM 79%/ acetic acid 1% (4 mL) and acetone (0.9 mmol; 66.6 μL). After 20 min 0.9 mL (0.9 mmol) of a 1 M solution of sodium cyanoborohydride in DMF were added and the
reaction mixture was shaken for 60 min. The resin packet was washed using the following washing sequence: 5 x DMF, 1 x DCM, 1 x MeOH, approximately 5 ml of solvent for each step. The completeness of the formation of the secondary amines was tested using the Kaiser test [if necessary the reaction can be repeated, also by using a different solvent system like DMF containing 1% acetic acid].
C. Synthesis of red[(CH3)2CH-NH-Tyr(tBu)-N(Me)-Tyr(tBu)- NH(Bzl)]; (red = reduced)
1. Reduction
Reduction can either be performed on solid support [procedure A] or in solution [procedure B].
Procedure A:
Into a 50 ml glass tube (teflon-lined cap) were added the resin packet and 310 mg boric acid (5.014 mmol). Under nitrogen atmosphere, 0.5 ml
trimethylborate (0.0042 mmol) were added, followed by the addition of 15 ml of 1 M borane-tetrahydrofuran complex (15 mmol). Following cessation of hydrogen evolution, the tube was sealed and heated at 65°C for 100 hr. The tubes were then removed, cooled to room temperature and 2ml methanol were added to quench excess reducing agent. The resin packet was washed with THF (1 x lmin x 10 ml) and MeOH (4 x 1 min x 10 ml). After drying the resin packet, it was covered with 15 ml piperidine and heated at 65°C for 18 hr. The resin packet was washed with DMF (2 x 1 min x 5ml), DCM (2 x 1 min x 5 ml), MeOH (1 x 1 min x 5 ml), DMF (2 x 1 min x 5ml), DCM (2 x 1 min x 5 ml) and MeOH (1 x 1 min x 5 ml).
Procedure B:
The following procedure was adapted from
Dooley, C.T., et al., Analgesia, INRC Proceedings, 1:400 (1995) (herein incorporated by reference). Into a 50 ml glass tube (teflon-lined cap) were added the compound (0.09 mmol; two backbone carbonyl groups) and 310 mg boric acid (5.014 mmol). Under nitrogen atmosphere, 0.5 ml trimethylborate (0.0042 mmol) were added, followed by the addition of 15 ml of 1 M borane-tetrahydrofuran complex (15 mmol). Following cessation of hydrogen evolution, the tube was sealed and heated at 60°C for 90 hr. The tubes were cooled to room temperature and 5ml methanol were added dropwise to remove excess reducing agent. Excess solvent was removed by immersion of the tube in a 55°C water bath under a constant nitrogen flow (10-15 psi). The compound subsequently underwent
successive washes and evaporations with methanol (2 x 5 ml). After addition of 2 N hydrogen chloride (3 mL; 6 mmol) in water/MeOH (1:3) the glass tube was sealed and heated at 60°C for 18 h to hydrolyze boron-nitrogen complexes. The tube was removed from heat, MeOH (2 ml) was added and the solvent evaporated. C. HF cleavage - Soluble Compounds
The compound was cleaved from the resin with hydrogen fluoride (5 mL per resin packet with 0.35 mL anisole added as scavenger) using a multiple vessel cleavage apparatus (Houghten, R. A., et al., Int. J.
Pept. Protein Res., 27:673 (1986)). If the compound has been reduced on the solid support, the cleavage time was 9 h at 0°C; the nonreduced compound was cleaved in 90 min at 0°C. The resulting compound was extracted by
sonicating with 50% aqueous acetonitrile (3 x 5 ml) .
The resulting solution was lyophilized and relyophilized twice more from 50% aqueous acetonitrile. EXAMPLE III
A. Identification Of Mu Selective Opioid Peptides By A Radioreceptor Assay
This example describes the identification of individual compounds, either contained within a synthetic combinatorial library mixture or prepared separately, as inhibitors of the μ-selective opioid peptide [3H]-[D-Ala2, MePhe4, Gly-Ol5 enkephalin ([3H]-DAMGO). Individual peptides were identified as capable of inhibiting [3H] - DAMGO by a radioreceptor assay. As detailed below, the compound libraries of the instant invention were screened at a single
concentration (0.08 mg/ml) in a radioreceptor assay using rat brain homogenates and [3H]-DAMGO as radioligand. IC50 values were determined for mixtures in the library which significantly inhibited the binding of [3H]-DAMGO. B. Radioreceptor Assays Selective For The Mu Receptor
Rat and guinea pig brains, frozen in liquid nitrogen, were obtained from Harlan Bioproducts for
Science (Indianapolis, IN). Frozen brains were thawed, the cerebella removed and the remaining tissue weighed. Each brain was individually homogenized in 40 ml Tris-HCl buffer (50 mM, pH 7.4, 4°C) and centrifuged (39000 x g) (Model J2-HC; Beckman Instruments, Fullerton, CA) for 10 min at 4°C. The pellets were resuspended in fresh Tris- HCl buffer and incubated at 37°C for 40 min. Following incubation, the suspensions were centrifuged as above, the resulting pellets resuspended in 100 volumes of Tris buffer and the suspensions combined. Membrane
suspensions were prepared and used in the same day.
Protein content of the crude homogenates ranged from
0.15-0.2 mg/ml as determined using the method described by Bradford (Bradford, Anal. Biochem. 72:248-254 (1976), which is incorporated herein by reference).
Binding assays were carried out in
polypropylene tubes. Each tube contained 0.5 ml of membrane suspension, 3 nM of the μ-selective opioid peptide [3H]-DAMGO (specific activity 36 Ci/mmol), 0.08 mg/ml compound mixture and Tris-HCl buffer in a total volume of 0.65 ml. Assay tubes were incubated for 60 min at 25°C. The reaction was terminated by filtration through GF-B filters (Wallac, Inc., Gaithersburg, MD). The filters were subsequently washed with 6 ml Tris-HCl buffer at 4°C. Bound radioactivity was counted on a Beta-plate Liquid Scintillation Counter (Life Technologies, Gaithersburg, MD) and expressed in counts per minute (cpm). Inter- and intra-assay variation standard curves were determined by incubation of [3H] - DAMGO in the presence of 0.13-3900 nM of unlabeled DAMGO. Competitive inhibition assays were performed as above using serial dilutions of the peptide mixtures. IC50 values were then calculated using the software GRAPHPAD (ISI, San Diego, CA). IC50 values of less than 1000 nM are indicative of highly active opioid compounds which bind to the μ receptor, with particularly active
compounds having IC50 values of 100 nM or less and the most active compounds with values of less than 10 nM.
In the following Table, the only variable occurs at R7. Thus, all of the following compounds, in reference to Formula I, have the following structure: X and Y are taken together to form a carbonyl group, R1 and R2 are each a hydrogen atom, R10 is absent, B is zero, AA, BB, and CC are zero, R6 is ethyl, R8 is napth-2-ylmethyl, and R9 is a hydrogen atom.
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
1 Protecting group removed before testing
EXAMPLE IV A. Assay for Kappa Opiate Receptor Inhibition
This example demonstrates the specificity of the novel selectively N-alkylated compounds of Formula I for the kappa opiate receptors.
Assays demonstrating selective inhibition of binding to kappa oppiate receptors for K receptors were carried out using [3H]-U69,593 (3 nM, specific activity 62 Ci/mmol) as the radioligand and tissue homogenates prepared from guinea pig brains (cortex and cerebellum) using Tris buffer containing 100 μM PMSF, 5 mM MgCl2 and 1 mg/ml BSA, pH 7.4. Sample tubes were incubated for 2.5 hr. Standard curves were prepared using 0.05-6300 nM naloxone.
Tritiated ligands, [3H] -DAMGO, [3H] -DPDPE and [3H]-[D-Ser2, Leu5, Thr6]enkephalin ([3H]-DSLET), Abuse (NIDA) repository, as prepared by Multiple Peptide
Systems (San Diego, CA), [3H]-U69,593 from Amersham
(Arlington Heights, IL) and [3H] -naltrindole from DuPont NEN Research Products (Los Angeles, CA). The average standard deviation for IC50 values was ±20%.
In the following Table 2, all compounds have either R1 or R2 as a hydrogen atom and the other taken together with R3 to form a pyrrolidine group. X and Y are taken together to form a carbonyl group, B is zero, AA, BB, and CC are zero except where noted, R6 is benzyl and R9 is a hydrogen atom. Thus, only R7 is varied as the compounds are tested in the assay.
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Protecting group removed before testing
EXAMPLE V
A. α-Glucosidase Inhibitor α-Glucosidases are not only essential to carbohydrate metabolism, but also vital for the
processing of various glycoproteins and glycolipids.
Inhibitors of these enzymes, in particular of α- glucosidase, are therefore of high therapeutic potential. α-glucosidase inhibitors are potent oral anti-diabetics
(Lebovitz, H.E. Drugs, 44(3):21-28 (1992)), and have been implicated in the blocking of microbial infection
(Fischer, P. B., et al. J.Virol. 69 ( 9) : 5791-5797 (1995); Rademacher, T.W., IN: Sandier, M. and Smith, J.H. (Eds.), Enzymes as Drugs Vol.2, Oxford University Press, Oxford, 333-343 (1994)) and tumor growth (Pili, R. et al., Cancer Res., 55:2920-2926 (1995)) . Most of the known natural and synthetic α-glucosidase inhibitors are sugar analogs, such as pseudooligosaccharides ( Bischoff, H., Eur. J. CIin. Investig., 24 (3) :3-10 (1994)), azasugars
(Wong, C.H., et al., J. Org. Chem., 60:1492-1501 (1995)), or indolizidine alkaloids (Elbein, A.D., Ann. Rev. Biochem., 56:497-534 (1987)). Glycosidase inhibitors often inhibit more than one glycolytic enzyme (Kajimoto, T., et al., J. Am . Chem. Soc. , 113:6187-6196 (1990)).
The results set forth below in Table 3 are obtained from an α-glucosidase inhibition assay performed in a 96-well format using p-nitrophenyl-α-D- glucopyranoside as chromogenic substrate and α- glucosidase from bakers yeast, essentially as described by Haslvorson and Ellias (Biochem. Bionhys. Acta, 30:28- 40 (1958)). The IC50 values represent the concentration necessary for 50% enzyme inhibition. The most active inhibitors are compounds of Formula I wherein X and Y are taken together to form a carbonyl group, B is zero, AA, BB, and CC are zero except were noted, R9 is a hydrogen atom, R8 is benzyl, R6 is naphth-2-ylmethyl, R3 is S- (N- (naphth-2-ylmethyl)indol-3-ylmethyl), R1 and R2 are each hydrogen, R10 is absent, and R7 is as set forth in the following Table 3 :
Figure imgf000109_0001
Figure imgf000110_0001
Numerous modifications and variations are possible in light of the above teachings and, therefore, within the scope of the appended claims, the invention may be practiced otherwise than as particulary described above.

Claims

We Claim :
1. A single compound or a library of an approxmiately equimolar mixture of two or more compounds of the Formula (I) :
Figure imgf000111_0001
Wherein : R1 and R2 independently are a hydrogen atom, an amino protecting group, C1 to C12 acyl, C3 to C10
cycloalkyl, C3 to C6 heterocycle, C1 to C12 alkyl, C1 to C12 substituted alkyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
R3, R5, and R7 are independently a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl,
substituted phenyl, C7 to C16 alkylaryl, C7 to C16
substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
R4 , R6 and R8 are independently a C1 to C18 substituent group; with the proviso that all but one of R4, R6 and R8 can simultaneously be the same group;
R9 is a hydrogen atom or a solid support; R10 is optionally present as a C1 to C18
substituent group when R1 and R2 are other than a hydrogen atom, an amino protecting group or when both R1 and R2 are C1 to C12 acyl groups; AA, BB, and CC are independently 0 to 5;
B is from 0 to 3; further wherein the stereochemistry at the carbons bonded to R3, R5, and R7 are independently R or S or a mixture of the two; further wherein when B is 2 or 3; each R4 and R5 can be the same or different; with the proviso that either R1 or R2 can be taken with R3; R4 can be taken with R5 ; R6 can be taken with R7; respectively and independently, to form a subtituted or unsubstituted pyrrolidine ring;
X and Y are either 1) each a hydrogen atom or 2) taken together to represent a carbonyl group; and a pharmaceutically acceptable salt, solvate or hydrate thereof.
2. A single compound of claim 1.
3. A single compound of claim 2, wherein X and Y are taken together to form a carbonyl moiety.
4. A single compound of claim 3, wherein B, AA, BB and CC are zero, except that AA can be zero or one when R, is a hydrogen atom and that CC can be zero or one when R3 is a hydrogen atom.
5. A single compound of claim 4, wherein R9 is a hydrogen atom and R10 is absent.
6. A single compound of claim 5 wherein R3 and R7 are independently chosen from the group consisting of S- or R-methyl, S- or R-benzyl, a hydrogen atom, S- or R- (but-2-yl), S- or R-[ 4-(N-methylamino)-n-butyl], S- or R-[4-(N-ethylamino)-n-butyl], S- or R-[4-(N-allylamino)- n-butyl], S- or R-[4-(N-benzylamino)-n-butyl], S- or R- [4-(N-(napth-2-ylmethylamino)-n-butyl], S- or R- [4- (amino)-n-butyl], S- or R-[sec-butyl], S- or R- (methylsulfinyl)eth-1-yl, S- or R-acetamido, S- or R-[2- (N,N-dimethyl)acetamido], S- or R- (N, N- diethyl)acetamido, S- or R-(N,N-diallyl)acetamido, S- or R-(n-allyl)acetamido, S- or R- (N,N-dibenzyl)acetamido, S- or R-(N-benzyl)acetamido, S- or R-(N,N-di(napth-2- ylmethyl))acetamido, S- or R-(N-(napth-2- ylmethyl))acetamido, S- or R-n-propylamine, S- or R- propionamido, S- or R-(N,N-dimethyl)propionamido, S- or R-(N,N-diethyl)propionamido, S- or R-(N,N- diallyl)propionamido, S- or R-(N,N-dibenzyl)propionamido, S- or R-(N,N-di(napth-2-ylmethyl)propionamido, S- or R- [ 3-(guanidino)-n-propyl], S- or R- [(N,N-diallyl)-3- guanidino-n-propyl], S- or R-[(N,N,N'-triallyl)-3- guanidino-n-propyl], S- or R-[(N,N,N'-trimethyl)-3- (guanidino)-n-propyl], S- or R-[(N,N,N'-triethyl)-3- (guanidino)-n-propyl], S- or R-hydroxymethyl, S- or R-[1 -(hydroxy)ethyl], S-phenyl, S- or R-[2-(carboxy)ethyl], S- or R-[iso-propyl], S- or R-[(indol-3-yl)methyl], S- or R-[(N-(methyl)indol-3-yl) methyl], S- or R-[(N- (ethyl)indol-3-yl)methyl], S- or R-[(N-(allyl)indol-3- yl) methyl], S- or R-[(N-(benzyl)indol-3-yl) methyl], S- or R-[(N-(naphth-2-ylmethyl)indol-3-yl)methyl], S- or R-(4-
(methoxy))benzyl, S - or R-(4-(ethoxy))benzyl, S- or R-
(4-(allyloxy))benzyl, S- or R-[4-hydroxybenzyl], S- or R- (n-butyl), S- or R-(n-propyl), S- or R-[(napth-2- yl)methyl], AA is zero or one when R7 is a hydrogen atom, CC is zero or one when R3 is a hydrogen atom, S- or R-
[cyclohexylmethyl], S- or R- (thiomethyl), or when either R1 or R2 are taken together with R3 to form an S- or R- pyrrolidine or S-[4-(hydroxy)pyrrolidine].
7. A single compound of claim 6, wherein R6 and R8 are independently methyl, ethyl, allyl, benzyl, or napth-2-ylmethyl.
8. A single compound of claim 7, wherein either R1 or R2 are each a hydrogen atom, or one of R1 or R2 is a hydrogen atom and the other is taken together with R3 to form an S-pyrrolidine ring.
9. A single compound of claim 8, wherein one of R1 or R2 is a hydrogen atom and the other is taken together with R3 to form an S-pyrrolidine ring.
10. A single compound of claim 9, wherein R6 is napth-2-ylmethyl and R8 is benzyl.
11. A single compound of claim 10, wherein R7 is S- or R-methyl, a hydrogen atom, S- or R-[3- (guanidino)-n-propyl], S- or R-[4-(N-benzylamino)-n- butyl], S-[iso-propyl], S-[2-(methylsulfinyl)ethyl], S- or R-(n-propyl), S- or R-(hydroxymethyl), S- or R-[n- butyl], R-[(napth-2-yl)methyl], or S-phenyl.
12. A single compound of claim 11, wherein R7 is S- or R-methyl.
13. A single compound of claim 8, wherein R1 and R2 are each a hydrogen atom and R3 is an S- benzyl group.
14. A single compound of claim 13, wherein R6 is ethyl and R8 is (napth-2-yl)methyl.
15. A single compound of claim 14, wherein R7 is S-methyl, S-(2-(methylsulfinyl)ethyl), a hydrogen atom, S-(4-(hydroxy)benzyl) or S-[(hydroxy)methyl] .
16. A single compound of claim 15, wherein R7 is S-methyl.
17. A single compound of claim 8, wherein R1 and R2 are each a hydrogen atom and R3 is R-[(N-(napth-2- ylmethyl)indol-3-yl) methyl].
18. A single compound of claim 17, wherein R6 is napth-2-ylmethyl and R8 is benzyl.
19. A single compound of claim 18, wherein R7 is S- or R-[3-(guanidino)-n-propyl] or S- or R- [4- (benzylamino)-n-butyl].
20. A single compound of claim 7, wherein either R1 or R2 is a hydrogen atom or is taken in
conjunction with R3 to form a pyrrolidine ring, and the other is C1 to C12 acyl, C3 to C10 cycloalkyl, C3 to C6 heterocycle, C1 to C12 alkyl, C1 to C12 substituted alkyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C1S alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle.
21. A single compound of claim 2, wherein X and Y are each a hydrogen atom.
22. A single compound of claim 21, wherein B, AA, BB and CC are zero, except that AA can be zero or one when R7 is a hydrogen atom and that CC can be zero or one when R3 is a hydrogen atom.
23. A single compound of claim 22, wherein R9 is a hydrogen atom and R10 is absent.
24. A single compound of claim 23, wherein R6 and R8 are independently methyl, benzyl or 4- hydroxybenzyl.
25. A single compound of claim 24, wherein R3 and R7 are independently S-benzyl or S-(4-hydroxybenzyl).
26. A single compound of claim 25, wherein R8 is benzyl, R7 is 4-hydroxybenzyl, R6 is methyl, and R3 is 4- hydroxybenzyl.
27. A single compound of claim 26, wherein a)Rα and R2 are the same and are methyl or a hydrogen atom;
b) either R1 or R2 is a hydrogen atom and the other is chosen from the group consisting of methyl, iso-propyl, cyclopropylmethyl, 4-hydroxymethyl, N-methylpiperidin-4- yl, and 3-(N,N-dimethylamino)-2-methyl-prop-2-en-1-yl.
28. A single compound of claim 25, wherein R8 is methyl, R7 is S-benzyl, R6 is 4-hydroxybenzyl, and R3 is S-(4-hydroxybenzyl).
29. A single compound of claim 28, wherein R1 and R2 are the same and are either a hydrogen atom or methyl, or one of R1 or R2 is a hydrogen atom and the other is methyl.
30. A single compound of claim 25, wherein R8 is methyl, R7 is S-(4-hydroxymethyl), R6 is benzyl, and R3 is S-(4-hydroxybenzyl).
31. A single compound of claim 30, wherein R1 and R2 are the same and are either a hydrogen atom or methyl, or one of R1 or R2 is a hydrogen atom and the other is methyl.
32. An approximately equimolar mixture of two or more compounds of claim 1.
33 An approximately equimolar mixture of two or more compound of claim 32, wherein X and Y are taken together to form a carbonyl group.
34. An approximately equimolar mixture of two or more compounds of claim 33, wherein B, AA, BB and CC are zero, except that AA can be zero or one when R7 is a hydrogen atom and that CC can be zero or one when R3 is a hydrogen atom.
35. An approximately equimolar mixture of two or more compounds of claim 34, wherein R9 is a solid support and R10 is absent.
36. An approximately equimolar mixture of two or more compounds of claim 35, wherein R3 and R7 are independently chosen from the group consisting of S- or R-methyl, S- or R-benzyl, a hydrogen atom, S- or R-(but- 2-yl), S- or R-[4-(t-butoxycarbonylamino)-n-butyl], S- or R-[sec-butyl], S- or R-(methylsulfinyl)eth-1-yl, S- or R-[ 3-(guanidino)-n-propyl], S- or R- [(N-PMO-3- (guanidino)-n-propyl], S- or R-(t-butyloxy)methyl, S- or R-[2-(t-butyloxy)ethy], S-phenyl, S- or R-[3-(t- butoxycarbonyl)-n-propyl], S- or R-[iso-propyl], S- or R- [(N-(t-butoxycarbonyl) indol-3-yl) methyl], S- or R-[4- hydroxybenzy1], S- or R-[ (4-(t-butoxy))benzyl], S- or R- (n-propyl), S- or R-(n-butyl), S- or R-[(naptp-2- yl)methyl], S- or R-(3-carboxy-n-propyl), S- or R- (cyclohexylmethyl), S- or R-[(4- methoxybenzylthio)methyl], S-[(4- methylbenzylthio)methyl], S- or R-thiomethyl, S- or R-[4-
(N-methyl-N-(2-butoxycarbonyl)ethyl], S- or R-[ 4-(N- ethyl-N-(t-butoxycarbonyl)amino)-n-butyl], S- or R- [4-
(N-allyl-N-(t-butoxycarbonyl)amino)-n-butyl], S- or R-[4- (N-benzyl-N-(t-butoxycarbonyl)amino)-n-butyl], S- or R-[4-
(N-(naphth-2-yl)-N-(t-butoxycarbonyl)amino)-n-butyl], S- or R-[2-(N,N-dimethyl)acetamido], S- or R- (N, N- diethyl) acetamido, S- or R-(N,N-diallyl)acetamido, S- or R- (n-allyl) acetamido, S- or R-(N,N-dibenzyl)acetamido, S- or R- (N-benzyl) acetamido, S- or R-(N,N-di(napth-2- ylmethyl))acetamido, S- or R-(N-(napth-2- ylmethyl))acetamido, S- or R-(N-propylamine), S- or R- propionamido, S- or R- (N, N-diethyl) propionamido, S- or R-
(N,N-diallyl)propionamido, S- or R-(N,N- dibenzyl)propionamido, S- or R-(N,N-di(napth-2- ylmethyl)propionamido, S- or R-[(N,N'-diallyl-N-PMC)-3- guanidino-n-propyl], S- or R-[N,N',N''-triallyl-N-PMC-3- guanidino-n-propyl], S- or R-[(N,N(,N''-trimethyl-N-PMC)-
3-(guanidino)-n-propyl], S- or R-[(N,N',N''-triethyl-N- PMC)-3-(guanidino)-n-propyl], S- or R-[(N-(methyl)indol- 3-yl)methyl], S- or R-[(N-(ethyl)indol-3-yl)methyl], S- or R-[(N-(allyl)indol-3-yl) methyl], S- or R-[(N-
(benzyl)indol-3-yl) methyl], S- or R-[(N-(naphth-2- ylmethyl)indol-3-yl) methyl], S- or R- (4-(ethoxy))benzyl, S- or R-(4-(methoxy))benzyl, S- or R-(4-
(allyloxy))benzyl, S- or R-(4-(benzoxy)benzyl, S- or R-
(4-Waphth-2-ylmethoxy)benzyl, AA is one or zero when R7 is a hydrogen atom, CC is one or zero when R3 is a hydrogen atom, or when either R1 or R2 are taken together with R3 to form an S- or R- pyrrolidine or S-[4-
(hydroxy) pyrrolidine].
37. An approximately equimolar mixture of two or more compounds of claim 36, wherein R6 and R8 are independently methyl, ethyl, allyl, benzyl, or napth-2- ylmethyl.
38. An approximately equimolar mixture of two or more compound of claim 37, wherein either R1 or R2 is a hydrogen atom or is taken in conjunction with R3 to form a pyrrolidine ring, and the other is C1 to C12 acyl, C3 to C1Q cycloalkyl, C3 to C6 heterocycle, C1 to C12 alkyl, C1 to C12 substituted alkyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C1S alkyl heterocycle.
39. An approximately equimolar mixture of two or more compounds of claim 37, wherein either R1 or R2 are each a hydrogen atom, or one of R1 or R2 is a hydrogen atom and the other is taken together with R3 to form an S-pyrrolidine ring.
40. An approximately equimolar mixture of two or more compounds of claim 34, wherein R9 is hydrogen and R10 is absent.
41. An approximately equimolar mixture of two or more compounds of claim 40, wherein R3 and R7 are independently chosen from the group consiting of S- or R- methyl, S- or R-benzyl, a hydrogen atom, S- or R-(but-2- yl), S- or R-[ 4-(N-methylamino)-n-butyl], S- or R-[4-(N- ethylamino)-n-butyl], S- or R-[4-(N-allylamino)-n-butyl], S- or R-[4-(N-benzylamino)-n-butyl], S- or R-[4-(N- (napth-2-ylmethylamino)-n-butyl], S- or R- [4-(amino)-n- butyl], S- or R-[sec-butyl], S- or R-(methylsulfinyl)eth- 1-yl, S- or R-acetamido, S- or R-[2-(N,N- dimethyl)acetamido], S- or R-(N, N-diethyl)acetamido, S- or R- (N,N-diallyl)acetamido, S- or R-(n-allyl)acetamido, S- or R-(N,N-dibenzyl)acetamido, S- or R- (N- benzyl)acetamido, S- or R-(N,N-di(napth-2- ylmethyl))acetamido, S- or R-(N-(napth-2- ylmethyl))acetamido, S- or R-propionamido, S- or R-(N,N- dimethyl)propionamido, S- or R- (N, N-diethyl) propionamido, S- or R-(N,N-diallyl)propionamido, S- or R-(N,N- dibenzyl)propionamido, S- or R-(N,N-di(napth-2- ylmethyl)propionamido, S- or R-[3-(guanidino)-n-propyl], S- or R- [(N,N-diallyl)-3-guanidino-n-propyl], S- or R- [(N,N,N'-triallyl)-3-guanidino-n-propyl], S- or R-
[(N,N,N'-trimethyl)-3-(guanidino)-n-propyl], S- or R- [(N,N,N'-triethyl)-3-(guanidino)-n-propyl], S- or R- hydroxymethyl, S- or R-[1 -(hydroxy)ethyl], S-phenyl, S- or R-[2-(carboxy)ethyl], S- or R-[iso-propyl], S- or R- [(indol-3-yl)methyl], S- or R-[(N-(methyl)indol-3- yl)methyl], S- or R-[(N-(ethyl)indol-3-yl)methyl], S- or R-[(N-(allyl)indol-3-yl)methyl], S- or R-[(N- (benzyl)indol-3-yl)methyl], S- or R-[(N-(naphth-2- ylmethyl)indol-3-yl)methyl], S- or R-(4-(ethoxy))benzyl, S- or R-(4-(methoxy))benzyl, S- or R-(4-
(allyloxy))benzyl, S- or R-[4-hydroxybenzyl], S- or R- (n- butyl), S- or R-(n-propyl), S- or R-[(napth-2-yl)methyl], AA is zero or one when R7 is a hydrogen, Ccis zero or one when R3 is a hydrogen atom, S- or R-[cyclohexylmethyl], S- or R-[thiomethyl], or when either R1 or R2 are taken together with R3 to form an S- or R- pyrrolidine or S- [4- (hydroxy)pyrrolidine].
42. An approximately equimolar mixture of two or more compounds of claim 41, wherein R6 and R8 are independently methyl, ethyl, allyl, benzyl, or napth-2- ylmethyl.
43. An approximately equimolar mixture of two or more compounds of claim 42, wherein is R6 is napth-2- ylmethyl, R3 is R-[(N-(naphth-2-ylmethyl)indol-3- yl)methyl], and R1 and R2 are the same and are each a hydrogen atom.
44. An approximately equimolar mixture of two or more compounds of claim 42, wherein R6 is ethyl, R3 is S-benzyl and R1 and R2 are the same and are each a hydrogen atom.
45. An approximately equimolar mixture of two or more compounds of claim 42, wherein R6 is naphth-2- ylmethyl, R3 is S-methyl, R1 and R2 are the same and are each a hydrogen atom.
46. An approximately equimolar mixture of two or more compounds claim 42, wherein either R1 or R2 is a hydrogen atom and the other is taken in conjuntion with R3 to form an S-pyrrolidine ring, and R6 is napth-2-ylmethyl.
47. An approximately equimolar mixture of two or more compound of claim 32, wherein X and Y are the same and are each a hydrogen atom.
48. An approximately equimolar mixture of two or more compounds of claim 47, wherein B, AA, BB and CC are zero, except that AA can be zero or one when R7 is a hydrogen atom and that CC can be zero or one when R3 is a hydrogen atom.
49. An approximately equimolar mixture of two or more compounds of claim 48, wherein R9 is a hydrogen atom and R10 is absent.
50. An approximately equimolar mixture of two or more compounds of claim 49, wherein R3 and R7 are independently chosen from the group consiting of S- or R- methyl, S- or R-benzyl, a hydrogen atom, S- or R-(but-2- yl), S- or R-[ 4-(4-methylamino)-n-butyl], S- or R-[4-(N- ethylamino)-n-butyl], S- or R-[4-(N-allylamino)-n-butyl], S- or R-[4-(N-benzylamino)-n-butyl], S- or R-[4-(N- (napth-2-ylmethylamino)-n-butyl], S- or R- [4-(amino)-n- butyl], S- or R-[sec-butyl], S- or R-(2-amino)ethyl, S- or R-(n-propyl) amine, S- or R-(methylsulfinyl)eth-1-yl, S- or R-[2-(N,N-dimethylamino) ethyl], S- or R- (N, N- diethylamino)ethyrl, S- or R-(N,N-diallylamino) ethyl, S- or R-(n-allylamino) ethyl, S- or R-(N,N- dibenzylamino) ethyl, S- or R-(N-benzylamino) ethyl, S- and R-(N,N-di(napth-2-ylmethyl)amino)ethyl, S- and R- (N- (napth-2-ylmethyl)amino)ethyl, S- or R-propionamido, S- or R-(N,N-dimethylamino)propyl, S- or R- (N,N- diethylamino)propyl, S- or R-(N,N-diallylamino)propyl, S- or R-(N,N-dibenzylamino) propyl, S- or R-(N,N-di(napth-2- ylmethyl)propionamido, S- or R-[3-(guanidino)-n-propyl], S- or R- [(N,N-diallyl)-3-guanidino-n-propyl], S- or R- [(N,N,N'-triallyl)-3-guanidino-n-propyl], S- or R-
[(N,N,N'-trimethyl)-3-(guanidino)-n-propyl], S- or R-
[(N,N,N'-triethyl)-3-(guanidino)-n-propyl], S- or R- hydroxymethyl, S- or R-[1 -(hydroxy)ethyl], S-phenyl, S- or R-[3-(hydroxy)-n-propyl], S- or R-[ iso-propyl], S- or R-[(indol-3-yl)methyl], S- or R-[(N-(methyl)indol-3- yl)methyl], S- or R-[(N-(ethyl)indol-3-yl)methyl], S- or R-[(N-(allyl)indol-3-yl)methyl], S- or R-[(N-
(benzyl)indol-3-yl)methyl], S- or R-[(N-(naphth-2- ylmethyl)indol-3-yl)methyl], S- or R-(4-(ethoxy))benzyl, S- or R-(4-(methoxy))benzyl, S- or R-(4-
(allyloxy))benzyl, S- or R-(4-hydroxybenzyl), S- or R-(n- butyl), S- or R-(n-propyl), S- or R-[(napth-2-yl)methyl], AA is zero or one when R7 is a hydrogen atom, CC is zero or one when R3 is a hydrogen atom, S- or R- (cyclohexylmethyl), S- or R-[thiolmethyl], S- or R- methylthiol, or when either R1 or R2 are taken together w th R3 to form an S- or R- pyrrolidine or S-[4-
(hydroxy)pyrrolidine].
51. An approximately equimolar mixture of two or more compounds of claim 50, wherein R6 and R8 are independently methyl, ethyl, allyl, benzyl, or napth-2- ylmethyl .
52. An approximately equimolar mixture of two or more compounds of claim 48, wherein R9 is a solid support and R10 is absent.
53. An approximately equimolar mixture of two or more compounds of claim 52, wherein R3 and R7 are independently chosen from the group consiting of S- or R- methyl, S- or R-benzyl, a hydrogen atom, S- or R-(but-2- yl), S- or R-[ 4-(N-methylamino)-n-butyl], S- or R- [4- (N,N-dimethylamino)-n-butyl), S- or R-[4-(N-methyl-N- ethylamino)-n-butyl), S- or R-[4-(N-ethylamino)-n-butyl], S- or R-[4-(N-methyl-N-ethylamino)-n-butyl], S- or R- [4- (N-allylamino)-n-butyl], S- or R-[4-(N-methyl-N- alkylamino)-n-butyl], S- or R-[4-(N-benzylamino)-n- butyl], S- or R-[4-(N-(napth-2-ylmethylamino)-n-butyl], S- or R-[4(N-methyl-N-benzylamino)-n-butyl], S- or R-[4- (amino)-n-butyl], S- or R-[sec-butyl], S- or R-(2- aminoethyl), S- or R-(methylsulfinyl) eth-1-yl, S- or R- acetamido, S- or R-[2-(N,N-dimethylamino)ethyl], S- or R- (N, N-diethylamino) ethyl, S- or R- (N,N- diallylamino) ethyl, S- or R-(n-allylamino) ethyl, S- or R- (N,N-dibenzylamino) ethyl, S- or R-(N-benzylamino)ethyl, S- or R-(N,N-di(napth-2-ylmethyl)amino)ethyl, S- or R- (N- (napth-2-ylmethyl)amino)ethyl, S- or R-(N-propylamine), S- or R-propionamido, S- or R-(N,N-dimethylamino)propyl, S- or R-(N,N-diethylamino)propyl, S- or R-(N,N- diallyl)propionamido, S- or R-(N,N-dibenzylamino)propyl, S- or R-(N,N-di(napth-2-ylmethyl)propionamido, S- or R- [3-(N-PMC-guanidino)-n-propyl], S- or R-[(N,N'-diallyl-N- PMC)-3-(guanidino)-n-propyl], S- or R-[(N,N',N''- triallyl-N-PMC)-3-(guanidino)-n-propyl], S- or R- [(N,N',N''-trimethyl-N-PMC)-3-(guanidino)-n-propyl], S- or R-[(N,N',N''-triethyl-N-PMC)-3-(guanidino)-n-propyl], S- or R-hydroxymethyl, S- or R-[1 -(hydroxy)ethyl], S- phenyl, S- or R-[3-(hydroxy)-n-propyl], S- or R-[ iso- propyl], S- or R-[(indol-3-yl)methyl], S- or R-[(N-
(methyl)indol-3-yl)methyl] ,S- or R-[(N-(ethyl)indol-3- yl)methyl], S- or R-[(N-(allyl)indol-3-yl)methyl], S- or R-[(N-(benzyl)indol-3-yl)methyl], S- or R-[(N-(naphth-2- ylmethyl)indol-3-yl)methyl], S- or R-(4-(ethoxy))benzyl, S- or R-(4-(methoxy))benzyl, S- or R-(4-
(allyloxy))benzyl, S- or R-[4-hydroxybenzyl], S- or R- [n- butyl], S- or R-(n-propyl), S- or R-[(napth-2-yl)methyl], S-methyl and CC is one, S- or R-[cyclohexylmethyl], S- or R-[thiolmethyl], AA is zero or one when R7 is a hydrogen atom, CC is zero or one when R3 is a hydrogen atom, or when either R1 or R2 are taken together with R3 to form an S- or R- pyrrolidine or S-[4-(hydroxy)pyrrolidine].
54. An approximately equimolar mixture of two or more compounds of claim 53, wherein R6 and R8 are independently methyl, ethyl, allyl, benzyl, or napth-2- ylmethyl.
55. A method for effecting analgesia in a mammal, which comprises administering an effective amount of a single compound of claim 1 in conjuction with a pharmaceutically-acceptable carrier.
56. A method of claim 55, wherein the single compound has X and Y taken together to form a carbonyl group, B, AA, BB and CC are zero, R9 is a hydrogen atom, R8 is napth-2-ylmethyl, R7 is S-methyl, R6 is ethyl, R3 is S-benzyl, and R1 and R2 are each a hydrogen atom.
57. A method of claim 55, wherein the single compound has X and Y taken together to form a carbonyl group, B, AA, BB and CC are zero, R9 is a hydrogen atom, R8 is benzyl, R7 is S-methyl, R6 is naphth-2-ylmethyl, R3 is taken in conjunction with either R1 or R2 to form an S- pyrrolidine ring and the other of R1 and R2 a hydrogen atom.
58. A method of effecting a decrease in the postprandial rise in the blood glucose levels of a mammal after ingestion of a carbohydrate load by said mammal, which comprises administering an effective amount of a single compound of claim 1 in conjunction with a
pharmaceutically-acceptable carrier.
59. A method of claim 58, wherein the single compound has X and Y taken together to form a carbonyl group, B, AA, BB and CC are zero, R9 is a hydrogen atom, R8 is benzyl, R6 is naphth-2-ylmethyl, R3 is R-(N-(naphth- 2-ylmethyl)indol-3-ylmethyl), R1 and R2 are each hydrogen, R10 is absent, and R7 is chosen from the group consisting of S-(4-(N-benzylamino)-n-butyl), R-(4-(N-benzylamino)-n- butyl), S-(3-g)anidino)-n-propyl), and R-(3-guanidino)-n- propyl).
60. A method of treating microbial infections in mammals, which comprises administering an effective amount of a single compound of claim 1 in conjunction with a pharmaceutically-acceptable carrier.
61. A method of claim 60, wherein the single compound has X and Y taken together to form a carbonyl group, B, AA, BB and CC are zero, R9 is a hydrogen atom, R8 is benzyl, R6 is naphth-2-ylmethyl, R3 is R-(N-(naphth- 2-ylmethyl)indol-3-ylmethyl), R1 and R2 are each hydrogen, R10 is absent, and R7 is chosen from the group consisting of S-(4-(N-benzylamino)-n-butyl), R-(4-(N-benzylamino)-n-butyl), S-(3-guanidino)-n-propyl), and R-(3-guanidino)-n-propyl).
62. A method of step-wise N-alkylation of the amide bond of the N-terminal residue of a compound of the Formula (II) :
Figure imgf000128_0001
Wherein :
R11 is independently a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle; ZZ is from zero or five;
And R12 is a solid support or a group of the Formula (III) :
Figure imgf000129_0001
Wherein R14 is a C1 to C18 substituent group;
Wherein W is 0 to 4;
R13 is independently a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
R15 is a solid support (when W is one) or a bond to the preceeding methylene group (when W is from two to four); YY is from zero to five;
Wherein the compound of the above formula is a) first reacted under anhydrous conditions in an inert atmosphere with an excess amount non-nucelophilic base having a pKa between about 18 to about 40; then
b) reacting the resulting anion under anhydrous conditions in an inert atmosphere in a polar aprotic solvent with an excess amount of an an alkylting agent of the formula
(LG)-Q Wherein LG is leaving group;
Q is a C1 to C18 substituent group; and repeating steps a) and b) as necessary to drive the alkylation to completion; with the proviso that all previous internal backbone amide bonds have been previously alkylated with a C1 to C18 substituent group and, when W is from 2 to 4, all of the R14 groups are not the same C1 to C18
substituent group.
63. A process of claim 62, wherein LG is iodo or bromo and the -CH2-Q moiety is methyl, ethyl, allyl, benzyl or napth-2-ylmethyl.
64. A process of claim 63, wherein R11 and R13 are independently chosen from the group consisting of S- or R-methyl, S- or R-benzyl, a hydrogen atom, S- or R- (but-2-yl), S- or R-[4-(t-butoxycarbonylamino)-n-butyl], S- or R-[4-(amino)-n-butyl], S- or R-[sec-butyl], S- or R- (methylsulfinyl) eth-1-yl, S- or R-[3-(guanidino)-n- propyl], S- or R-[(N-PMC)-3-(guanidino)-n-propyl], S- or R-(t-butoxy)methyl, S- or R-[2-(t-butoxy)ethy], S-phenyl, S- or R-[2-(t-butoxycarbonyl)ethyl], S- or R- [iso- propyl], S- or R-[(N-(t-butoxycarbonyl)indol-3- yl)methyl], S- or R-[4-hydroxybenzyl], S- or R-[(4-(t- butoxy))benzyl], S- or R-[n-propyl], S- or R-(n-butyl), S- or R-[(napth-2-yl)methyl], S- or R-(2-carboxyethyl), S- or R-(cyclohexylmethyl), S-[(4- methoxybenzylthio)methyl], S- or R-[(4- methylbenzylthio)methyl], S- or R-thiomethyl, S- or R- [4- (N-methyl-(N-(t-butoxycarbonly))amino)-n-butyl], S- or R- [ 4-(N-ethyl-(N-(t-butoxycarbonly))amino)-n-butyl], S- or R-[4-(N-allyl-(N-(t-butoxycarbonly))amino)-n-butyl], S- or R-[4-(N-benzyl-(N-(t-butoxycarbonly))amino)-n- butyl], S- or R-[4-(N-(naphth-2-yl)-(N-(t- butoxycarbonly))amino)-n-butyl], S- or R-acetamino, S- or R-[2-(N,N-dimethyl)acetamido], S- or R-(N, N- diethyl)acetamido, S- or R-(N,N-diallyl)acetamido, S- or R-(n-a-lyl) acetamido, S- or R- (N,N-dibenzyl)acetamido, S- or R-(N-benzyl)acetamido, S- or R-(N,N-di(napth-2- ylmethyl))acetamido, S- or R-(N-(napth-2-ylmethyl))acetamido, S- or R-(n-propyl)amine, S- or R- propionamido, S- or R-(N,N-diethyl)propionamido, S- or R- (N,N-diallyl)propionamido, S- or R-(N,N- dibenzyl)propionamido, S- or R-(N,N-di(napth-2- ylmethyl)propionamido, S- or R-[(N,N'-diallyl-N-PMC)-3- guanidino-n-propyl], S- or R-[(N,N',N''-trimethyl-N-PMC)- 3-(guanidino)-n-propyl], S- or R-[(N,N',N''-triethyl-N- PMC)-3-(guanidino)-n-propyl], S- or R-[(N,N',N''-trialkl- N-PMC)-3-guanidino-n-propyl], S- or R-[(indol-3- yl)methyl], S- or R-[(N-(methyl)indol-3-yl)methyl], S- or R-[(N-(ethyl)indol-3-yl)methyl], S- or R-[(N-
(allyl)indol-3-yl)methyl], S- or R-[(N-(benzyl)indol-3- yl)methyl], S- or R-[(N-(naphth-2-ylmethyl)indol-3- yl)methyl], S- or R-(4-(ethoxy))benzyl, S- or R-(4-
(methoxy))benzyl, S- or R-(4-(allyloxy))benzyl, S- or R-
(4-(benzoxy)benzyl, S- or R-(4-(naphthl-2- ylmethoxy)benzyl, ZZ is one or zero when R1x is a hydrogen atom, YY is one or zero when R13 is a hydrogen atom, or when either R13 is taken together with R14 to form an S- or R- pyrrolidine or S-[4-(hydroxy)pyrrolidine].
65. A method of synthesizing and testing for biological activity a library of an approximately equimolar amount of compounds of the following Formula (IV) :
Figure imgf000132_0001
Wherein in the above Formula (IV) :
R19, R21 and R23 independently are a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16
substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
R25 is a hydrogen atom or a solid support; R20, R22 and R24 are independently a C1 to C18 substituent group;
AA, BB and CC are independently 0 to 5 ;
B is from 0 to 3;
X and Y are taken together to form a carbonyl group or are separate and are each a hydrogen atom;
R16, R17 and R18 independently are a hydrogen atom, an amino protecting group, C1 to C12 acyl, C3 to C10 cycloalkyl, C3 to C6 heterocycle, C1 to C12 alkyl, C1 to C12 substituted alkyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle; R16 is optionally present as a C1 to C18 substituent group when R1 and R2 are other than a hydrogen atom or an amino protecting group;
Wherein said library of compounds is composed of SL physically separate sublibraries; wherein SL is equal to (2B+4);
Further wherein each sublibrary is composed of physically separate mixtures, wherein the number of said mixtures is equal to the number of different substituents incorporated at Rfix, which Rfix can be any one of R19, R20, R21, R22, R23, or R24 in the above Formula IV;
Wherein the compounds of the above Formula IV are synthesized and tested as follows:
(a) For each sublibrary SL, choosing Rfic from R19, R20, R21, R22 , R23, or R24;
(b) Dividing a solid support into
approximately equal separate portions with the number of portions equal to the number of substituents to be incorporated at R23, and couple each physically separate portions of solid support to one of the monomers
containing a single substituent at R23, then mixing all of said physically separate portions; (c) Dividing the mixed solid support from step (a) into approximately equal separate portions in a number equal to the number of different substituents to be incorporated at R24 by alkylation, alkylating each physically separate solid support mixtures with one alkyl group, then mixing said resins;
(d) When B is 1 through 3, dividing each of said solid support portions into a number of
approximately equal separate portions, said number equal to the number of substituents at R21, coupling one said monomer containing a single substituent R23 to each separate solid support portion then mixing said portions; (e) When B is 1 to 3, separating said mixture of solid support portions into a number of approximately equal physically-separate portions, said number equal to the number of alkyl substituents at R20, alkylating each physically separate portion with one such alkylating agent, and mixing all the resultant solid support portions;
(f) Optionally repeating steps (d) and (e) one or two times when B is two or three,
respectively;
(g) Dividing the mixture of solid support portions from either step (c), (e), or step (f) into approximately equal separate portions equal to the number of substituents to be placed at R19, coupling one such monomer containing a single R19 to each physically
separate solid support portion, and mixing said portions;
(h) Dividing the mixture of portions from step (g) into a number of approximately equal separate portions, said number equal to the number of alkyl substituents at R22 to be utilized, alkylating each said separate portion with a single alkyl group R23;
(i) Optionally adding R17 and/or R18 by reductive alkylation;
(j) Optionally adding the quaternary substituent R16; (k) Optionally reducing the interior amides, thus converting X and Y taken together are a carbonyl oxygen to wherein each X and Y is a hydrogen atom; (1) Cleaving said molecules from the solid support;
(m) Testing each portion of each SL sublibraries in the appropriate biological screen or screens; and determining from the results of said screens which substitutent at Rfix is the best.
(n) Optionally synthesizing the molecule of Formula (I) containing the best (Rfix) substitutent at
R19 , R20 , R21 , R22 , R23 , or R24 ;
With the proviso that for each sublibrary SL the first solid support mixing step immediately following the introduction of Rfix is omitted;
Further wherein:
(1) each coupling step in the above series of steps ((b), (d), (f) and (g)) involves a substrate of the Formula (V) :
Figure imgf000137_0001
With an excess of an active acylating form of the monomer of the Formula (VI) :
Figure imgf000137_0002
Wherein in the above Formulas (V) and (VI)
SS is a solid support;
R26 are two hydrogen atoms each bound to the nitrogen atom;
R28 is a C1 to C18 substituent group;
R27 is independently a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
RVAR can be the same or different as R27 and is chosen from the same group of substituents as R27;
DD and EE are independently 0 to 5;
X and Y are either taken together to form a carbonyl oxygen;
PG is an amino protecting group other than trityl;
A is a group, when taken with the preceeding carbonyl group; that forms an active acylating agent; and
C is from 0 to 4;
(2) Each alkylating step in the above steps (c), (e), (f) and (h) requires reacting a substrate of the Formula (VII) :
Figure imgf000138_0001
With an excess of an alkylating agent of the Formula (VIII):
(viii) (LG)-Q
Under anhydrous conditions, and an inert atmosphere in a polar, aprotic solvent;
Wherein in the above Formulas (VII) and (VIII) :
LG is a leaving group under the conditions of the alkylation;
Q is a C1 to C18 substituent group;
FF is 0 to 5;
X and Y are taken together to form a carbonyl oxygen;
R31 is a hydrogen atom when R29 is a trityl group or it is a C1 to C1B substituent group;
R30 is independently a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
R29 is a trityl group when R31 is a hydrogen atom or is a group of the Formula (IX):
Figure imgf000140_0001
Wherein in the above Formula (IX) :
X and Y are as X and Y above ;
GG is 0 to 5;
C is from 1 to 4 ;
R33 is independently a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
R32 is a hydrogen atom if R32 is bonded to the N- terminal amino group or otherwise it is a C1 to C18 substituent wherein one such C1 to C18 substituent differs from the other substituents; (3) Optinal reductive alkylation of the
N-terminal nitrogen group as described above in step (i) of a compound of the Formula (X) :
Figure imgf000141_0001
Under mildly acidic conditions with a ketone or aldehyde containing the R34 and/or R35 groups followed by the treatment of a reducing agent;
Wherein in the above Formula (X) :
X and Y are taken together to form a carbonyl oxygen;
HH, II and JJ are independently 0 to 5 ;
B is from 0 to 3;
R39 , R41 and R37 are the same or different and are chosen from the group consisting of independently a hydrogen atom, Ci to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
R40 and R42 are different and are a C1 to C18 substituent group;
R34 or R35 when B is zero, is optionally one or two hydrogen atoms attached to the nitrogen atom, or is a optionally one or more, same or different groups, chosen from the group consiting of a hydrogen atom, an amino protecting group, C1 to C12 acyl, C3 to C10 cycloalkyl, C3 to C6 heterocycle, C1 to C12 alkyl, C1 to C12 substituted alkyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
R36 is a hydrogen atom or a bond to a R34 or R35 group before the reduction occurs and when B is from 1 to 3; R38 is a C1 to C18 substituent group different from at least one other R40, R42, or R38 group;
(4) Optional reduction of the amide bonds as described above in step (j) of a compound of Formula (X) wherein X and Y are taken together to form a carbonyl group, before or after it is cleaved from the solid support, using a boron reducing agent; and
(5) Optional quaternization of the terminal amino groups with excess amount of an alkylating agent of above of the formula :
(LG)-Q
Where (LG) and Q are as defined above in a polar, aprotic solvent.
66. A method for the iterative synthesis and screening of a library of an approximately equimolar amount of compounds of the Formula (XI) :
Figure imgf000143_0001
Wherein in the above Formula (XI) :
R4B is a hydrogen atom or a solid support; R45 and R47 are different and are each a C1 to C18 substituent group;
KK and LL are independently 0 to 5;
R44 and R46 are independently chosen from the group consisting of independently a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
X and Y are either taken together to form a carbonyl group or are separate and are each a hydrogen atom;
R43 is one or two hydrogen atoms, or groups of the formula Ra, Rb and Rc , wherein Ra and Rb independently are a hydrogen atom, an amino protecting group, C1 to C12 acyl, C3 to C10 cycloalkyl, C3 to C6 heterocycle, C1 to C12 alkyl, C1 to C12 substituted alkyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle; Rc is
optionally present as a C1 to C18 substituent group when Ra and Rb are other than a hydrogen atom or an amino
protecting group; and
Wherein the method comprises:
(a) Splitting a solid support into a number of approximately equal, separate portions, the number of said portions being equal to the number of monomers containing different substituent groups at R46;
(b) Coupling each different monomer containing one of the number of substituent groups at R46 to a separate portion of the solid support;
(c) Mixing all of the separate portions of solid support;
(d) Splitting the solid support mixture into approximately equal, separate portions, the number of portions equal to the number of different substituents to be added at R47;
(e) Alkylating each separate portion of solid support with a single alkylating agent, each agent containing a unique alkyl group at R47, thus adding a single alkyl group at R47 to the plurality of the compounds bonded to each separate portion of solid support;
(f) Mixing all of the separate portions of solid support ;
(g) Splitting the solid support mixture into a number of approximately equal, separate portions, the number of said portions equal to the number of different substituents to be added at R44; (h) Coupling each monomer containing a single substituent group at R44 to a separate portion of the solid support, thus coupling a single different monomer to the plurality of the compounds bonded to each separate portion of the resin; (i) Splitting each of the separate portions of solid support into a number of approximately equal physically-separate portions, wherein the number of portions is equal to the number of different substituents to be added by alkylation at R45; (j) Alkylating each separate portion of solid support with a separate alkylating agent containing a single different R45 group, thus adding a single different alkyl group at R45 to the plurality of the compound bonded to each separate portion of the resin; (k) Cleaving the generated compound mixtures of Formula (XI) from each separate portion of solid support and testing each separate mixture from each separate portion of solid support in the appropriate biological screen or screens, and determining from the results of said screens which mixture contains the best combination of substituents R44 and R45;
(1) Repeating steps (a) through (e), wherein the substituents at R46 and R47 are the same used in said original steps (a) through (e);
(m) Coupling the monomer containing the most active R44 substituent to each of the separate portions of resin from step (1);
(n) Alkylating each of the portions from step (m) with the best alkyl group at R45 determined in step (k); (o) Cleaving each separate mixture of compounds of the above Formula (XI) from the solid support, testing each separate mixture of compounds in the same biological screens as in step (k), and
determining the most active substituent at R47 in those screens;
(p) Repeating steps (a) and (b), wherein the same group of monomers containing the various substituent R46 are used as in the original step (a);
(q) Alkylating each separate resin portion from step (p) with an alkylating agent placing the best alkyl group at R47 as such alkyl group was determined in step (o);
(r) Coupling to each separate portion of resin the monomer containing the best R44 substituent as such substituent was determined in step (k);
(s) Alkylating each separate portion of resin with a group that was the best alkyl group R45 as such group determined in step (k);
(t) Cleaving each separate compound from the solid support, and testing each separate mixture of compound separately in the same screens as in steps (o) and (k) in order to determine the best substituents at R46;
(aa) Optionally reductively alkylating and quaternizing the N-terminal amino group (R43) , either before or after cleavage of the compound from the solid support; and
(bb) Optionally reducing the interior amide groups before or after cleavage of the compound from the solid support such that X and Y in Formula (XI) are each a hydrogen atom;
Further wherein: (1) each of the above coupling steps (b), (h), (l), (m), (p) or (r), involves a substrate of the Formula (XII) :
Figure imgf000148_0001
With an excess of an active acylating form of the monomer of the Formula (XIII) :
Figure imgf000148_0002
Wherein in the above Formulas (XII) and (XIII)
SS is a solid support;
R49 is two hydrogen atoms;
R51 is a C1 to C18 substituent group R50 is independently a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
RVAR2 can be the same or different as R50 and is chosen from the same group of substituents as R50;
MM and NN are independently 0 to 5;
X and Y are either taken together to form a carbonyl group or are separate and are each a hydrogen atom;
PG is an amino protecting group other than trityl;
A is a group, when taken with the preceeding carbonyl group; that forms an active acylating agent; and
C is 0 or 1;
(2) Each of the above alkylating steps (e), (j), (l), (m), (q) and (s), requires reacting a substrate of the Formula (XI)) :
Figure imgf000150_0001
With an excess of an alkylating agent of the Formula (XV) :
(XV) (LG)-Q
Under anhydrous conditions, and an inert atmosphere in a polar, aprotic solvent;
Wherein in the above Formulas (XIV) and (V) :
LG is a leaving group under the conditions of the alkylation;
Q is a C1 to C18 substituent group;
OO is 0 to 5;
X and Y are taken together to form a carbonyl group; or are separate and are each a hydrogen atom;
R54 is a hydrogen atom or it is a C1 to C1B substituent group; R53 is independently a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
R52 is a trityl group if R54 is a hydrogen atom or is a group of the Formula (XVI) :
Figure imgf000151_0001
Wherein in the above Formula (XVI) :
X and Y are as X and Y above;
PP is 0 to 5;
R55 is a trityl group;
R56 is independently a hydrogen atom, C1 to C12 alkyl, C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle; and (3) Optional reductive alkylation of the N-terminal nitrogen group of a compound of the
Formula (XVII) :
Figure imgf000152_0001
Under mildly acidic conditions with a ketone or aldehyde containing the R1 and/or R2 groups followed by treatment with a reducing agent;
Wherein in the above Formula (XVII) :
X and Y are taken together to form a carbonyl group;
QQ and RR are independently 0 to 5;
R58 and R60 are the same or different and are chosen from the group consisting of independently of a hydrogen atom, C1 to C12 alkyl , C1 to C12 substituted alkyl, phenyl, substituted phenyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle;
R59 and R61 are the same or different and are a C1 to C18 substituent group;
R57 is either two hydrogen atoms attached to the nitrogen atom, or is a single hydrogen atom and another group bonded to the nitrogen atom which group is selected from the group consisting of a hydrogen atom, an amino protecting group, C1 to C12 acyl, C3 to C10 cycloalkyl, C3 to C6 heterocycle, C1 to C12 alkyl, C1 to C12 substituted alkyl, C7 to C16 alkylaryl, C7 to C16 substitued alkylaryl, a C6 to C15 alkyl heterocycle, or a substituted C6 to C15 alkyl heterocycle; (4) Optional reduction of the amide bonds of a compound of Formula (XI), before or after it is cleaved from the solid support, using a boron-based reducing agent, such as borane, sodium borohydride, and the like.
PCT/IB1997/000349 1996-03-05 1997-03-05 Selectively n-alkylated peptidomimetic combinatorial libraries and compounds therein WO1997033174A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP97908448A EP0890101A4 (en) 1996-03-05 1997-03-05 Selectively n-alkylated peptidomimetic combinatorial libraries and compounds therein
AU20405/97A AU720632B2 (en) 1996-03-05 1997-03-05 Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
JP09531626A JP2001502293A (en) 1996-03-05 1997-03-05 Selective N-alkylated peptidomimetic combinatorial libraries and compounds therein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61139096A 1996-03-05 1996-03-05
US08/611,390 1996-03-05

Publications (1)

Publication Number Publication Date
WO1997033174A1 true WO1997033174A1 (en) 1997-09-12

Family

ID=24448833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1997/000349 WO1997033174A1 (en) 1996-03-05 1997-03-05 Selectively n-alkylated peptidomimetic combinatorial libraries and compounds therein

Country Status (5)

Country Link
EP (1) EP0890101A4 (en)
JP (1) JP2001502293A (en)
AU (1) AU720632B2 (en)
CA (1) CA2248078A1 (en)
WO (1) WO1997033174A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038397A1 (en) * 1999-11-22 2001-05-31 Abbott Laboratories N-alkylated peptides having antiangiogenic activity
WO2001055091A1 (en) * 2000-01-25 2001-08-02 The Procter & Gamble Company Solid-supported process for making n-substituted peptide mimetic compounds
US6777535B1 (en) 1999-11-22 2004-08-17 Abbott Laboratories N-alkylated peptides having antiangiogenic activity
JP2010511637A (en) * 2006-12-06 2010-04-15 南▲開▼大学 Polypeptide polymer and synthesis method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE66205B1 (en) * 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5480971A (en) * 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
METHODS IN MOLECULAR AND CELLULAR BIOLOGY, 1996, Vol. 6, DORNER B. et al., "Generation of Peralkylated Peptidomimetic Combinatorial Libraries", pages 17-22. *
PROC. EUR. PEPT. SYMP., 23, 1994, HOUGHTEN R.A. et al., "Libraries from Libraries: The Generation of Peptidomimetic Combinatorial Diversities", pages 459-460. *
PROC. NATL. ACAD. SCI. U.S.A., November 1994, Vol. 91, No. 23, OSTRESH J.M. et al., "Libraries from Libraries: Chemical Transformation of Combinatorial Libraries to Extend the Range and Repertoire of Chemical Diversity", pages 11138-11142. *
See also references of EP0890101A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038397A1 (en) * 1999-11-22 2001-05-31 Abbott Laboratories N-alkylated peptides having antiangiogenic activity
US6777535B1 (en) 1999-11-22 2004-08-17 Abbott Laboratories N-alkylated peptides having antiangiogenic activity
WO2001055091A1 (en) * 2000-01-25 2001-08-02 The Procter & Gamble Company Solid-supported process for making n-substituted peptide mimetic compounds
JP2010511637A (en) * 2006-12-06 2010-04-15 南▲開▼大学 Polypeptide polymer and synthesis method thereof

Also Published As

Publication number Publication date
JP2001502293A (en) 2001-02-20
EP0890101A4 (en) 1999-12-08
EP0890101A1 (en) 1999-01-13
AU720632B2 (en) 2000-06-08
CA2248078A1 (en) 1997-09-12
AU2040597A (en) 1997-09-22

Similar Documents

Publication Publication Date Title
US6143932A (en) Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
EP4003528A1 (en) Bicyclic peptide ligands specific for epha2
JP3943593B2 (en) Synthesis of N-substituted oligomers
AU2010321240B2 (en) Template-fixed peptidomimetics with CCR10 antagonistic activty
Heidler et al. N-Acyl-N-alkyl-sulfonamide anchors derived from Kenner’s safety-catch linker: powerful tools in bioorganic and medicinal chemistry
WO1998033776A1 (en) Combinatorial libraries of hydantoin and thiohydantoin derivatives, methods of making the libraries and compounds therein
KR20010022924A (en) Phenethylamine derivatives
JPH11500741A (en) Library of backbone cyclized peptide analogs
HU228073B1 (en) New dolastatin derivatives, their preparation use of them and pharmaceutical compositionx containing them
AU2002234564B2 (en) Template-fixed peptidomimetics as inhibitors of serine proteases
KR20220007098A (en) Bicyclic peptide ligand specific for OX40
JP2000512979A (en) Combinatorial library by self-deconvolution method
US6194544B1 (en) Cyclic semi-random peptide libraries
JPH10510814A (en) Amino acid for producing betide and screening method and production method of betide library
US20190153620A1 (en) Libraries of diverse macrocyclic compounds and methods of making and using the same
CA2759468A1 (en) Insulinotropic peptide synthesis using solid and solution phase combination techniques
AU720632B2 (en) Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
Morimoto et al. Synthesis of a large library of macrocyclic peptides containing multiple and diverse N-alkylated residues
Park et al. The use of one-bead one-compound combinatorial library method to identify peptide ligands for α4β1 integrin receptor in non-Hodgkin's lymphoma
US6251854B1 (en) N-methyl-d-aspartate receptor channel blockers and method for identifying such
Nandhini et al. 2-Methoxy-4-methylsulfinylbenzyl Alcohol as a Safety-Catch Linker for the Fmoc/t Bu Solid-Phase Peptide Synthesis Strategy
US6638941B1 (en) Conformationallly constrained peptidomimetics as β-turn templates and modulators of SH3 domains
AU735939B2 (en) Peptide synthesis with sulfonyl protecting groups
Hruby et al. Applications of synthetic peptides
Son et al. Total chemical synthesis of an Orf virus protein, ORFV002, an inhibitor of the master gene regulator NF‐κB

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997908448

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2248078

Country of ref document: CA

Ref country code: CA

Ref document number: 2248078

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 531626

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1997908448

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997908448

Country of ref document: EP